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Abstract 
 
Parkinson's disease (PD) is characterized by a progressive loss of nigrostriatal dopaminergic  
neurons. Non-dopaminergic neurotransmission is also impaired. Intraneuronal Lewy bodies, 
the pathological hallmark of PD, have been observed in serotoninergic, noradrenergic, and 
cholinergic neurons. Dysfunction of these systems could play a role in the occurrence of 
non-motor symptoms including fatigue. However, the extent of non-dopaminergic 
degeneration in PD, rates of its progression, and its contribution to the development of non-
motor symptoms is unclear.  
 
First, I used 
18
F-dopa Positron Emission Tomography (PET), a marker of  
monoaminergic terminal function, to assess the involvement of dopaminergic, 
noradrenergic, and serotoninergic pathways in PD and in parkin-linked parkinsonism, a 
genetic form of PD. I found that parkin patients and PD patients have distinct patterns of 
monoaminergic involvement, with more widespread dysfunction in PD.  
 
In a second study, I used serial 
18
F-dopa PET to assess longitudinal changes in tracer uptake 
in brain monoaminergic structures over a 3-year period in a group of PD patients. I also 
assessed the relationship between striatal function decline and dysfunction in extra-striatal 
areas in the same patients. I found that the degeneration in extrastriatal monoaminergic 
structures in PD occurs independently from nigrostriatal degeneration and at a slower rate. 
Brain compensatory mechanisms disappear within the first years of disease. 
 
I then used 
18
F-dopa and 
11
C-DASB PET to investigate whether fatigue in PD is associated 
with dysfunction of dopaminergic/serotoninergic innervation. I found that PD patients with 
fatigue show severe loss of serotoninergic innervation in basal ganglia and limbic areas.  
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Finally, I assessed the relationship between 
18
F-dopa uptake and measurements of 
serotonin transporter availability by 
11
C-DASB PET within brain serotoninergic structures 
and I provided evidence for the hypothesis that 
18
F-dopa PET can be used to evaluate the 
distribution and the function of serotoninergic systems in the brain of PD patients.  
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General introduction and Background 
 
1 
 
1.1 Idiopathic Parkinson’s disease  
 
Parkinson‟s disease (PD) is a chronic and progressive degenerative neurological 
disorder characterized by the degeneration of dopamine neurons in the substantia 
nigra, an important relay station in the motor system. The disease, which causes a 
prominent movement disorder, was first described by James Parkinson in 1817 and 
named paralysis agitans by Marshall Hall in 1841. Since then, remarkable advances 
have been made in understanding the pathophysiology of the disease and in 
developing effective symptomatic treatments. The introduction of levodopa, the 
amino-acid precursor of dopamine, in 1967 represented a milestone in the treatment of 
PD. The drug, which remains the mainstay approach for controlling PD symptoms, has 
significantly affected the natural history of the disease. Before the introduction of 
levodopa, PD caused severe disability in 16% of patients within 5 years of onset, in 
37% in the following 5 years, and in 42% of those surviving for 15 years. The 
mortality rate was three times higher than that of the general population matched for 
age, sex and racial origin (Fahn, 1995). Treatment with levodopa and, more recently, 
with other dopamine replacement therapies have near normalized life expectancy; 
death rates in patients with PD and non-parkinsonian individuals are now 
approximately equal (Hohen, 1992). However, a longer disease duration will also 
result in the development of a more advanced and widespread neurodegenerative 
process, which in turn leads to the occurrence of more complex symptoms and 
complications. Additionally, complications of long-term exposure to levodopa must 
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now be considered as part of the natural history of the disease. For these reasons, PD is 
now considered the clinical manifestation of a multisystem degenerative process, 
affecting not only the dopaminergic system, as initially thought, but also 
serotoninergic, cholinergic, noradrenergic, and other central neurotransmitter systems. 
 
1.2 Epidemiology of Parkinson’s disease 
 
PD affects at least 4 million people worldwide. Although the disease targets all ethnics 
groups, some race/ethnicity groups seem to have a lower incidence, including the 
black populations of South Africa and Nigeria and African-Americans (Martilla and 
Rinne, 1989; Richards & Chaudhuri, 1996; Van Den Eeden et al., 2003). However, 
this may represent ascertainment bias as black persons living in Mississippi appeared 
to be affected to a similar degree as the white population (Schoenberg et al., 1985). 
Lower incidence has also been reported in Asian populations (Muangpaisan et al., 
2009). Men have a higher prevalence rate than women. In general, it is reported that 
men are about 1.5 times more likely to develop PD than women. However, this 
difference is not the same across different studies, and is more pronounced in people 
with an older age of onset and in Western populations (Taylor et al., 2007). The 
disease onset is uncommon before the sixth decade and the prevalence rates increase 
with age. Results from seven population-based studies performed in European 
countries suggest that the overall prevalence of PD in people aged over 65 is 1.8%, 
with an increase from 0.6% for persons aged 65 to 69 years to 2.6% for people aged 
85 to 89 years (de Rijk et al., 2000).  
 
1.1 Aetiology and pathogenesis of Parkinson’s disease 
 
The aetiology of PD is unknown and a number of possible factors must be considered. 
In fact, it is likely that the cause of PD is multifactorial, with contributions from aging, 
genetic predisposition, exposure to toxins, and impaired oxidative mechanisms 
(Jankovic, 1993). These factors are briefly summarized in the following paragraphs. 
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1.3.1 Aging 
Attrition of nigral neurons occurs as part of the normal aging process (Hirai, 1968; 
Mann, 1988). However, this cellular loss is most evident in the dorsal tier and pars 
lateralis of the substantia nigra pars compacta, whereas the pathological process in PD 
targets the ventrointermediate and ventrolateral regions of this structure - see 
paragraph 1.5.3.  The nigral neuronal loss in PD patients has been estimated to occur 
ten times more rapidly than in normal aging, and motor symptoms begin when less 
than 60% of neurones remain  (Gibb and Lees, 1994), suggesting that age is not the 
primary cause of PD. Nevertheless, advanced age seems to be a contributing factor for 
specific clinical features. Diederich and colleagues (2003) reported that PD patients 
with old age onset (>78 years) had more severe rigidity, bradykinesia, and axial 
impairment than patients with middle-age onset (between 43 and 66 years) with 
similar disease duration, even when adjusting for comorbidities. Severity of tremor, 
however, was not different between the two groups. 
 
1.3.2 Environmental factors 
In 1979, Davis and colleagues reported a case of chronic parkinsonism in a chemist 
after intravenous injection of a mixture of 1-methyl-4-phenyl-4-propionoxypiperidine 
(MPPP), a potent meperidine analogue, and 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP).  Shortly after this first observation, Ballard and colleagues 
(1985) reported 7 additional cases of parkinsonism induced by MPTP. Autopsy of 
these cases revealed selective destruction of the dopaminergic neurons of the pars 
compacta of the subtantia nigra.  MPTP is oxidized to MPP+ (1-methyl-4-
phenylpyridinium) by the enzyme monoamine oxidase type B, one of the isoenzymes 
that catabolise dopamine. MPP+ is a highly toxic molecule that is taken up by the 
dopamine transporter, accumulates in mitochondia and interferes with the function of 
Complex I of the respiratory chain, causing depletion of ATP and cell death. MPTP is 
currently used to produce animal lesion models of PD in various animal species, 
including rodents and non-human primates. Other exogenous toxins which are 
reported to induce parkinsonism include manganese (Calne et al., 1994), carbon 
monoxide (Pavese et al., 1999), and tetrahydroisoquinolone (Yoshida et al., 1993). 
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Rural living, farming experience, herbicide or pesticide exposure, and industrial 
chemical exposure have been suggested to be associated with an increased risk of 
developing PD and are possibly related to exposure to unknown toxins (Mizuno et al., 
2004). Rotenone and paraquat, two common pesticides, cause mitochondrial 
dysfunction and promote alpha-synuclein aggregation in rodents (Uversky et al., 
2002). 
 
A number of infections have been associated with parkinsonism. One of the most 
highlighted epidemics of viral parkinsonism is that following the outbreak of 
encephalitis lethargica (von Economo's encephalopathy) from 1917 to 1926. The main 
interest in this disease was the long latent period - in some cases years or decades - 
from acute infection to the appearance of parkinsonism, suggesting that the infection 
might have triggered premature death of nigral neurons.  However, in postencephalitic 
parkinsonism the protein that aggregates abnormally is tau and not alpha-synuclein, in 
contrast to PD. Other viruses known to induce parkinsonism include Coxsackie, 
Japanese encephalitis B, St. Louis, West Nile and HIV viruses (Jang et al., 2009). 
However, virologic studies performed on brains of PD patients using electron 
microscopy and immunofluorescent studies have failed to detect specific viral particles 
or antibodies (Schwartz and Elizan, 1979). 
 
A history of minor head trauma is also more common in PD (Semchuk et al., 1993).  
 
1.3.3 Genetic factors 
Although PD was initially considered to be a sporadic degenerative disorder, it is now 
well established that genetic factors are important in PD and that the disease can arise 
as a result of a variety of genetic mutations. Several studies have indicated that PD is 
more common among relatives of index cases. Over the last decade, possible causative 
genes have been investigated in several kindreds with family history of PD. So far 9 
genetic defects have been identified in these families and linkages have been reported 
for at least four more (Farrer, 2006; Schapira, 2006; Lesage and Brice, 2009). 
Recessive forms of young onset PD are known to be caused by mutations in parkin 
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(PARK2), PINK1 (PARK6), DJ-1 (PARK7) and ATP13A2 (PARK9) genes. 
Autosomal dominant forms of parkinsonism are caused by missense mutations and 
duplication of alpha-synuclein (PARK1/4), by mutations in the gene for leucine-rich 
repeat kinase 2 (LRRK2) (PARK8) and ubiquitin carboxy-terminal hydrolase L1 
(UCHL1) (PARK5). Susceptibility genes such as mutations in the glucocerebrosidase 
A (GBA) gene have also been reported. From a clinical perspective, familial 
parkinsonisms often present with clinical features resembling idiopathic PD. However, 
neuropathological (Mori et al., 1998; Hayashi et al., 2000; van de Warrenburg et al., 
2001; Farrer et al., 2001; Morales et al., 2002; Farrer et al., 2004; Sasaki et al, 2004; 
Zimprich et al., 2004; Khan et al., 2005a) and Positron Emission Tomography (PET) 
(Khan, 2002a; Khan, 2002b; Hering, 2004; Scherfler. 2004; Khan et al., 2005a; Adams 
et al., 2005; Hernandez et al., 2005) findings in these patients suggest that their 
pathology is distinct from PD. One of the aims of this thesis is to further clarify the 
pathological process in genetic forms of parkinsonism.  
 
1.3.4 Abnormality in oxidative mechanisms 
Aerobic cells use molecular oxygen as the terminal electron acceptor in oxidative 
phosphorylation, the mitochondrial metabolic pathway that leads to the generation of 
energy-storing adenosine triphosphate (ATP). On the other hand, oxidation reactions 
lead to the formation of reactive oxygen derivates including superoxide anion radical, 
hydrogen peroxide, and hydroxy radicals. These highly reactive and unstable 
molecules with an unpaired electron can react with membrane lipids, inducing lipid 
peroxidation and cell damage. However, under physiological conditions, reactive 
oxygen derivates are cleared by glutathione and oxyradical scavenger enzymes such as 
superoxide dismutases, catalases, glutathione peroxidase, and peroxiredoxins. 
Oxidative stress is associated with increased production of oxidizing species or a 
significant decrease in the capability of antioxidant defences.  Additionally, oxidation 
reactions are facilitated by accumulation of transition metals including iron, copper, 
and manganese.  
The production of free radicals is accelerated in the dopaminergic neurons of the 
substantia nigra due to the oxidative metabolism of dopamine and the high 
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concentration of iron and neuromelanin, which has a high affinity for iron (Youdim et 
al., 1994). 
PD patients have been reported to have increased iron levels and a 40 % decrease in 
levels of glutathione in the substantia nigra pars compacta  both of which could 
promote a marked increase in oxidative reactions (Gerlach et al., 1994; Sian et al., 
1994). Oxidative metabolism of exogenously administered levodopa could also 
potentially generate toxic free radicals and induce further oxidative stress. However, 
the effect of levodopa on dopaminegic neurons in vivo is controversial; in vitro cell 
culture studies have suggested it is toxic but in vivo studies have reported protective 
effects at therapeutic doses (Fahn, 1996; Murer et al., 1998; Conway et al., 2001). A 
recently performed randomized, double-blind, placebo-controlled trial to assess the 
effect of levodopa on the rate of progression of PD (ELLDOPA study) failed to give a 
definitive answer. The results of the ELLDOPA study will be further discussed in 
paragraph 1.6.2.1.3. 
 
1.3.5 Pathogenesis  
Despite the well-characterized pathological process, the molecular mechanisms, which 
lead to progressive neuronal degeneration in PD, remain elusive. Several factors and 
processes including oxidative stress and free radical generation, failure of the 
ubiquitin-proteasome system (UPS), mitochondrial dysfunction, glutamate receptor 
mediated excitotoxicity, apoptosis, and inflammation all seem to be involved in PD 
pathology. 
The effects of oxidative stress have been described in the previous paragraph.  
The UPS is a multicomponent pathway that identifies abnormal proteins and tags them 
with ubiquitin for degradation by the 26/20S proteasome.  In addition to degrading 
misfolded
 
and damaged proteins, the UPS system is also essential in regulating cellular 
signaling pathways involved in proliferation, adaptation
 
to stress, regulation of cell 
size, and cell death. 
In recent years, evidence for UPS dysfunction in PD has arisen from molecular studies 
in cell cultures, animal lesion models of PD, as well as human studies on postmortem 
brains from PD patients (McNaught et al., 2002; Petrucelli and Dawson, 2004; 
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Bukhatwa et al., 2010; Xie et al., 2010). These studies indicate that impaired capacity 
of the UPS to clear aberrant, misfolded proteins promotes their aggregation and 
degeneration of dopaminergic neurons.  
Mitochondrial dysfunction results in oxidative stress, as respiratory failure leads to 
uncoupling of ATP production and excessive oxygen free-radical formation with 
consumption of glutathione. However, respiratory failure also results in cellular death 
via excitotoxic release of glutamate and influx of calcium into cells (Beal, 1992; Celsi 
et al., 2009). Several laboratories have reported deficiencies of mitochondrial electron 
transport chain complex I in the substantia nigra of PD patients (Mizuno et al.,1989; 
Schapira et al., 1990; Shapira et al., 1998).  Interestingly, similar reductions in 
complex I have been reported in platelets, fibroblasts, and muscle of PD patients, 
although these findings are less consistent (Krige et al., 1992; Benecke et al., 1993; 
Anderson et al., 1993; Haas et al., 1995; Wiedemann, et al., 1999; Hanagasi et al., 
2005). 
An increasing body of evidence suggests that modifications in the mechanisms that 
control the apoptotic cascade, known as programmed cell death, may play a central 
role in the neurodegenerative process characterizing PD (Anglade et al., 1997; Tatton, 
2000; Hartmann et al., 2001; Singh and Dikshit, 2007). Enhanced expression of 
several pro-inflammatory cytokines and apoptosis-related proteins including IL-2, IL-
4, IL-6, interferon-gamma, NF-kappaB, CD95/Fas, and the tumor suppressor protein 
p53 has been reported in the parkinsonian brain (Mogi et al., 1994; Mogi et al., 1995; 
de la Monte et al., 1998; Mogi et al., 2007). A significant increase in caspase 
activation has also been observed in dopaminergic neurons of PD patients (Mogi et al., 
2000; Hartmann et al., 2001; Anderson et al., 2001). 
Excitotoxicity mediated by overactivity of glutamatergic output from the subthalamic 
nucleus is another proposed pathogenic mechanism for neuronal degeneration in PD 
(Choi, 1988; Beal, 1992). Excess glutamate release could induce excitotoxic damages 
in targets of the subthalamic nucleus including the nigra and pallidum (Rodriguez et 
al., 1998).  
Activation of microglia in response to acute and chronic brain insults is thought to 
represent a reparative measure in the affected areas. These cells are able to promote 
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neuronal survival by releasing growth factors, walling off necrotic tissue, and stripping 
and remodeling synapses (Kim and de Vellis, 2005). However, there is cumulative 
evidence suggesting that activated microglia may also cause neuronal death through 
the release of a variety of cytokines and other neurotoxic factors (Wilms et al., 2003). 
It is possible that in conditions characterized by extensive chronic microglial 
activation, these harmful effects overcome the beneficial ones leading to a self-
propagating cycle, where activated microglia promote further neurodegeneration and 
subsequent further induction of microglia activation with production of neurotoxic 
factors. 
 
1.4 Clinical features of Parkinson’s disease 
 
1.4.1 Motor symptoms 
PD is clinically diagnosed when asymmetrical limb bradykinesia along with one or 
more of the following resting tremor, rigidity or postural instability.  
 
Bradykinesia is the most characteristic symptom of PD. The term refers to slowness in 
the initiation and execution of movements. Bradykinesia results in loss of facial 
expression, impairment of fine motor movements, and loss of spontaneous movements 
such as decreased arm swing and reduced blinking and swallowing. It also leads to 
hypophonic dysarthria with slowing of lip, tongue and pharyngeal muscles movements 
during talking, difficulty in rising from a chair and initiating gait, and shuffling gait 
with shorter steps. 
 
Resting tremor is one of the most easily recognizable and noticeable features of PD 
and is the initial symptom in approximately 50% of patients (Jankovic, 2003).   The 
tremor, characteristically in the 3-6Hz range, may appear unilaterally in the fingers 
and thumb or in a leg but eventually spreads to involve both the arm and leg and then 
the opposite limbs. In severe cases, the tremor involves all four limbs, the head, the 
lips and eyelids. Only 15% of the patients never have a tremor throughout their disease 
course (Jankovic, 2003). 
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Rigidity is increased muscle tone, which in combination with a resting tremor may 
produce a characteristic cogwheel phenomenon when the limb is passively moved. 
Rigidity usually appears unilaterally and proximally in an upper limb, spreading later 
to involve all the muscles of that limb and eventually the opposite side and muscles of 
the neck and trunk. 
 
As PD becomes more advanced, many patients develop gait and balance problems and 
these can lead to recurrent falls. Unfortunately, neither postural instability nor 
tendency to fall are improved by dopaminergic therapy, implying that dopaminergic 
pathways may not be involved in the pathogenesis of these symptoms.  
Recent observations suggest that dysfunction of the pedunculopontine nucleus (PPN) 
is an important causative factor for postural instability and gait disturbances. In animal 
models, lesioning of the PPN causes akinesia (Aziz et al., 1998; Munro-Davies et al., 
1999). Conversely, akinesia in MPTP lesioned primate model of PD is improved by 
stimulating the PPN at low frequencies (Nandi et al., 2004). Further evidence pointing 
to the role of the PPN in modulating gait in humans comes from post-mortem studies 
of patients with advanced PD disease, progressive supranuclear palsy, and multisystem 
atrophy, as the extent of PPN degeneration in the brains of these patients correlates 
with their levels of pre-mortem gait dysfunction (Jellinger et al., 1988). Low 
frequency deep brain stimulation of the PPN is emerging as a treatment for postural 
and gait disorders non-levodopa responsive in PD patients.  
 
Other motor features of PD include eyelid apraxia, blepharospasm, micrographia, and 
freezing of gait, a sudden and transient inability to move as if the feet were glued to 
the ground. 
 
1.4.2. Non-motor symptoms spectrum  
Non-motor symptoms are very common in PD patients but are generally under-
appreciated by clinicians and healthcare professionals. The spectrum of non-motor 
symptoms in PD is wide and includes hyposmia, autonomic dysfunction, chronic 
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fatigue, sleep disorders, mood disorders, psychosis, impaired cognition and dementia 
(Chaudhuri et al., 2006). Some of these symptoms may be present long before the 
development of the classical motor syndrome (“pre-motor features”), while others 
complicate the advanced stages of the disease with a negative impact on patients‟ 
quality of life.  
 
Olfactory dysfunction (hyposmia) is a frequent non-motor symptom in PD patients, 
affecting up to 60% of patients. It generally is an early feature of PD, often preceding 
the motor symptoms so providing a potential marker of subclinical disease.  
 
Autonomic dysfunction is commonly seen in the middle to late stages of PD. An early 
onset of autonomic features generally suggests atypical parkinsonian syndromes and 
particularly multiple system atrophy. Autonomic symptoms seen in PD patients 
include orthostatic hypotension, constipation, seborrhoea and excessive sweating, 
drooling, dysphagia, urinary disturbances, erectile difficulties and ejaculatory 
disturbances in the male and vaginismus and anorgasmia in the female.  
 
Disabling fatigue is estimated to occur in about one-third of PD patients and manifests 
as a feeling of constant exhaustion or tiredness, either mental, physical, or both. 
(Brown et al., 2005). The reason for the high prevalence of fatigue in PD remains 
poorly understood. One of the aims of this thesis will be to elucidate possible 
pathophysiological mechanisms underlying chronic fatigue in patients with PD who 
experience this symptom. 
  
Sleep disorders in PD can be categorised as insomnia, parasomnias (dreams / 
nightmares / somnambulism / sleep behavior disorder), and daytime somnolence 
(Garcia-Borreguero et al., 2003). Although sedative dopaminergic drugs and systemic 
problems can play a part in the pathogenesis of these disorders, it has been suggested 
that degeneration of the central nervous system neurons in PD may affect central sleep 
regulatory centres, which modulate wakefulness and REM sleep (Rye and Jankovic, 
2002). These centres include the noradrenergic locus ceruleus, serotoninergic dorsal 
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raphe, histaminergic tuberomammilary nucleus, dopaminergic ventral tegmental area, 
and the hypothalamus.  
 
Depression is also common in PD having a reported prevalence that varies from 10 to 
45%, depending on the criteria used for diagnosis (Burn, 2002). Symptoms of 
depression can precede the onset of motor symptoms in PD patients but the precise 
pathophysiological substrates of depression in PD remain obscure. Although a pure 
reactive basis cannot be excluded and may certainly play a significant role, it is also 
conceivable that depression in PD could be the result of damage to serotoninergic and 
noradrenergic pathways along with loss of limbic dopaminergic neurotransmission. 
 
Finally, the incidence of dementia in PD patients is about six-times higher than that in 
age-matched healthy people and increases exponentially with age. Reported 
prevalences vary from 0-80% across different series but averages at around 40% 
(Emre, 2003). Dementia in PD patients is characterized by a dysexecutive syndrome 
along with impairment of visuospatial capacities, attentional control, and short-term 
memory. Compared with Alzheimer‟s disease, language is relatively preserved. Many 
of these cognitive deficits are thought to be associated with degeneration of the medial 
substantia nigra and ventral tegmental area and subsequent loss of mesolimbic and 
mesocortical dopaminergic projections. However, reported pathological changes in PD 
patients with dementia also include: a) direct involvement of the cortex by Lewy body 
pathology, the pathological hallmark of PD, which targets the cingulate gyrus and 
association areas; b) cholinergic cell loss in the nucleus basalis of Meynert; c) 
incidental Alzheimer‟s disease; d) vascular pathology. 
 
In summary, non-motor symptoms are associated with significant morbidity since they 
have functional effects on the patients‟ working and social life (Chaudhuri et al., 
2006). However, many patients do not develop disabling non-motor symptom and 
continue to function relatively well, especially in early disease stages. The variability 
in the expression of non-motor symptoms reflects the heterogenous extent and 
progression of the degenerative process at extrastriatal sites. 
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1.5 The pathological characterization of Parkinson’s disease 
 
1.5.1 Pathological hallmarks of Parkinson‟s disease 
The cardinal pathological feature of the PD consists of the formation of proteinaceous  
intraneuronal inclusions (Lewy bodies and Lewy neuritis) and progressive neuronal 
loss particularly targeting the substantia nigra pars compacta.   
 
1.5.2 Lewy bodies and Lewy neurites 
The presence of Lewy bodies and Lewy neurites is a prerequisite for the post mortem 
diagnosis of PD. The major component of Lewy bodies and Lewy neuritis is an 
aggregated form of alpha-synuclein, a presynaptic protein that is probably involved in 
controlling synaptic plasticity (Mezey et al., 1998).  The mechanisms leading to the 
development of Lewy neurites and Lewy body remain unknown. Oxidative stress and 
nitrosylation could cause a change in the conformation of normal alpha-synuclein 
molecules leading to aggregation and formation of insoluble intraneuronal inclusions 
(Mezey et al., 1998).     
 
1.5.3 Nigrostriatal dysfunction 
The substantia nigra, the largest nucleus in the midbrain, is an anatomically 
heterogeneous structure that is composed of two zones: the pars reticulata, a pale 
ventral area with a relatively small number of cells, and the pars compacta, a darkly 
pigmented dorsal area packed with dopaminergic perikarya that contain neromelanin, a 
polymer of dopamine or its metabolite (Hassler, 1937). The pars compacta is divided 
into two tiers: ventral and dorsal. The ventral tier has two further divisions (ventro-
medial and ventro-lateral), whereas the dorsal tier has three further divisions: dorso-
medial, dorso-lateral, and pars lateralis. 
The initial neuronal loss in the substantia nigra in PD involves the caudal pars 
compacta in the lateral ventral tier, which projects specifically to dorso-lateral 
putamen (Fearnley and Lees, 1991; Damier et al., 1999). As PD progresses, nigral 
pathology extends medially and dorsally into the dorsal tier and the contiguous ventral 
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tegmental area (Damier et al., 1999; Fearnley and Lees, 1991), with consequent loss of 
nigral projections to the rostral putamen, caudate nucleus, nucleus accumbens, and 
globus pallidus (Kish et al., 1988; Jan et al., 2000).  
Loss of nigral cells results in profound dopamine depletion in the nigrostriatal 
projections, which, in turn, leads to increased inhibitory output activity from the basal 
ganglia to the ventral thalamus and the frontal cortex implicated in the control of 
motor performance. When 80% of striatal dopamine and 50% of the nigra compacta 
cells have been lost, classical motor signs of PD become manifested (Fearnley and 
Lees, 1991).  The classical model of basal ganglia function proposes that signals from 
the cerebral cortex loop through the basal ganglia and are then returned after focussing 
and filtering back to the cortex (Obeso et al., 2000). Afferent inputs from the cerebral 
cortex and the substantia nigra pars compacta converge on the striatum, from which 
two pathways with opposing effects project to the internal pallidum, the main output 
nucleus of the basal ganglia. The direct pathway involves monosynaptic outputs from 
the striatum that inhibit the globus pallidus interna and the substantia nigra pars 
reticulata.  The indirect pathway involves polysynaptic outputs from the striatum to 
globus pallidus interna via inhibition of the globus pallidus externa, which in turn 
inhibits the subthalamic nucleus. The subthalamic nucleus sends excitatory output to 
the globus pallidus interna and the substantia nigra pars reticulata. Therefore, the 
direct and indirect pathways have opposing actions on the globus pallidus interna. 
Activity of the direct pathway inhibits internal pallidum output, while activity in the 
indirect pathway facilitates internal pallidum output.  Projections from the globus 
pallidus interna and the substantia nigra pars reticulata inhibit the ventral lateral 
nucleus of the thalamus which send excitatory efferents to the cerebral cortex. The net 
effect is that the direct pathway acts to facilitate thalamocortical activity, whereas 
activity in the indirect pathway inhibits this. Dopamine activates the direct and inhibits 
the indirect pathway. Therefore, reduction of dopamine levels in PD induces increased 
inhibitory output from the globus pallidus interna/substantia nigra par reticulata with 
subsequent increased inhibition of the thalamocortical pathway leading to suppression 
of movement. 
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1.5.4 Involvement of non-dopaminergic pathways 
Although nigrostriatal dopaminergic denervation remains the pathological hallmark of 
PD, neuropathological studies and biochemical and neuroimaging findings in PD 
patients have documented the occurrence of concomitant degeneration in non-
dopaminergic pathways, including serotonin, noradrenaline, and acetylcholine 
neuronal systems. Dysfunction of these systems could contribute to the development 
of both motor and non-motor features and may provide targets for pharmacological 
interventions to treat these symptoms.  
The pathological evidence of the involvement of non-dopaminergic pathways in PD is 
briefly reviewed in the following paragraphs. Neuroimaging findings will be discussed 
elsewhere (paragraph 1.6.3). 
 
1.5.4.1 Involvement of serotoninergic pathways 
In the normal brain, serotoninergic neurons are located predominantly in the raphe 
nuclei complex in the midline of the brainstem (Dahlström and Fuxe, 1964). The more 
rostral cell groups in the pontine and midbrain raphe including the dorsal raphe nuclei 
send extensive projections to the basal ganglia, frontal cortex, limbic system, and 
diencephalon, whereas the caudal raphe nuclei in the medulla project towards the 
spinal cord and brain stem.  
A reduction of serotonin and its metabolite has been reported in brains of patients with 
PD, although not to the same degree as dopamine loss (Scatton et al., 1983; Shannak et 
al., 1994; Kish et al., 2008). In early post-mortem studies depletion of serotonin was 
observed in hypothalamus (Shannak et al., 1994) as well as in the caudate nucleus, 
hippocampus and frontal cortex  (Scatton et al., 1983) of PD patients. The 5-
hydroxyindoleacetic acid to serotonin ratio, a catabolic index to identify changes in the 
ratio of catabolic processes and transmitter synthesis, appears to be increased in the 
caudate nucleus and frontal cortex but not in the other cortical areas (Scatton et al., 
1983). A recent pathological study has extended some of these early findings, showing 
preferential loss of serotonin in the caudate compared with the putamen (Kish et al., 
2008). However, some patients had normal levels in both structures. Other serotonin 
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markers including serotonin transporter, 5-hydroxyindoleacetic acid, and tryptophan 
hydroxylase were also reduced, with the caudate more affected than putamen.   
The loss of striatal serotonin in PD may be secondary to neurodegeneration within the 
raphe nuclei. Indeed, Lewy bodies are seen in the raphe nuclei in association with 
neuronal loss (D‟Amato et al., 1987; Halliday et al., 1990 Braak et al., 2003). 
However, none of these studies reported any correlation with motor disability, 
dyskinesia, mood or psychiatric comorbidities. Conversely, Paulus and Jellinger 
(1991) reported a lower density of neurons in the dorsal raphe nuclei in PD patients 
with depression compared to non-depressed PD patients. Depressed PD patients also 
show reduced cerebrospinal fluid levels of 5-hydroxyindoleacetic acid (Mayeux et al., 
1984).  
 
1.5.4.2 Involvement of cholinergic pathways 
The nucleus basalis of Meynert and the PPN in the brainstem, the two major sources 
of cholinergic projections in the brain, are affected in PD. The nucleus basalis together 
with the medial septum, and the vertical and horizontal limbs of the diagonal band of 
Broca constitute the basal forebrain cholinergic complex which extensively innervate 
the cerebral cortex (Mesulam and Geula, 1988), whereas brainstem cholinergic 
neurons primarily innervate thalamus, cerebellum, several brainstem nuclei, the 
striatum, and the spinal cord (Pahapill and Lozano, 2000; Hamani et al., 2007). 
Several post-mortem studies have shown that significant loss of cholinergic neurons in 
the nucleus basalis is an early phenomenon in PD (Candy et al., 1983, Arendt et al., 
1983; Nakano and Hirano, 1984; Tagliavini et al., 1984). Tagliavini and colleagues 
(1984) reported a mean 45.8% reduction in nucleus basalis neurons of PD patients 
compared to age-matched controls. Additionally, numerous surviving cells contained 
Lewy inclusion bodies. The percentage loss of cells in these patients (range from 
29.9% to 68.3%) did not correlate with the duration of illness, age of the patients, their 
mental state or drug regime.  There is evidence that the neuronal loss from the nucleus 
of Meynert may be greater in PD than in Alzheimer‟s disease (Arendt et al., 1983).  
Cortical acetylcholinesterase activity, a presynaptic cholinergic marker, is also 
decreased significantly in the frontal cortex of both demented and non-demented 
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parkinsonian subjects compared to controls, probably as a consequence of the 
dysfunction of the basal forebrain cholinergic complex (Ruberg et al., 1986). 
 
The PPN comprises two histochemically different structures, the pars compacta 
(PPNc) and the pars dissipatus (PPNd), which are thought to have different 
physiological roles. The PPNc has predominantly cholinergic neurons and is part of 
the ascending reticular activating system. It is involved in frontal cortical activation, 
including focused attention during behavioural tasks and the sleep wake cycle 
(Brudzynski et al., 1986; Rye, 1997; Pahapill and Lozano, 2000). The PPNd contains 
glutamatergic projections and is involved in the generation of axial and proximal gross 
limb movements (Brudzynski et al., 1986; Nandi et al., 2002; Winn, 2006).  
Human post-mortem studies in Parkinsonian patients demonstrate loss of cholinergic 
neurones in PPNc, the degree of which clinically correlates with the patients‟ pre-
mortal gait dysfunction and postural instability (Hirsch et al., 1987; Jellinger, 1988; 
Zweig et al., 1989).  
The PPN is a novel target for deep brain stimulation (DBS), and low frequency 
modulation alleviates postural instability and gait dysfunction. 
 
1.5.4.3 Involvement of noradrenergic pathways 
Compared with dopamine deficiency, the degree of noradrenaline decrease in PD is 
moderate (Ehringer and Hornykiewicz, 1998). In the normal brain there are two main 
noradrenergic pathways. The caudal complex is composed of groups of neurons 
mainly located in the medullary ventrolateral reticular formation, the dorsal vagal 
complex, and the nucleus of the solitary tract. These noradrenergic neurons project to 
the hypothalamus, the locus coeruleus, and the spinal cord (Moore and Bloom, 1979). 
The rostral complex is located in the pons and mainly comprises the locus ceruleus 
and the subceruleus. The locus ceruleus is the principal noradrenergic cell
 
group in 
brain. Through a widespread efferent projection system, this nucleus supplies 
noradrenaline throughout the entire brain (Moore and Bloom, 1979). The involvement 
of locus coeruleus in PD has been well documented by various neuropathological 
series (Mann, 1983; German et al., 1992; Forno, 1996). Intracellular Lewy bodies 
 36 
(Forno, 1996), neurofibrillary tangles, neuronal loss, and reactive fibrosis have all 
been observed (Bertrand et al., 1997). Bertrand and colleagues (1997) have reported a 
70 % reduction of coeruleus neurons in PD patients compared with age-matched 
controls.  Degeneration was more pronounced in the middle and the caudate segment 
of the locus coeruleus, although the entire nucleus was affected. The authors suggested 
that the neuronal loss might begin in the middle segment of the nucleus and 
subsequently spread towards its caudal part. However, other authors have reported 
comparable cell loss throughout the rostral-caudal extent of the nucleus in PD patients  
(German et al., 1992). Similar magnitudes of reduced noradrenergic innervation of the 
motor and prefrontal regions of the cortex have been reported in PD patients (Gaspar 
et al., 1991).  
 
1.5.4.4 Involvement of other neurotransmitters/modulators 
The concentrations of GABA in the striatum of PD patients can be increased 
compared to age-matched healthy volunteers (Perry et al., 1983; Kish et al., 1986). 
The GABA elevation appears to be most pronounced in the caudal subdivision of the 
putamen (Kish et al., 1986). Milder non-significant elevations of GABA levels were 
observed in the intermediate and rostral putamen, in the head of the caudate nucleus, 
and in the external and internal globus pallidus, whereas levels in other extrastriatal 
brain areas including thalamus, subthalamic nucleus and substantia nigra were normal. 
A significant negative correlation between increased GABA levels and reduced 
dopamine levels was observed in the caudal putamen (Kish et al., 1986). 
Glutamate concentrations can also be elevated in the PD striatum compared to age-
matched controls, with a statistically significant increase in the putamen and a trend 
towards increased concentrations in the subthalamic nucleus (Kish et al., 1986). 
Abnormalities in glutamate transmission have been associated with the presence of 
levodopa-induced dyskinesias in animal models of PD (Oh et al., 1998; Chase et al., 
2000; Nash et al., 2002; Calon et al., 2002; Robelet et al., 2004). High levels of 
extracellular glutamate and increased expression of the glial glutamate transporter 
GLT1 have been observed in the striatum and substantia nigra of dyskinetic 6-OHDA 
lesioned rats after chronic levodopa treatment (Robelet et al., 2004). When nigral 
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lesioned rats develop dyskinesias after chronic levodopa exposure increased 
phosphorylation of striatal NMDA receptor subunits is found (Chase et al., 2000) 
while NMDA and AMPA receptor upregulation is seen in MPTP-lesioned monkeys 
(Calon et al., 2002).  
In the human brain, the striatum contains the highest concentrations of adenosine A2A 
receptors (Svenningsson et al., 1997; Svenningsson et al., 1999; Jenner et al., 2009). 
A2A sites are found mainly on the spinous processes of the medium spiny neurones of 
the indirect pathway (Jenner et al., 2009) and are G protein coupled. Their activation 
leads to inhibition of D2 receptors and an overall suppression of indirect pathway 
activity (Svenningsson et al., 1999). A2A receptor mRNA expression has been 
reported to be elevated in dyskinetic patients (Calon et al., 2004) and in dyskinetic 
animal models of PD (Kaelin-Lang et al., 2000). 
Finally, enkephalin and dynorphin are transmitted by functionally distinct indirect and 
direct striatal GABAergic pathways to the external and internal globus pallidus and are 
thought to play a neuromodulatory role in motor function (Austin and Kalivas, 1990). 
High levels of enkephalin are observed in the external pallidum and striatum of 6-
OHDA-lesioned rats after levodopa replacement therapy (Engber et al., 1991; Taylor 
et al., 1992), and increases in enkephalin gene expression have been reported in the 
putamen of MPTP-exposed nonhuman primates with levodopa-induced dyskinesias 
(Jolkkonen et al., 1995). In PD patients with levodopa-induced dyskinesias, Nisbet and 
colleagues (1995) have reported statistically significant increases in preproenkephalin 
messenger RNA expression in the body of the caudate and in the intermediolateral 
putamen.  
Since the intrinsic neuronal population of the basal ganglia is preserved in PD the 
observed changes in GABA, glutamate, adenosine and neuropeptide levels are likely 
to reflect changes in basal ganglia function secondary to loss of dopaminergic input 
and non-physiological exposure to exogenous levodopa. 
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1.5.5 The Braak hypothesis 
The recognition of the importance of alpha-synuclein, the main component of Lewy 
bodies, in the pathophysiology of familial and sporadic PD (Trojanowski and Lee, 
2003) has led to a new concept of the neuropathology of PD as a synucleinopathy. 
Using synuclein immuno-cytochemistry, Braak and colleagues (2004) have reported 
that the intraneuronal lesions in PD evolve sequentially, beginning in the dorsal 
nucleus of the vagus and ascending in a predictable manner throughout vulnerable 
regions of the gray matter. Based on this observation Braak and colleagues (2004) 
have proposed a six-point staging procedure for the pathological process in PD.  
They propose that Lewy body pathology begins in the medulla oblongata and olfactory 
structures in stage 1 and spreads to the pons by stage 2. The substantia nigra and 
midbrain brain nuclei are only affected by stage 3, when motor symptoms appear. In 
stage 4 limbic areas become affected and, in stages 5 to 6, inclusions appear in the 
association and primary neocortex. Figure 1-1 shows the Braak stages in the 
development of PD. 
 
 
Figure 1-1 Braak stages in the development of Parkinson’s disease. Lewy body 
pathology begins in the medulla oblongata, olfactory structures, and pons (stages 1 
and 2). In stages 3 and 4, pathology progressively spreads to the substantia nigra, 
other midbrain brain nuclei, and the limbic areas. In stages 5 to 6, inclusions appear 
in the association and primary neocortex. First signs of motor parkinsonism start in 
stage 4 and 5 
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1.5.6 Controversies 
In other neuropathologic studies only one third of incidental Lewy body cases conform 
to Braak
 
staging (Dickson, 2010) and brains with prominent neurodegeneration and 
alpha-synuclein
 
pathology in the substantia nigra pars compacta and higher brainstem 
structures in the
 
absence of medullary involvement are recorded  (Jellinger, 2003; 
Parkkinen et al., 2003; Kalaitzakis et al., 2008). Additionally,
 
Braak staging is based 
exclusively on the presence of immunoreactive Lewy neurites and Lewy bodies,
 
and it 
is unclear whether these
 
alpha-synuclein-related pathologic changes correlate with
 
neuronal dysfunction or loss. 
 
 
1.6 Functional imaging with Positron Emission Tomography in Parkinson’s 
disease 
 
1.6.1 Introduction 
Over the last two decades, functional neuroimaging with positron emission 
tomography (PET) has increasingly been employed to understand the complex pattern 
of basal ganglia functional neuroanatomy in humans and to elucidate 
pathophysiological mechanisms underlying PD and other common movement 
disorders. To date, PET has been mainly employed in PD to evaluate: (1) presynaptic 
dopaminergic terminal function, (2) postsynaptic dopaminergic receptor status, (3) the 
changes in levels of dopamine in the synaptic cleft, (4) changes in cerebral 
metabolism, (5) the consequences of striatal dysfunction on cortical activation, (6) the 
contribution of neuroinflammation to the pathogenesis of PD, (7) changes in non-
dopaminergic transmitters.  
Figure 1–2 is a schematic representation of a striatal presynaptic dopamine terminal 
showing neurobiological substrates for imaging techniques.  
 
1.6.2 Assessment of dopaminergic dysfunction 
1.6.2.1 Presynaptic dopamine function 
PET has extensively been employed to investigate presynaptic dopamine function in 
PD and atypical parkinsonisms. The technique detects the functional activity of intact 
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dopaminergic neurons within the affected striatum. This can be achieved by 
measuring: (1) striatal aromatic amino acid decarboxylase (AADC) activity with 
18
F-
dopa PET; (2) availability of presynaptic dopamine transporter (DAT), which is the 
plasma membrane transporter responsible for the high-affinity uptake of dopamine, 
with PET tracers such as 
11
C-CFT, 
18
F- CFT, and 
11
C-RTI-32; (3) the density of 
vesicular monoamine transporter, which is the vesicular transporter responsible for the 
transport of dopamine from the cytoplasm into secretory vesicles, with 
11
C/
18
F-
dihydro-tetrabenazine PET.  Table 1-1 summarizes functional imaging strategies for 
the assessment of presynaptic nigrostriatal terminals. 
 
 
Figure 1–2. Schematic representation of a striatal presynaptic dopamine terminal 
showing neurobiological substrates of PET tracers. SPECT tracers for dopamine 
receptors (
123
I-IBZM) and dopamine transporter  (
123
I-FP-CIT, 
123
I-altropane, 
99m
TC-
TroDAT) are also represented  
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18
F-dopa PET was the first neuroimaging technique used in research. The metabolism 
of intravenously injected 
18
F-dopa will be described in detail in chapter 3. Briefly, 
striatal uptake of 
18
F-dopa depends upon five processes: (a) transport across the blood-
brain barrier, (b) uptake into dopaminergic neurons, (c) metabolism by AADC, (d) 
vesicular storage of 
18
F-dopamine, (e) degradation of 
18
F-dopamine. Among these 
processes, AADC activity and density of the axonal terminal plexus are the principal 
determinants of 
18
F-dopa uptake as measured by the influx constant Ki over 90 
minutes. Therefore, measurements of 
18
F-dopa uptake in the striatum in PD reflect the 
number of remaining dopaminergic cells. This is supported by human and MPTP-
lesioned monkey autopsy studies which have demonstrated that reduced striatal 
18
F-
dopa uptake correlated well with nigral neuronal counts (Snow et al., 1993; Pate et al., 
1993). However, in early stages of disease, 
18
F-dopa PET may underestimate the 
extent of the degenerative process due to compensatory upregulation of AADC in 
functioning terminals (Ribeiro et al., 2002).  
 
Putamen uptake of 
18
F-dopa in PD correlates with motor impairment. Several authors 
have described a significant inverse correlation between 
18
F-dopa uptake and the 
degree of motor disability as measured by the Hoehn and Yahr and Unified 
Parkinson‟s Disease Rating (UPDRS) scales (Brooks et al., 1990a; Broussolle et al., 
1999; Vingerhoets et al., 1997). 
Interestingly, putamen levels of 
18
F-dopa uptake correlate inversely with the degree of 
rigidity and bradykinesia but not with severity of tremor suggesting that pathways 
other the nigrostriatal pathway might be implicated in the pathogenesis of this last 
symptom (Otsuka et al., 1996). 
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Table 1.1 Summary of functional imaging strategies for the assessment of  
presynaptic nigrostriatal terminals  
 
 Biological Marker     Neuroimaging 
       Technique 
              Tracer 
Metabolism of levodopa: 
(a) aminoacid transport into dopamine   
neurons 
(b) metabolism by AADC * 
(c) vesicular storage of 
18
F-dopamine 
(d) metabolism of 
18
F-dopamine to HVA and 
DOPAC 
 
            PET 
                    18
F-dopa           
Presynaptic dopamine transporter (DAT) 
 
            PET 
11
C –CFT, 18F-CFT,  
11
CRTI-32, 
18
F-FP-CIT, 
11
C-methylphenidate 
                                    
Type-2 vesicular monoamine transporter 
(VMAT2) 
            PET 
11
C/
18
F-dihydrotetrabenazine 
AADC= aromatic amino acid decarboxylase,  *
18
F-dopa uptake primarily reflects 
AADC activity 
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As discussed in paragraph 1.5.3, the neurodegenerative process in PD is not uniform. 
The ventrolateral nigral dopaminergic projections to the dorsal putamen are more 
affected than the dorsomedial projections to the head of caudate (Fearnley and Less, 
1991). Similarly, reduction in 
18
F-dopa uptake is maximal in the putamen when 
compared to the caudate. Patients with hemiparkinsonism have more pronounced 
reduction in the dorsal posterior putamen controlateral to the side of clinical symptoms 
(Morrish et al., 1995), whereas patients with bilateral disease present with reductions 
extending into the ventral and anterior putamen and dorsal caudate. Finally, when PD 
is in more advanced stages, the uptake within the ventral head of caudate also falls.   
 
18
F-dopa has also been used to assess disease progression in vivo.  Several series have 
now demonstrated that loss of striatal 
18
F-dopa uptake occurs more rapidly in PD 
patients than in age-matched controls (Vingerrhoets et al., 1994, Morrish et al., 1996, 
1998, Nurmi et al., 2001, 2003). In early PD patients, putaminal 
18
F-dopa uptake has 
been reported to decline annually by around 10% of baseline (5% of the normal mean), 
whereas when disease duration is longer, the annual loss is reduced (Morrish et al., 
1996). Caudate uptake decreases at a slower rate than putamen. It must be 
acknowledged that decreases in striatal 
18
F-dopa uptake over the time do not provide 
an accurate measure of the neurodegenerative process as they reflect both a failure of 
compensatory mechanisms (AADC upregulation) and neuron loss. Nonetheless, this 
approach potentially provides an objective biological marker for objectively 
monitoring disease progression in vivo in PD. 
In more recent years, the possibility of analyzing changes in 
18
F-dopa uptake across 
the whole brain at a voxel level with statistical parametric mapping (SPM) has enabled 
several groups to explore compensatory responses in extrastriatal pathways at different 
stages of the disease. Increased 
18
F-dopa uptake, which probably reflects both a 
compensatory hyperactivity of AADC and uptake of 
18
F-dopa into serotoninergic 
terminals, in dorsolateral prefrontal cortex, anterior cingulate, and globus pallidus 
interna compared to normal controls was found in early PD patients but not in more 
advanced cases (Rakshi et al., 1999; Kaasinen et al., 2000; Whone et al., 2003). 
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Interestingly, globus pallidus interna 
18
F-dopa uptake is increased by 30–40% at the 
onset of PD symptoms - whereas putamen 
18
F-dopa uptake is reduced by 30–40% - but 
it subsequently falls as the disease advances and symptoms become more severe 
(Whone et al., 2003). Enhanced function of the dopamine projections to the globus 
pallidus interna is possibly important in maintaining a normal pattern of pallidal output 
to the ventral thalamus and motor cortex in early PD, whereas the loss of this 
compensatory pathway in advanced disease may be a pivotal step in the progression of 
the disease. 
11
C-dihydrotetrabenazine is a PET tracer that binds to the vesicular monoamine 
transporter (VMAT2). Lee and colleagues (2000) compared striatal PET 
measurements obtained with 
11
C-dihydrotetrabenazine, 
18
F-dopa, and  
11
C-methylphenidate, a DAT ligand. They found that 
18
F-dopa Ki was reduced less 
than 
11
C-dihydrotetrabenazine binding potential in the parkinsonian striatum, whereas 
the 
11
C-methylphenidate binding potential was reduced more than the  
11
C-dihydrotetrabenazine binding potential. This finding suggests the presence of 
relative AADC upregulation and DAT downregulation in the striatum of parkinsonian 
patients. It also indicates that 
11
C-dihydrotetrabenazine binding probably gives the 
most reliable measurement of the density of dopaminergic terminals. 
Presynaptic dopaminergic terminal function in PD can also be assessed with single 
photon emission computed tomography (SPECT). Several SPECT ligands (such as 
123
I--CIT, 123I-FP-CIT, 123I-altropane, and 99mTc-TRODAT-1) are available for 
imaging DAT. Most of these ligands bind non-selectively to dopamine, noradrenaline, 
and serotonin transporters. However, since the majority of transporters within the 
striatum are dopaminergic, reductions in striatal uptake of these tracers provide a 
useful marker of DAT functional loss in that region. It must be taken into account that 
DAT binding may underestimate true terminal density due to the relative 
downregulation of DAT in remaining neurons as a response to reductions in synaptic 
dopamine. Additionally, there is evidence that DAT binding decreases with age (3.3 % 
to 10% per decade) in healthy subjects (vanDyck et al., 1995; Tissingh et al., 1997; 
Pirker et al., 2000).  
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The assessment of presynaptic dopaminergic dysfunction with PET has some 
important clinical applications which will be discussed below. 
 
1.6.2.1.1 Detection of preclinical disease 
In several studies, evaluation of  the dopaminergic pre-synaptic system has allowed 
detection of preclinical dysfunction. In kindreds with familial PD, about 25% of 
asymptomatic family members showed abnormal reduction of putaminal 
18
F-dopa 
uptake, and around one-third of those with abnormal imaging developed clinical 
parkinsonism over a five-year follow-up (Piccini et al., 1997a). Another study by the 
same authors has reported abnormal putaminal 
18
F-dopa uptake in 18% of 
asymptomatic dizygotic co-twins and in 55% of asymptomatic monozygotic co-twins 
of patients with idiopathic PD. Subsequently, two of the ten asymptomatic 
monozygotic co-twins who had reduced 
18
F-dopa iptake developed clinical 
parkinsonism over four years while all ten co-twins showed a decrease in putaminal 
18
F-dopa uptake (Piccini et al., 1999a). Taken together, these findings suggest an 
important role for inheritance even in apparently sporadic PD. Khan and colleagues 
(2005b) have reported reductions of 
18
F-dopa uptake in caudate putamen, ventral and 
dorsal midbrain in asymptomatic carriers of a single parkin mutation compared to 
normal subjects. However, the rate of nigrostriatal dysfunction progression seems to 
be slow in these subjects suggesting that heterozygous parkin gene mutations are 
unlikely to represent a major risk factor for late onset PD (Pavese et al., 2009). 
In summary, 
18
F-dopa PET has been capable of detecting preclinical dopaminergic 
dysfunction when present in subjects who are at risk for PD. It is easy to predict that 
this ability will be of importance if neuroprotective agents become available for PD. 
 
1.6.2.1.2 Differential diagnosis between Parkinson‟s disease, essential tremor, and 
other parkinsonian syndromes 
All the above-mentioned PET tracers differentiate clinically probable PD from normal 
subjects or patients with essential tremor with a sensitivity of around 90%. Post-
neuroleptic parkinsonism can be separated from PD as 
18
F-dopa PET and DAT 
imaging show an intact pre-synaptic dopaminergic system in the former (Burn and 
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Brooks, 1993; Eerola et al., 2005). Unfortunately, the ability of 
18
F-dopa PET and 
markers of DAT binding to differentiate between the different dopamine deficient 
parkinsonian syndromes is poor due to the overlap of individual ranges of putamen 
and caudate tracer uptake in PD, Multiple System Atrophy, and Progressive 
Supranuclear Palsy patients (Burn et al., 1994).  Table 1-2 gives an overview of 
neuroimaging findings in parkinsonian syndromes. 
 
1.6.2.1.3 Evaluation of disease modifying agents in Parkinson‟s disease 
To date no treatment is available to slow down the progression of PD and agents with 
neuroprotective effects are greatly needed. Due to its capacity to objectively follow 
loss of dopamine terminal function in PD, 
18
F-dopa PET provides a potential tool for 
monitoring the efficacy of such agents. 
Over the past years, an increasing body of basic science evidences suggest that 
dopamine agonists may have neuroprotective effects by slowing down the progression 
of PD. Based on that, several clinical trials have been performed to directly compare 
the effects of dopamine agonists and LD on the natural course of PD in de novo 
patients (Table 1-3). In all these studies, the effect of the drugs on disease progression 
was evaluated using clinical and imaging outcome measures with 
18
F-dopa PET or 
123
I--CIT SPECT.  
The first 
18
F-dopa PET study to be reported was a 5-year double-blind trial comparing 
ropinirole with levodopa in 268 de novo patients (056 study) (Rascol et al., 2000). A 
small subgroup of these patients (N=45) had 
18
F-dopa PET, which showed a trend 
towards slower loss of tracer uptake in the ropinirole group (Rakshi et al., 2002).  
A more extensive 
18
F-dopa PET study (REAL-PET) was conducted over two years in 
186 patients with early PD randomized to ropinirole or levodopa (Whone et al., 2003). 
Region of interest analysis showed a significantly slower reduction in putaminal 
18
F-
dopa uptake over two years with ropinirole compared with levodopa (13.4% vs 
20.3%).  
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Table 1.2 Summary of striatal functional imaging in Parkinson’s disease and other parkinsonisms 
 
 
18
F-dopa uptake DAT binding  Dopamine D2 receptor 
binding 
Glucose metabolism 
Parkinson‟s disease reduced with a 
typical rostro-caudal 
gradient 
reduced increased in untreated 
patients/normal in treated 
patients 
 
normal or increased in the 
striatum 
MSA reduced reduced reduced reduced  
 
PSP reduced reduced reduced reduced  
 
CBD reduced reduced reduced reduced  
 
Essential Tremor normal normal normal hyperactivity of cerebellar- 
thalamo-cortical pathways 
Vascular parkinsonism normal/reduced normal/reduced normal / reduced reduced 
 
Drug-induced parkinsonism  normal normal reduced normal 
     DAT=Dopamine transporter, MSA=Multiple System Atrophy, PSP= Progressive Supranuclear Palsy, CBD=Corticobasal Degeneration 
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The PELMOPET study evaluated pergolide versus levodopa monotherapy in 294 PD 
patients over three years. Eighty-eight patients in this study underwent 
18
F-dopa PET. 
Over three years, a similar decrease in mean putaminal Ki/Occ was found in the two 
groups, although a weak trend was observed in favour of pergolide (7.9%, vs 14.5% in 
the levodopa group) (Oertel et al., 2000).  
An 
18
F-dopa PET was performed to evaluate the neuroprotective effect of riluzole 
(daily doses of 50mg and 100 mg) versus placebo in early PD. The trial was 
interrupted after the first interim analysis  (when half of the patients had completed the 
two year trial) as no clinical differences were seen between the three groups. 
Concordantly, in the subgroup of patients who had 
18
F-dopa PET similar decreases in 
mean putaminal Ki values were seen in the patients whether treated with riluzole or 
placebo (Pavese et al., 2005).  
In the CALM-PD trial, patients were randomized to double-blind therapy with 
levodopa or pramipexole. Eighty-two patients in this study had 
123
I--CIT SPECT to 
assess striatal DAT binding (Parkinson Study Group, 2002). Patients initially treated 
with pramipexole demonstrated a significantly attenuated loss of striatal 
123
I--CIT 
uptake from baseline compared with those in the levodopa group (16% vs 25.5%) at 
46 months.  
Finally, a randomized, double-blind, placebo-controlled trial has also been performed 
to assess the toxicity of levodopa by determining its effect on the rate of progression 
of PD as judged clinically and by changes in DAT availability (ELLDOPA study). 
This study failed to give a definitive answer, as clinical and imaging findings were 
discordant. Levodopa slowed the progression of PD in a dose dependent manner based 
on clinical ratings but the mean percent decline in the 
123
I--CIT uptake was 
significantly greater with levodopa than with placebo (Fahn et al., 2004). 
 
In conclusion, functional imaging studies in these trials have provided a valuable 
adjunct to clinical data but they have all failed to demonstrate an unequivocal 
neuroprotective effect of any of the agents trialled. It has been argued that several 
possible factors may have influenced and confounded the neuroimaging findings 
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including direct effects of the drug itself on tracer binding, differential compensatory 
up- or down-regulation of dopamine terminal function, and differential loss of cases 
from treatment arms. Despite these criticisms, functional imaging can offer an 
objective method of assessing disease progression in PD and remains an important 
potential adjunct for monitoring neuroprotection in this disease (Brooks, 2003). 
However, in designing future studies, which are greatly needed, all the above 
mentioned confounding factors must be addressed in order to better validate the 
imaging outcome. 
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Table 1-3. Clinical Trials of putative neuroprotective agents in Parkinson’s disease 
 
Study 
medication  
Study Name  Imaging technique Follow-up 
duration 
 
Striatal decline 
in the treated 
group 
Striatal decline in 
the comparison 
group 
Ropinirole
1
 056 
18
F-dopa PET 
 
24 months 13% 18% 
Pramipexole
1
 CALM-PD 
 
123
I--CIT SPECT 46 months 16% 25.5% 
Ropinirole
1
 REAL-PET 
 
18
F-dopa PET 24 months 13.4% 20.3% 
Riluzole 
2
 
 
NA 
18
F-dopa PET 24 months 21% (50mg) 
18% (100mg) 
 
15% 
1=compared to levodopa, 2=compared to placebo 
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1.6.2.1.4 Evaluation of restorative approaches in Parkinson‟s disease  
The goal of restorative therapies in PD is to correct the basic chemical defect of the 
disease by increasing the production of dopamine in the brain. These procedures 
include transplantation of foetal or engineered stem cells, growth factors and viral 
gene therapy. At this time, all the restorative therapies are experimental and are not 
available as treatment. Transplantation of human foetal dopamine neurons in patients‟ 
striatum has been the most investigated among these procedures and 
18
F-dopa PET has 
been used to demonstrate in vivo that graft cells survive and store dopamine. Several 
small open series showed significant clinical improvement and increases from baseline 
of 
18
F-dopa uptake after striatal grafting (Remy et al., 1995; Wenning et al., 1997; 
Piccini et al., 1999b; Hauser et al., 1999; Brundin et al., 2000; Piccini et al., 2000). 
Using 
18
F-dopa, it has been possible to demonstrate in vivo that graft cells survive up 
to 10 years. 
11
C-raclopride PET provides a marker of fluxes in synaptic dopamine and 
has been used to show that grafts are able to release dopamine following a 
methamphetamine challenge (Piccini et al., 1999b). Most importantly, grafts form 
connections in the host brain which restore activation of motor cortical areas during 
limb movement (Piccini et al., 2000).  
Unfortunately, the first two double blind controlled trials of foetal dopamine cell 
transplantation into putamen failed to replicate the promising results of the open 
studies. In fact, despite both post-mortem and 
18
F-dopa evidence of graft function, 
neither of these trials demonstrated significant clinical improvements. Nevertheless, 
there were indications that younger, less affected patients could benefit from 
transplantation (Freed et al., 2001; Olanow et al., 2003). A serious adverse event seen 
in these two trials was the occurrence of problematic “off” period dyskinesias 
affecting up to 56% of the implanted patients. It has been suggested that graft induced 
dyskinesias may be associated with uncontrolled dopamine release from grafts and 
greater baseline dopamine loss in the ventral putamen (Ma et al., 2002). A recent 
review argued against these hypotheses (Hagell et al., 2002; Piccini et al., 2006). 
Piccini and colleagues have also used SPM to interrogate functional maps of 
18
F-dopa 
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uptake of individual PD patients before and one and two years after neural transplant 
(2006). The patients with the best functional outcome after transplantation exhibited 
no dopaminergic denervation in areas outside the grafted areas either preoperatively or 
at one or two years post-operatively. In contrast, patients with no or modest clinical 
benefit showed reduction of 
18
F-dopa in ventral striatum prior to or following 
transplantation. These findings indicate that poor outcome after transplantation is in 
part associated with progressive dopaminergic denervation in areas outside the grafted 
area, a process which may have started already before surgery. 
 
Infusion of glial cell line derived neurotrophic factor (GDNF) via a catheter into the 
putamen is another restorative approach that has been tested in PD. GDNF, which is a 
potent neurotrophic factor, is known to protect dopamine neurones in rodent and 
primate lesion models of PD. Gill and colleagues have examined the safety and 
efficacy of putaminal infusion of GDNF in five patients with PD. A significant 
improvement in all UPDRS score was seen after 12 months of treatment and PET 
studies revealed a 28 % increase in putaminal 
18
F-dopa uptake (Gill et al., 2003). A 
subsequent randomized placebo-controlled study, however, failed to show a sustained 
clinical benefit of this procedure (Lang et al., 2006).  
 
1.6.2.2 Postsynaptic dopamine function 
Both PET and SPECT ligands have been used to examine post-synaptic dopaminergic 
receptor availability in PD. 
11
C-raclopride, a D2/3 receptor ligand, has been used in 
many PET studies. With one exception (Dentresangle et al., 1999), these studies have 
generally shown a mild increase in putaminal 
11
C-raclopride binding in de novo 
(untreated) PD patients suggesting an increase in D2 receptor availability in early 
stages of the disease (Rinne et al., 1993; Sawle et al., 1993; Turjanski et al., 1997). In 
one study, 
11
C-raclopride binding inversely correlated with presynaptic reduction of 
18
F-dopa uptake in patients with early disease (Sawle et al., 1993). As disease 
progresses and dopaminergic therapy is started, 
11
C-raclopride binding normalizes in 
the putamen and often decreases in the caudate (Antonini et al., 1994; Brooks et al., 
1992; Turjanski et al., 1997; Dentresangle et al., 1999). Whilst increased putaminal 
 53 
11
C-raclopride binding in de novo patients may represent a compensatory response 
involving receptor upregulation, it could equally reflect reduced competition from low 
levels of synaptic dopamine. Subsequent reduction of D2 binding in more advanced 
patients may reflect chronic exposure to dopaminergic treatment. The real significance 
of these changes in D2 receptor availability, however, remains unclear. 
Scherfler and co-workers (2006) investigated D2 receptor availability in patients with 
parkin-linked parkinsonism. Interestingly, never-treated patients, similarly to 
idiopathic PD patients, showed an increased putaminal 
11
C-raclopride binding 
compared to normal subjects, whereas levodopa-treated patients showed significant 
reductions in 
11
C-raclopride binding in both caudate and putamen. The authors 
interpreted these findings as parkin cases having a greater sensitivity to D2 
downregulation following exposure to dopaminergic medication compared with 
idiopathic PD patients. 
The availability of post-synaptic D2 receptors can also be evaluated with the SPECT 
tracer 
123
I-iodobenzamide (IBZM). Striatal 
123
I-IBZM binding is normal in patients 
with early PD and is either normal or mildly reduced in patients with more advanced 
disease (Playford and Brooks, 1992; Schwarz et al., 1993; Schulz et al., 1994). In 
contrast, striatal 
123
I-IBZM binding is more consistently reduced in multiple system 
atrophy suggesting that 
123
I-IBZM SPECT may be a useful tool for differentiating the 
two conditions (Schulz et al., 1994). 
Expression of extratriatal D2 and D3 receptors has also been investigated with the 
high affinity PET ligand 
11
C-FLB 457. Advanced but not early PD patients showed 
reduced 
11
C-FLB 457 binding in thalamus, anterior cingulate, dorsolateral prefrontal 
and temporal cortex (Kaasinen et al., 2000, 2003). The physiological significance of 
loss of extrastriatal dopamine D2 receptor function in PD patients remain to be 
ascertained but it may contribute to the occurrence of cognitive and emotional deficits. 
Striatal D1 receptor binding can be assessed with the PET tracer 
11
C-SCH23390 
(Rinne et al., 1990; Sinotoh et al., 1993; Turjanski et al., 1997). Striatal D1 receptor 
availability, as measured by this ligand, is generally preserved in de novo PD patients 
but slightly reduced in patients who have been chronically treated with levodopa in 
good agreement with post-mortem reports.  
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Dopamine D1 and D2 receptor availability changes associated with levodopa-induced 
dyskinesias have also been investigated. Two PET studies found no difference in 
striatal D1 and D2 receptor binding between stable responders and dyskinetic patients 
matched for disease duration (Turjanski et al., 1997; Kishore et al., 1997). These 
findings suggest that changes in presynaptic function and/or downstream postsynaptic 
(cellular) transmission, rather than dopamine receptor density are more likely to be 
responsible for the development of motor complications in PD.    
 
1.6.2.3 Changes in levels of dopamine in the synaptic cleft 
A number of studies have confirmed the ability of 
11
C-raclopride PET to detect in vivo 
increases in synaptic cleft dopamine levels following pharmacological or behavioural 
challenges, evidenced as decreases in D2 receptor availability (Laruelle, 2000). It has 
been estimated that a 10% reduction in the availability of D2 receptors for 
11
C-
raclopride binding reflects a five-fold increase in synaptic dopamine levels (Breier et 
al., 1997). 
Piccini and colleagues (2003) evaluated the endogenous release induced by 
methamphetamine in striatal and cortical areas in normal subjects and patients with 
advanced PD. In the PD group, the mean reductions in caudate and putamen 
11
C-
raclopride binding were significantly smaller than in the normal subjects (8% vs 17% 
in caudate and 7% vs 25% in putamen). In individual patients, the percentage 
reduction in putamen 
11
C-raclopride binding following methamphetamine correlated 
with both putaminal 
18
F-dopa uptake and UPDRS scores when withdrawn from 
medication. SPM also detected reduced striatal dopamine release after amphetamine in 
PD but, interestingly, dopamine release was preserved in cortical areas (dorsal and 
ventrolateral prefrontal and orbito-frontal areas). These findings indicate that 
dopamine release in frontal areas after a pharmacological challenge is preserved even 
in late stage of PD and support the hypothesis that reduced striatal rather than frontal 
release of endogenous dopamine may be more relevant to the executive disabilities 
associated with PD.    
11
C-raclopride PET has also been used to estimate the changes in synaptic levels of 
dopamine induced by exogenous levodopa in PD patients (Tedroff et al. 1996; de la 
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Fuente-Fernandez et al., 2001, 2004; Pavese et al., 2006). These studies have shown 
that striatal reductions in 
11
C-raclopride binding after administration of levodopa 
become larger as the disease progresses. The increasing amplitude of the synaptic 
dopamine response to levodopa with PD severity reflects a failure of terminals to store 
and so buffer swings in dopamine and so may be responsible for the emergence of 
peak-dose dyskinesias and fluctuating motor responses (de la Fuente-Fernandez et al., 
2004).  
The increased synaptic dopamine levels that result from levodopa administration in 
more advanced PD patients probably reflect the reduced dopamine storage capacity of 
the severely affected putamen. However, another possible explanation could be 
reduction of DATs available to clear the transmitter. In line with this theory, Sossi and 
colleagues (2007) found a significant negative correlation between changes in synaptic 
dopamine concentration and binding of the DAT marker 
11
C-methylphenidate. Greater 
reductions in 
11
C-raclopride, indicative of lower changes in synaptic dopamine 
concentration and lower dopamine turnover, were observed to be associated with 
lower 
11
C-methylphenidate binding. This finding suggests that DAT might play an 
important functional role in maintaining synaptic dopamine levels when oral levodopa 
is administered. Decreases in DAT availability may result in greater oscillations in 
synaptic dopamine levels concentration, contributing to the development of motor 
complications as the disease progresses.  
The relationship between clinical improvement and in vivo synaptic dopamine release 
after a single oral dose of levodopa (250 mg levodopa/25 mg carbidopa) has been 
investigated in advanced PD (Pavese et al., 2006). Individual improvements in 
UPDRS scores induced by levodopa correlated significantly with reductions in 
putaminal 
11
C-raclopride binding potential. Additionally, large putaminal 
11
C-
raclopride binding changes were associated with higher dyskinesias scores. When 
motor UPDRS sub-items were examined, improvements in rigidity and bradykinesia, 
but not in tremor or axial symptoms, correlated with putamen dopamine release. In 
summary, these findings indicate that in advanced PD the improvements of rigidity 
and bradykinesia and the presence of dyskinesias after a single dose of oral levodopa 
is governed by the levels of dopamine generated at striatal D2 receptors. They also 
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confirm that relief of parkinsonian tremor and axial symptoms is not related to striatal 
synaptic dopamine levels and presumably occurs via extra-striatal and/or non-
dopaminergic mechanisms  
Besides pharmacological challenges, endogenous release of dopamine in normal 
subjects and PD patients (less frequently) has been demonstrated during repetitive 
transcranial magnetic stimulation (Strafella et al., 2001, 2003), the performances of 
behavioural rewarded tasks (Koepp et al 1998; Lawrence and Brooks, 1999) or simple 
fingers movements (Goerendt et al., 2003) contributing to the understanding of the 
complex basal ganglia network. 
Finally, Evans and colleagues (2006) have reported that PD patients with compulsive 
use of dopaminergic drugs (Dopamine dysregulation syndrome, DDS) (Giovannoni et 
al., 2000) exhibited enhanced levodopa-induced dopamine release in ventral striatum 
compared with PD patients who are not compulsively taking their medication. Ventral 
striatal dopamine release in DDS patients correlated with self-reported compulsive 
drug “wanting” but not “liking” providing evidence that links sensitization of ventral 
striatal circuitry to compulsive drug use.  
In conclusion, the 
11
C-raclopride PET paradigm provides a valid and useful research 
tool to evaluate the function of the presynaptic terminals in both normal subjects and 
patients with dopaminergic dysfunction. 
 
1.6.3 Assessment of non-dopaminergic pathways 
PET has also been used to explore the dysfunction of non-dopaminergic 
neurotransmitter systems. 
 
1.6.3.1 Assessment of brain serotoninergic function 
Function of the serotoninergic system has been investigated in PD patients with 
several PET and SPECT ligands. 
11
C- DASB PET measures levels of the brain 
serotonin transporter (SERT), a marker of serotoninergic terminal function. In 
advanced PD patients, 
11
C- DASB binding levels have been reported to be 
significantly lower than those in controls in all examined brain areas, including 
orbitofrontal cortex (-22%), caudate (-30%), putamen (-26%), and midbrain (-29%) 
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suggesting that a modest, widespread loss of brain serotoninergic innervation is a 
feature of advanced PD. Interestingly, a non-significant 7% reduction was also 
observed in dorsolateral pre-frontal cortex, an area implicated in major depression 
(Guttman et al., 2007).  
11
C-WAY 100635 is a PET ligand which binds to serotonin 5-HT1A receptors. These 
receptors are both presynaptic somatodendritic autoreceptors localized on 5-HT cell 
bodies in the midbrain raphe nuclei, where they inhibit serotonin release, and are also 
distributed postsynaptically on cortical pyramidal neurons and on glia having the 
highest density in the hippocampus, low density in the striatum and are absent in the 
cerebellum. Doder and colleagues (2000) reported a 25% reduction of 
11
C-WAY 
100635 binding in midbrain raphe in PD patients compared to healthy controls. 
Interestingly, the magnitude of 
11
C-WAY 100635 binding reduction was similar in PD 
patients with and without a history of depression suggesting that serotoninergic loss 
may not be relevant to the development of depression in PD. However, severity of 
total tremor and resting tremor in PD correlated with decrease in median raphe 5-HT1A 
receptor binding and this observation suggests a possible role of serotoninergic 
neurons in the pathogenesis of tremor. 
 
1.6.3.2 Assessment of brain cholinergic function  
PET tracers to image the cholinergic system have also been developed and several 
reports of findings in patients with PD are now available. Cortical 
acethylcholinesterase (AChE) activity in PD with and without dementia has been 
investigated with the PET ligands 
11
C-methylpiperidin-4-yl acetate (
11
C-MP4A) and
 
11
C- methyl-4-piperidinyl propionate (
11
C-PMP), acetylcholine analogues that serve as 
selective substrates for AChE (Bohnen et al., 2003; Hilker 2005). Hilker and 
colleagues (2005) have assayed cortical AChE activity in PD with 
11
C-MP4A PET. 
They found that cholinergic function was lost throughout the cortex in parallel with 
loss of striatal dopaminergic function in PD, demented cases showing the most severe 
reductions. Bohen and colleagues (2003) used 
11
C-PMP PET to investigate cortical 
AChE activity in PD with and without dementia and patients with Alzheimer‟s 
disease. The greatest reduction in cortical AChE activity was again found in PD 
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patients with dementia (PDD). Interestingly, patients with Alzheimer‟s disease, despite 
being matched to PD patients for dementia severity, showed less reduction in 
cholinergic innervation than PDD, the lateral temporal cortex being selectively 
targeted. These results provide a rationale for the usage of AChE inhibitors in PD 
dementia as well as Alzheimer‟s disease. 
Muscarinic acetylcholine receptor availability has also been assessed in PD. Asahina 
and colleagues (1998) reported that binding of the muscarinic M1 receptor PET ligand 
11
C-NMPB was significantly higher in the frontal cortex of PD patients. One of the PD 
patients in this study had dementia and he had the highest binding in frontal and 
temporal areas. The authors suggested that the increased muscarinic receptor 
availability in frontal cortex in PD reflected denervation hypersensitivity caused by 
loss of ascending cholinergic input to the cortex.  
Bohnen and colleagues (2009) have recently investigated the role of cholinergic and 
dopaminergic neurotransmission in the occurrence of recurrent falls in patients with 
PD. Seventeen PD patients with a previous history of recurrent falls and 27 patients 
who had no falls were investigated. Patients were divided into fallers and non-fallers 
based on their answer to item 13 of the UPDRS. Patients with a score of 1 or higher 
were classified as fallers. Each patient underwent 
11
C- PMP PET to assess brain AchE 
activity and 
11
C-DTBZ PET to measure nigrostriatal dopaminergic function. There 
was no significant difference in nigrostriatal dopaminergic activity between fallers and 
non-fallers, providing further evidence that the impairment of nigrostriatal 
dopaminergic transmission does not play a direct role in the occurrence of tendency to 
fall in PD. Conversely, the PD fallers had significantly lower thalamic AchE activity 
than controls and PD non-fallers. Cortical AchE activity was also reduced in the PD 
fallers compared to non-fallers though this did not reach statistical significance. Loss 
of thalamic cholinergic function is likely to reflect loss of input from the degenerating 
PPN nucleus, which is the principal source of cholinergic innervation to the thalamus. 
However, AchE activity in the PPN itself was not measured in this study due to the 
small size of this nucleus and resolution limitations of PET. In conclusion, this paper 
suggests an association between cholinergic dysfunction and fall status in PD, 
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providing possible new targets for pharmacological interventions in those patients with 
poor balance and a tendency to fall.  
 
1.6.3.3 Assessment of brain noradrenergic function 
11
C-RT132 is a PET tracer that binds with similar affinity to both dopamine and 
noradrenaline membrane transporters. PD patients with depression have been reported 
to have lower 
11
C-RT132 binding in locus coeruleus and several areas of the limbic 
system than non-depressed PD patients (Remy et al., 2005).  
In areas with low dopaminergic innervation such as locus coeruleus, 
11
C-RT132 
mainly reflects the density of noradrenergic neurons. In the other areas a combined 
involvement of both dopaminergic and noradrenergic pathways is more likely. This 
finding suggests an important role of noradrenaline but also limbic dopamine 
dysfunction in the pathogenesis of depression in patients with PD.  
 
1.6.3.4 Assessment of other neurotransmitter systems 
The striatal and extrastriatal opioid binding in PD has been investigated by Piccini and 
colleagues (1997b) with 
11
C-diprenorphine PET. They found significantly reduced 
striatal and thalamic opioid binding in dyskinetic but not non-dyskinetic patients. SPM 
showed additional binding reductions in cingulate and prefrontal areas. These findings 
are compatible with enhanced endogenous opioid transmission, which in turn would 
dampen inhibitory output from the internal segment of the globus pallidus to thalamus, 
possibly causing dyskinesias.   
 
1.6.4 Changes in cerebral metabolism and cerebral blood flow 
18
F-deoxyglucose (FDG) PET is a marker of hexokinase activity which regulates 
regional cerebral
 
glucose metabolic rate (rCMRglc). In contrast to other 
neurodegenerative parkinsonism such as multiple system atrophy and progressive 
supranuclear palsy where resting striatal metabolism is reduced, in PD it is usually 
normal or slightly elevated (Antonini et al., 1997; Jul et al., 2004).  
The distinctive patterns of regional glucose metabolism in each of these conditions can 
be useful for differentiating PD from other parkinsonisms. Eckert and co-workers 
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(2005) reported that 
18
FDG PET separates PD from other parkinsonian syndromes 
with 95% sensitivity and 94% specificity when computer assisted methodologies are 
applied to discriminate patterns of rCMRglc covariance at a voxel level. The relative 
pallidal and putaminal hypermetabolism observed in PD may represent metabolic 
compensatory responses to dopamine deficiency (Lozza et al., 2002).  
Other metabolic abnormalities observed in PD include thalamic hypermetabolism and 
regional metabolic decrements in the lateral and mesial premotor cortex, the 
supplementary motor area, the dorsolateral prefrontal cortex, the temporo-parietal 
cortex, and the parieto-occipital association regions (Eidelberg et al., 1990; Antonini et 
al., 1998; Hu et al., 2000; Fukuda et al., 2001). 
The presence of cognitive impairment and depression are associated with further 
reductions in temporo-parietal and frontal metabolism (Hu et al., 2000; Berding et al., 
2001; Mentis et al., 2002), whereas treatment with dopaminergic drugs can normalise 
metabolic patterns in PD. These confounding factors need to be considered when 
designing 
18
FDG PET studies in PD. 
Several studies have compared changes in neuronal activity during the execution of 
simple motor tasks, such as cued or freely chosen finger or hand movements, in 
normal subjects and PD patients. The striatum receives input from all cortical areas 
and, via the internal pallidum and the ventral thalamus, in turn sends output principally 
to frontal lobe areas (premotor, supplementary motor, and prefrontal areas) that are 
related with motor preparation and planning. The basal ganglia are involved in many 
neuronal pathways subserving emotional, motivational, associative and cognitive 
functions. The effects of the striatal dysfunction in PD and the changes induced by 
dopaminergic treatments on this complex network of neuronal circuits has been 
extensively studied with PET and more recently with fMRI. A short summary of these 
studies will be reported in this section.  
Using H2
15
O PET to detect changes in regional cerebral blood flow (rCBF), Playford 
and colleagues (1992) found that PD patients showed reduced neuronal activity in the 
rostral supplementary motor area (SMA) and right dorsolateral prefrontal cortex 
(DLPFC) compared to normal subjects during the execution of free-choice joystick 
movements.  Similar findings were observed in PD patients during the execution of 
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fingers movements (Jahanshahi et al., 1995). These findings suggest reduced 
thalamocortical activation in PD. The administration of the non-selective 
dopaminergic agonist apomorphine normalized the activation pattern as patients 
switched to “on” state (Jenkins et al., 1992). PET studies and, more recently, fMRI 
studies have also shown higher activation in lateral premotor and parietal areas in PD 
patients compared to healthy subjects during sequential manual movements (Samuel et 
al., 1997; Catalan et al., 1999; Sabatini et al., 2000; Haslinger et al., 2001). The 
hyperactivity in these areas may represent compensatory mechanisms to loss of medial 
frontal activation but this is still debated. 
 
1.6.5 Contribution of neuroinflammation to the pathogenesis of Parkinson‟s disease 
Microglia constitute 15% of normal white cells and are the natural immune defence of 
the brain. They are normally in an inactive state but any change in brain milieu due to 
trauma, stroke, infection, or neurodegeneration can cause them to become activated. 
The isoquinoline 
11
C-(R)-PK11195 PET is a selective in vivo marker of activated 
microglia. The 18 kDa translocator protein (TSPO), which was previously known as 
the peripheral benzodiazepine receptor, is expressed on the mitochondrial membranes 
of activated but not resting microglia and has a binding site for 
11
C-(R)-PK11195  
(Banati et al., 2000). Two papers have reported significant increases in 
11
C-(R)-
PK11195 binding in both striatal and extrastriatal regions in PD patients compared to 
normal controls (Ouchi et al., 2005; Gerhard et al., 2006). Increased levels of activated 
microglia have also been observed in patients with multiple system atrophy (Gerhard 
et al., 2003). Taken together these findings support the hypothesis that 
neuroinflammatory responses, as evidenced by activated microglia, contribute to 
neuronal loss in PD and in other neurodegenerative diseases. 
 
1.7 Functional neuroimaging in genetic forms of Parkinson‟s disease  
Due to the limited series of post-mortem cases, functional neuroimaging techniques 
play an important role to better understand the pathological processes of genetic forms 
of PD and the possible differences from the more common idiopathic PD. 
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In PARK1 due to mutations in the alpha synuclein gene striatal
 18
F-dopa uptake 
reductions resemble those observed in idiopathic PD with a caudal-rostral gradient 
loss of uptake (Samii et al., 1999). A similar pattern is also observed in another 
autosomic dominant form PARK8 caused by mutations in the gene for LRRK2 
(Adams et al., 2005). Autosomic recessive forms of PD, PARK2 (parkin-mutations), 
PARK6 (Pink1), and PARK7 (DJ1) are associated with more severe, symmetrical, and 
uniform reduction of 
18
F-dopa uptake (Broussolle et al., 2000; Hilker et al., 2001; 
Khan et al., 2002b; Bonifati et al., 2003; Scherfler et al., 2004).  
Results from a recent study with clinical and PET longitudinal follow-up in patients 
with parkin-linked confirm clinical impression that disease progression in these 
patients is slower than that of idiopathic later onset PD patients (Pavese et al., 2009). 
In the group of patients with parkin-linked parkinsonism, the loss of nigrostriatal 
function, as measured by annual reduction 
18
F-dopa uptake, occurred at a slow rate 
(0.5% and 2% annual reduction in putamen and caudate 
18
F-dopa uptake over five 
years). This is slower than in idiopathic PD patients (Morris et al., 1998) where 
putamen 
18
F-dopa uptake has been reported to decline annually by around 9% of 
baseline (5% of the normal mean) while caudate uptake decreases at a slower rate 
(3.5% of baseline; 2.8% of the normal mean). Reduction of midbrain 
18
F-dopa uptake 
in the parkin patients can also be detected at a rate of 0.59% per annum. The annual 
rate of decline in the total UPDRS scores was 1.2 %, slightly slower than the 1.58% 
reported for PD (Jankovic and Kapadia, 2001). 
 
D2 receptor availability, measured with 
11
C-raclopide PET, has been reported to be 
normal in PARK8 (Adams et al., 2005) and in treated PD, but is reduced in treated 
parkin-patients (Hilker et al., 2001; Portman et al., 2001; Scherfler et al., 2004, 2006). 
These findings suggest a greater susceptibility of D2 expression to downregulation 
following exposure to dopaminergic medication in parkin-disease than in idiopathic 
PD.  
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Aim and research questions to be 
addressed 
 
2 
 
2.1 Aim and research questions to be addressed 
A better understanding of the pharmacological involvement of systems beyond the 
nigrostriatal dopaminergic pathway is still required in PD. The heterogeneous nature 
of the disease, once motor symptoms develop, suggests that the onset and progression 
of non-dopaminergic involvement is highly variable. Onset and progression of non-
dopaminergic involvement will depend on the cause/s of the syndrome. 
Approximately, 5% of PD patients have a clear familial aetiology with a recessive or 
dominant Mendelian mode of inheritance. Serotoninergic and noradrenergic functions 
in patients with genetic parkinsonism have yet to be investigated in vivo. A better 
understanding of the neurodegenerative process in these monogenic variants of PD 
could potentially shed light on the molecular pathogenesis of non-dopaminergic 
dysfunction in idiopathic PD. 
 
The neurochemical substrates underlying the numerous non-motor symptoms are 
unclear and remain to be established. 
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In the present project I have used PET imaging to: 
 
1) assess in vivo the involvement of non-dopaminergic pathways in idiopathic  PD 
and in genetic forms of parkinsonism by using 
18
F-dopa PET as a marker of 
monoaminergic function in the brain. 
 
2) assess with serial 18F-dopa PET scans the rate of progression of the degenerative 
process in extrastriatal monoaminergic structures, including locus coeruleus, 
hypothalamus, ventral anterior thalamus, and red nucleus.  
 
3) elucidate possible pathophysiological mechanisms underlying chronic fatigue in 
PD by investigating dopamine and serotonin function in the basal ganglia and in 
the limbic system of PD patients with a without a complain of fatigue. 
 
4) verify the hypothesis that 18F-dopa PET can be used to evaluate the distribution 
and the function of serotoninergic systems in the brain by assessing correlations 
between 
11
C-DASB binding values and 
18
F-dopa Ki values within serotoninergic 
structures. 
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Methodology 
 
3 
 
3.1 Introduction 
 
This chapter outlines the methodology employed in the studies reported in the 
experimental chapters of this thesis. The first section of the chapter provides a 
background description of basic principles of PET scanning and the characteristics of 
the PET scanners used for the experiments. The following sections describe the 
radioligands administered and the standard processing procedures that have been used 
to analyze the PET images. 
The characteristics of the subjects investigated, the clinical assessments performed, 
and the statistic applied in each study will be described in the methods section of the 
respective experimental chapters. 
 
3.2 PET (Positron Emission Tomography) 
 
3.2.1 Introduction 
PET is a scintigraphic technique that employs extremely short-lived radioisotopes 
linked to chemical compounds of biological interest. Following intravenous injection, 
PET radiotracers can be monitored in body organs in real time and, depending upon 
their metabolic fate, provide functional information such as blood flow, receptor 
density, metabolic rates in health and disease. Therefore, the technique has been 
widely used in several medical specialties including neurology, psychiatry, oncology, 
and cardiology. Within the neurosciences, brain PET has been used in the 
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investigation of dementia, epilepsy, stroke, PD, Huntington‟s disease and other 
neurodegenerative disorders. 
 
After administration, positron-emitting radioisotopes, which have an excess of 
protons, decay and are detected as pairs of photons (annihilation event). The photons 
travel in opposite directions and are detected simultaneously as a coincident event by 
the PET scanner.  The tomograph includes multiple rings of bismuth germanate 
(BGO) crystal detectors coupled with photomultiplier tubes. When two photons are 
detected in close temporal proximity by two opposed detectors in the ring, they are 
likely to have originated from a single annihilation event in the body, somewhere 
along the line between the two detectors. These lines of coincidence are recorded by 
the PET computer system. By measuring the number and directions of these lines a 
quantitative 3D image of tracer distribution can then be reconstructed using 
backprojection. More details about PET production of PET radiotracers and physical 
properties of radioactive decay by positron emission are provided in the paragraphs 
below. 
 
3.2.2 Production of positron emitting isotopes 
The short-lived radioisotopes (
11
C, 
18
F) employed in PET are typically produced in a 
cyclotron which acts to accelerate subatomic particles such as protons, deuterons, or 
helium nuclei. A beam of these particles is then directed to bombard stable elements 
on a target leading to formation of positron emitting unstable isotopes.  The cyclotron 
contains both a magnetic field and an electric field at right angles within a vacuum 
chamber (Birattari et al., 1987). The core of the cyclotron contains an ion source 
emitting charged particles, generally protons or deuterons. Following emission, the 
charged particle is accelerated by the electric field along a path, which is made circular 
by the presence of the magnetic field. As the charged particle accelerates it gains 
energy until it is focused by an electrostatic deflecting beam to bombard a target. 
Once the radioisotope has been produced, the next step in the production of the 
radiotracer is the incorporation of the isotope into an organic compound of biological 
interest. This is achieved by replacing one atom of the organic compound with the 
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radioactive nuclide, without significantly affecting the biochemical properties of the 
initial compound. 
 
3.2.3 Positron detection 
The radiotracer is usually administered by intravenous bolus injection and, after an 
appropriate uptake period, the concentration of tracer in the tissue, in our case the 
brain, is measured by the tomograph.  
During the imaging period, the unstable nucleus of the short-lived isotope decays into 
a more stable structure by emitting positrons, subatomic particles having the same 
mass and energy as the electrons but exhibiting a positive charge. Each emitted 
positron travels for a short distance from the site of origin (usually 1-3 millimeters) 
and gradually loses kinetic energy as it passes through the surrounding tissue. When 
most of its kinetic energy has been lost, the positron combines with an electron in the 
immediate area.  This reaction results in the annihilation of both particles, their mass 
being conserved as energy in the form of emission of two high-energy 511 keV 
photons of electromagnetic gamma radiation (gamma rays). The two 511 keV photons 
are emitted in opposite directions at approximately 180 degrees from each other and 
travel through the brain and the skull before reaching the scintillation crystals of the 
PET detector ring at near opposite sites (Figure 3-1). When they absorb gamma rays, 
scintillation crystals emit low energy photons of visible light. The photomultipler tube 
then enhances the light signal and converts the scintillation events into electrical 
pulses. 
When two photons are detected within a very short time interval (on the order of 6 to 
12 nanoseconds) by opposed detectors in the ring, they are assumed to have arisen 
from the same annihilation event. This is referred to as a coincidence event and is 
indicative that the annihilation occurred at some point along a straight line, called 
coincidence line or line of response (LOR), between the two detectors. By detecting 
multiple LORs from the emission site a reasonably precise localization of the origin of 
the annihilation events can be computed. 
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During a PET scan several million coincidence events are recorded forming a large 
number of coincidences lines. These are recorded by the PET computer system and 
saved as a two-dimensional matrix referred to as a sinogram (Figure 3-2). More 
 
 
 
 
 
 
 
 
 
 
Figure 3-1 Diagram of a PET detector ring showing two photons from a single 
annihilation event in the body reaching opposite crystals 
 
precisely, a sinogram is a histogram of the response count for a particular pair of 
detectors. 
 
 
 
Figure 3-2 Diagram of a PET acquisition and image reconstruction 
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The size of the crystals in the detection system is a major factor determining the 
resolution of the PET scanner. The maximal theoretical image resolution possible is 
1.1 to 1.2 times greater than the width of the individual detector crystals. Ring 
diameter, detector decoding systems, and the average distance positrons travel before 
annihilating with an electron, however, act to lower the spatial resolution of the PET 
scanner.  
Early PET scanners had only a single ring of detectors and the acquisition of data and 
subsequent reconstruction was restricted to a single transverse plane (2D 
reconstruction). Modern scanners contain multiple rings, resulting in an effective 
cylinder of detectors and allow coincidences to be detected between rings as well as 
within rings and subsequent reconstruction of the entire brain volume (3D 
reconstruction). 3D reconstruction offers higher sensitivity (because more 
coincidences are detected and used) and, therefore, less noise but is more sensitive to 
the effects of scatter and random coincidences described in the next paragraph.  
 
3.2.4 Detection of random and scattered events and attenuation correction  
Before a three dimensional image can be reconstructed the sinogram data must be 
corrected for false positive coincidence and for absorption of photons by the body 
(attenuation correction). 
There are two types of false positive coincidence that can be recorded by the PET 
computer system known as random and scattered events.  
Random coincidence happens when two photons from different individual events are 
detected within coincidence resolving time and computed as a true event. The most 
common
 
method of correcting for random coincidences is the real-time
 
subtraction of a 
delayed coincidence channel (Dyson, 1960; Noll, 1999). Briefly, random events are 
identified by introducing a significant delay into one side of the coincidence detection 
circuit. Under these circumstances, coincidences resulting from a single annihilation 
event are not detected and the number of coincidences found is a good estimate of the 
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number of random coincidences. The estimated number of random coincidences is 
then subtracted from the measured data in each LOR. 
 
Scattered coincidences occur when one or both gamma rays have been deflected off 
line by an interaction with an atomic nucleus in the tissue before being detected. If the 
remaining energy of the gamma rays is above the energy threshold of the detector 
window, the coincidence will still be counted. However, the line of assumed response 
will be between the wrong pair of detectors and this will cause the site of the 
annihilation event to be falsely localized. Several methods are available in order to 
correct for scatter during the reconstruction process. In the case of the PET studies 
reported in this thesis a dual-window scatter correction was applied (Shao et al., 1996; 
Grootoonk et al., 1996). Briefly, dual-window scatter correction is applied by adapting 
the detector properties such that the gamma rays are collected at two different energy 
windows simultaneously, the data window, set at the energy level of emitted 
unscattered photons, and the scatter window, set at a lower energy level appropriate 
for scattered photons (Grootoonk et al., 1996). 
 
Although the photons of gamma radiation produced by the annihilation event have 
high 511 keV energy levels, some of them are absorbed by the surrounding tissue 
through which they have to pass to reach the detectors. This process is known as 
attenuation and results in a loss of detection of true coincidence events, which can 
range between 50 to 95%. Loss of counts due to attenuation increases image noise, 
image artefacts, and image distortion. Therefore, attenuation correction of data is 
necessary in order to obtain accurate qualitative and quantitative PET measurements 
(Phelps, 1997). 
The tissue attenuation is measured by performing two additional scans, known as 
blank and transmission emission scans. The blank emission scan is performed with no 
subject in the camera to detect levels of background radiation. The transmission scan 
is generally performed prior to the injection of the radiotracer by exposing the subject 
to be imaged to an external rotating positron source emitting 511 keV gamma 
radiation. The tissue attenuation of 511 keV photons along all coincidence lines is then 
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calculated as the ratio of the blank and transmission scan data (measured blank 
count/measured transmission count) and this factor is applied to each LOR in the 
emission data (de Kemp and Nahmias, 1994; Xu et al., 1991). 
 
Sinogram data must also be corrected for detector non-uniformity, detector dead-time 
correction (refractory period after the detection of a photon) and detector-sensitivity 
correction (for both inherent detector sensitivity and changes in sensitivity due to 
angle of incidence). Non-uniformity is corrected by scanning a phantom source of 
radioactivity and calibrating the detectors. Dead time is rarely a problem with 
radiopharmaceuticals due to the low count rates involved. Specific details regarding 
correction for angles of incidence are outside the remit of this thesis and will not be 
further discussed.  
 
3.2.5 PET image reconstruction 
After these corrections have been performed the image can be reconstructed using a 
filtered back-projection algorithm. The algorithm, similar to that used in computed 
tomography (Kinahan and Rogers, 1989), comprises the projection of sinograms 
recorded at different angles to produce a 3D image of tissue radioactivity.  
After reconstruction, data are presented in the form of a series of three-dimensional 
images acquired during contiguous periods of time during the scan (3D dynamic 
images). The scanning period is divided into time intervals, generally referred to as 
time frames. The length of the time frames is variable and defined according to the 
characteristics of the radiotracer. The first frames following radiotracer injection 
reflect blood flow and radioligand delivery and are generally very short (15-60 
seconds). Towards the end of the scan, the time frames become longer in order to 
maintain reasonable signal to noise ratio despite the decrease in detected count rate 
due to radioactive decay over the scanning period. The total length of the scanning 
period depends on the characteristics of each specific tracer and the kinetic model 
required for its analysis. 
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3.2.6 PET scanners 
PET scanning took place at the Cyclotron Building, Hammersmith Hospital, in the 
facility of Hammersmith Imanet, GE Healthcare, London, UK. I used two different 
PET scanners for the research studies in this thesis. However, in each study, all 
patients were scanned with a single camera, as specified in the respective experimental 
chapters.  
The ECAT EXACT HR++ (CTI/Siemens 966) camera covers an axial field of view of 
23.4 cm and provides 95 transaxial planes. The tomograph has a spatial resolution of 
5.6 mm after image reconstruction (Spinks et al., 2000). A transmission scan, used to 
correct for attenuation of emitted radiation by skull and soft tissues, was acquired 
using a single rotating photon point source of 150 MBq of 
137
Cs.  The high resolution 
and sensitivity of this tomograph permits interrogation of the function of subcortical 
nuclei. 
The ECAT EXACT HR+ (CTI/Siemens 962) camera covers an axial field of view of 
15.5 cm and provides 63 transaxial planes. This tomograph has an axial resolution of 
5.4 mm full width at half maximum (FWHM) and a transaxial resolution of 5.6 mm 
FWHM at 10 cm distance from the centre (Brix et al., 1997).  Head position was 
checked using a short two-minute transmission scan using an external rotating 
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Ge 
source. A 10-minute transmission scan was then performed to measure tissue 
attenuation. 
Subjects were positioned in the scanners such that their orbitomeatal plane was 
parallel to the transaxial plane of the tomograph. Head position was carefully 
monitored with a video camera and by direct observation throughout. 
 
3.3 
18
F-dopa 
 
3.3.1 Introduction  
I have used 
18
F-dopa [
18
F-Fluorodopa] PET, a marker of neuronal AADC activity, to 
assess the function of the monoaminergic systems in PD patients (Figure 3-3). 
The use of 
18
F-dopa PET to visualize the nigrostriatal dopaminergic pathway in the 
living brain was first introduced by Garnett and colleagues in 1983.  Following 
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intravenous administration, the metabolic pathways for 
18
F-dopa are qualitatively 
 
 
 
 
 
 
 
 
 
 
Figure 3-3 Dash formula of 
18
F-dopa and PET image of 
18
F-dopa uptake (axial plane 
at basal ganglia level) 
 
similar to those for exogenous levodopa, although quantitative differences have been 
observed (Firnau et al., 1988; Melega et al., 1990). Similar to exogenous levodopa, 
18
F-dopa is transported across the blood-brain barrier by the neutral amino acid carrier 
(Leenders et al., 1986) and then converted by AADC to 
18
F-dopamine (Firnau et al., 
1987). The rate of AADC activity is the limiting step in 
18
F-dopamine formation. 
Striatal 
18
F-dopamine is then metabolised to 
18
F- DOPAC (dihydroxyphenylacetic 
acid) and 
18
F-HVA (homovanillic acid) by monoamine oxidase B and catechol-O-
methyltransferase.  
A comprehensive kinetic analysis of striatal 
18
F-dopa uptake and washout is complex 
because of its peripheral and central metabolism. However, over the 90 minutes 
duration of a PET scan it is reasonable to assume that the fluorine radioisotope taken 
up by the brain remains trapped within the nerve terminals as 
18
F-dopamine and its 
metabolites. 
18
F-dopa uptake in the striatum can, therefore, be regarded as irreversible 
and analysed as an influx constant using a graphical approach to linearise the time 
course of the data.  
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Multiple-time graphical (Patlak) analysis evaluates the unidirectional uptake of tracer 
from the time course of the total tissue radioactivity. The method is suitable for single 
or multiple compartment models, as long as net uptake is irreversible, in other words 
the tracer is trapped in the region and cannot leave during the study. It assumes that 
the flow of the injected tracer is unidirectional into the compartment, follows first-
order kinetics and, if the tracer is metabolised, it occurs only in an irreversible manner 
so that the metabolites are also irreversibly trapped. The method also requires the 
identification of: (i) a lower time limit when all tissue free and exchangeable tracer 
pools have reached equilibrium with the arterial plasma, and (ii) an upper time limit 
before significant product loss occurs. In conclusion, graphical analysis is based on the 
assumption that following equilibration between exchangeable tissue pools and 
plasma, the apparent distribution space of the tracer, plotted against the normalised 
plasma integral of the tracer, will increase linearly as long as there is no product loss. 
The slope of the linear portion of the graph is an influx rate constant (Ki) and reflects 
specific tracer accumulation.  
The Patlak plot can also be employed using a non-specific tissue reference input 
function as a replacement for the plasma input function provided there is a region 
which represents the exchangeable tissue compartment in areas of specific binding 
(Patlak and Blasber, 1985). Striatal 
18
F-dopa Ki values are commonly computed by 
graphical analysis using the occipital cortex as reference input function, as this region 
is known to have the lowest dopamine concentration (Brown et al., 1979) and lowest 
AADC activity (Lloyd and Hornykiewicz, 1972). The cerebellar cortex can also be 
used as a reference region. However, the degree of cerebellar volume available 
depends on the PET scanner‟s field of view. 
In summary, the pattern of regional 
18
F-dopa uptake in the brain depends upon five 
processes: 1) passage of the ligand through the blood-brain barrier; 2) uptake into 
presynaptic terminals; 3) conversion to 
18
F-dopamine by AADC; 4) trapping of 
18
F-
dopamine in neurons (5) degradation of 
18
F-dopamine. Among these processes, the 
principal determinants of uptake as shown by the influx constant Ki, are the AADC 
activity and the density of the axonal plexus.  
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3.3.2 Extra-striatal uptake of 
18
F-dopa 
In the striatum where the nigrostriatal terminals are the major monoaminergic 
constituent, 
18
F-dopa uptake reflects presynaptic dopaminergic function. Indeed, as 
mentioned in Chapter 1 (paragraph 1.6.2.1), post-mortem and animal studies have 
shown that striatal 
18
F-dopa uptake correlates with both nigrostriatal cell counts and 
levels of dopamine in striatal terminals (Snow et al., 1993; Pate et al., 1993). However, 
18
F-dopa PET can also be used to evaluate the distribution and the function of the 
other monoaminergic systems in the brain. 
18
F-dopa uptake, when expressed as an 
influx constant, Ki, reflects the activity of AADC contained in the axonal plexus 
(Snow et al. 1993) and AADC is contained in the terminals of all monoaminergic 
neurons, including noradrenaline and serotonin systems. Measurements of 
18
F-dopa 
uptake into serotoninergic and noradrenergic structures, therefore, provide an 
indication of the functional integrity of these nerve terminals (Brown et al. 1999). 
Moore and colleagues have demonstrated that 
18
F-dopa uptake can be reliably 
quantitated in a variety of extra-striatal regions in normal brain (2003) and in patients 
with idiopathic PD (2008). Figure 3-4 shows examples of 
18
F-dopa uptake in the 
hypothalamus and midbrain raphe of a healthy volunteer. 
 
 
 
Figure 3-4. 
18
F-dopa uptake in the hypothalamus and midbrain raphe of a healthy 
volunteer 
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3.3.3 Radiopharmaceutical preparation 
18
F-dopa was supplied by Hammersmith Imanet.  
The radiotracer was synthesized as previously described (Namavari et al., 1992) by 
18
F-fluorine reaction with the DOPA precursor (4, 5-Di-BOC-N-ormyl-2-trimethyl-L-
phenylalanine ethyl ester).  
18
F-fluorine was produced by the 
18
O(p,n) 
18
F reaction, 
bombarding enriched 
18
O-oxygen with 19MeV protons at 40A for 30-45 minutes 
followed by a second bombardment of 19 MeV protons on 0.2% fluorine in argon 
during which time the 
18
F bound to the target walls is isotopically exchanged.   
A sample from each synthesis is then taken for quality assurance and analysed using 
reverse phase high pressure liquid chromatography.  
The radiochemical purities of synthesis requested to proceed with injection was 95.0% 
or higher. 
 
3.3.4 Patient preparation and scan protocol 
All patients were asked to stop their dopamine replacement therapy for at least 12h 
before PET. Cabergoline was stopped 3 days before scanning because of its longer 
half-life. To improve availability of 
18
F-dopa to the brain, patients were pretreated 
with 150 mg of carbidopa, a peripheral inhibitor of AADC, 1 hour prior to scanning 
(Hoffman et al., 1992). 
The scanning protocol involved list mode (event-by-event) 3D acquisition over 95 
minutes subsequently divided into 26 time frames following a bolus injection of 110 
MBq of 
18
F-dopa. 
 
3.4 
11
C-DASB [N,N-dimethyl-2-(2-amino-4-cyanophenylthio) benzylamine]  
 
3.4.1 Introduction  
11
C-DASB [N,N-dimethyl-2-(2-amino-4-cyanophenylthio) benzylamine]  PET, is a 
marker of serotonin transporter (SERT) binding and reflects functional integrity of the 
serotoninergic system in PD patients (Figure 3-5). SERTs facilitate the inactivation of 
serotonin by uptake from the synaptic cleft into the presynaptic nerve terminals. SERT 
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availability on the serotonin presynaptic terminals is thought to reflect the degree of 
serotonin innervation in that region.  
11
C-DASB has high specificity and sensitivity for SERT (nanomolar affinity) and 
much lower affinity for the dopamine and norepinephrine transporters (micromolar 
 
 
 
 
 
 
 
 
Figure 3-5 Dash formula of 
11
C-DASB and PET image of 
11
C-DASB binding (axial 
plane at basal ganglia level) 
 
affinity) (Houle et al., 2000). The main advantage of 
11
C-DASB over other SERT 
radiotracers available for human brain imaging, such as 
11
C (+)McN5652, is its higher 
ratio of specific binding to non-specific binding in vivo. The binding potential values 
(an index of available receptor density proportional to the ratio of Bmax:Kd) found 
with 
11
C-DASB PET are approximately two to threefold greater than those found with 
11
C- (+)McN5652 PET in the same cerebral areas when using the same modelling 
method. Furthermore, binding potential values found with 
11
C-DASB PET are reliable 
for most brain regions under test-retest conditions (Kim et al., 2006). For all these 
reasons, 
11
C-DASB PET has represented a major advance in brain imaging of the 
SERT in living humans.  
11
C-DASB PET images in humans show high binding in the midbrain, thalamus and 
striatum, moderate binding in the medial temporal lobe and anterior cingulate, and low 
binding in neocortex (Frankle et al., 2006). The cerebellum (excluding vermis) is 
regarded as a region with extremely low or undetectable specific SERT binding  
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(Cortes et al., 1988). A recent study has reported that SERT density in the cerebellar 
cortex is less than 3% of the striatal values, as measured with Western blot method 
(Kish et al., 2005). I have therefore used the cerebellum (excluding vermis) as a 
reference region for the analysis of 
11
C-DASB PET images in this research project. 
 
3.4.2 Radiopharmaceutical preparation 
11
C-DASB was supplied by Hammersmith Imanet.  
11
C was produced by the 
14
N(p, a)
11
C reaction using natural nitrogen gas 
The radiotracer was synthesized from the precursor (3-amino-4-(2-
methylamminoethylphenylsulphanyl)-benzonitrile by alkylating with 
11
C-methyl 
iodide.  
11
C-Methyl iodide was prepared by reduction of 
11
CO2 with LiAlH4 to 
11
CH3OH followed by iodination with hydriodic acid.  The crude drug substance was 
then purified by preparative reverse phase high pressure liquid chromatography.  The 
radiochemical purities of synthesis requested to proceed with injection was 95.0% or 
higher. 
 
3.4.3 Patient preparation and scan protocol 
All patients were asked to stop their dopamine replacement therapy for at least 12h 
before PET. Cabergoline was stopped 3 days before scanning because of their longer 
half-life. The patients were also requested to refrain from consuming alcohol, coffee or 
caffeine or xanthine containing products from 12 hours prior to radiotracer 
administration.Smoking or other use of nicotine-containing products was not allowed 
during the study. 
The scanning protocol for 
11
C-DASB involved 3D acquisition over 90 minutes and 30 
seconds (17 time frames) following a bolus injection of 450 MBq of 
11
C-DASB.  
 
3.5 Analysis of 
18
F-dopa and 
11
C-DASB PET images 
 
3.5.1 Introduction  
The following paragraphs and the flowcharts in figure 3-6 and figure 3-7 outline the 
standard processing procedures used to analyze 
18
F-dopa and 
11
C-DASB PET images. 
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Study specific procedures will be described in details in the respective experimental 
chapters along with a brief summary of the standard procedures employed. 
 
3.5.2 Generation of parametric images of 
18
F-dopa 
The reconstructed dynamic image series of 
18
F-dopa uptake were analyzed using 
Kronos, software developed in-house and written in IDL (Interactive Data Language; 
Research Systems International). The software, which has been previously validated 
(Rakshi et al., 1996), creates parametric images of 
18
F-dopa influx constant Ki„s 
[mL∙min-1∙g-1] (Ki maps) at a voxel level for the whole brain, using the reference tissue 
adaptation of the multiple-time graphical approach
 
(Patlak et al., 1985). The resulting 
parametric images contain all the transaxial planes from the tip of the vertex to the 
base of the cerebellum. 
 
The occipital cortex was used to provide a reference region input function (Brooks et 
al., 1990b). A standard size ellipse was used to sample both the right and left occipital 
hemispheres over 5 transaxial planes. The linear portion of the Patlak plot, the gradient 
of which provides the Ki value, was taken from the time frame closest to 24 minutes 
until the time frame closest to 91 minutes.  
 
Additionally, all 26 frames of the dynamic 
18
F-dopa time series were integrated to 
form a summated image (ADD image) reflecting both tracer delivery and specific 
uptake. ADD images are required for spatial normalization purposes, as explained in 
paragraph 3.5.4. 
 
In order to optimise image quality, the quality of the reference region input function 
time activity curves, alignment of Ki maps and corresponding ADD images were all 
audited. 
 
3.5.3 Generation of parametric images of 
11
C-DASB 
Parametric images of specific 
11
C-DASB binding potentials [BPND
 
(non-displaceable) 
in consensus nomenclature (Innis et al.,
 
2007)] were generated on a voxel wise basis 
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for the whole brain using a basis function implementation of the simplified reference 
tissue compartmental model with the cerebellum providing the reference tissue input 
function (Lammertsma and Hume, 1996; Gunn et al., 1997).  
 
The simplified reference tissue compartmental model allows estimation of the 
parameters R1 (relative rate of radioligands delivery normalized to the cerebellum) 
and binding potential (BP).  
 
BP is defined as: 
 
BP=f2Bmax/[KD(1+F1/KDi)] 
 
Where f2 is the free fraction of the non specifically bound radioligands in the tissue,  
Bmax is the total concentration of specific binding sites, KD is the dissociation constant 
of the radioligands indicating its affinity, and F1 and KDi are respectively the free 
concentration and the dissociation constant of competing endogenous ligand. 
 
Integrated ADD images of the data from the 17 time frames were also created for 
spatial normalization purposes.  
 
In order to optimise image quality, the quality of the reference region input function 
time activity curves, alignment of parametric images of 
11
C-DASB BPND, and 
corresponding ADD images were all audited. 
 
3.5.4 Spatial normalization  
Spatial normalization is an image registration method, which consists in registering 
individual brains to a standard template in stereotaxic space. The normalization of 
individual brain images into the same orientation and shape minimizes spatial 
differences between subjects and deform human brain scans so that one location in 
one subject's brain scan corresponds to the same location in another subject's brain 
scan (Figure 3-8). 
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 Figure 3-6. Flowchart of 
18
F-Dopa PET Analysis 
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Figure 3-7. Flowchart of 
11
C-DASB PET Analysis. SRTCM= simplified  
reference tissue compartmental model 
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Figure 3-8 Example of spatial normalization. The individual PET image (A) is 
registered to the template in stereotaxic space (B). The resulting normalized image (C) 
will have the same standard spatial coordinates as previously normalized images (D) 
 
To effect spatial normalization, the algorithm available in SPM software was used 
(www.fil.ion.ucl.ac.uk/spm) implemented in Matlab5, which transforms individual 
brain images into standard Montreal Neurological Institute (MNI) stereotaxic space.  
ADD images were used to determine spatial transformation parameters, as they 
contain emission data reflecting both delivery and specific tracer binding and provide 
greater anatomical detail than parametric Ki images. 
First the ADD images of 
18
F-dopa and 
11
C-DASB uptake were normalized to a 
smoothed PET ADD image template in MNI space.  The 
18
F-dopa and 
11
C-DASB 
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templates in MNI space used for spatial normalization were created in-house from 
healthy control subjects. Having normalized the ADD images to MNI space, the 
parametric images were then spatially normalized using the same parameters created 
during transformation of the ADD images.  
Since the accuracy of the stereotaxic normalization is essential for the subsequent 
analysis of PET images, the outcome was audited by comparing the normalized ADD 
image and the normalized parametric image of each patient to the template in all three 
planes. Cases where stereotaxic normalization was considered non successful were 
excluded from further analyses. 
 
3.5.5 PET analysis 
Parametric images of 
18
F-dopa Ki and 
11
C-DASB BPND were analysed using two 
different methods: (i) a region of interest (ROI) approach; and (ii) SPM, allowing 
exploratory  group comparisons throughout the entire brain volume at a voxel level 
without requiring an a priori hypothesis. These two methods, which provide 
complementary information, are described below: 
 
3.5.5.1 Region of interest approach  
The region of interest (ROI) approach samples tracer uptake in preselected areas of the 
brain that have been identified to respond to specific research questions, based on an a 
priori hypothesis.  
To extract ROI data standard object maps in MNI space were applied. These standard 
object maps contain defined ROIs that have been free hand traced using ANALYZE 
software (Mayo clinic, MN) onto the single subject MRI in MNI space available in 
SPM. Details concerning the object maps employed in each study of this research 
project will be provided in the respective experimental chapters.  The standard object 
maps were applied to each spatially normalized image of 
18
F-dopa Ki or 
11
C-DASB 
BPND and corresponding ADD images. Visual inspection of each plane for both 
images was made to ensure correct placement of the object regions over the 
correspondent structures. Manual corrections were made for any misalignment 
between Ki maps and the object maps to ensure the template was placed over the Ki 
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map target region, as described by Whone and colleagues (2004). Cases where 
misalignment was considered excessive were excluded from further analyses. 
After applying target regions to structures, 
18
F-dopa Ki and 
11
C-DASB BPND values 
were quantified using ANALYZE software. 
18
F-dopa Ki and 
11
C-DASB BPND
 
values 
obtained from the different ROIs were averaged
 
over both hemispheres for statistical 
analysis. Figure 3-9 shows an example of placement of ROIs on a normalized PET 
image of 
18
F-dopa Ki and co-registrered MRI.  
 
 
 
Figure 3-9 Example of standard object map applied onto a spatially normalized image 
of 
18
F-dopa Ki  (right) and onto a standard T1 MRI in stereotaxic space (left) to 
demonstrate anatomical details 
 
3.5.5.2 Statistical parametric mapping (SPM) 
SPM allows significant differences in mean tracer binding to be localised across scan 
datasets in voxel clusters of the brain volume and allows both between‐ group and 
within‐ group analyses. It requires that all the individual brain images have been 
spatially normalized into stereotaxic space and spatially smoothed using an isotropic  
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Gaussian kernel. This spatial filter accommodates inter‐ individual anatomic 
variability and improves signal to noise for the statistical analysis. 
After spatial smoothing the parametric images are entered into a design matrix so that 
parametric images are combined to form groups and subsequent comparisons can be 
made at a voxel level using the general linear model (Friston et al., 1995). 
 
 
 
 
 
 
 
 
 
 
Figure 3-10. Example of a between-group comparison with statistical parametric 
mapping (SPM). SPM performs statistical comparisons across scan
 
datasets in 
analogous voxel regions of the brain volume. Voxels with significant differences in 
tracer uptake are automatically overlaid onto a standard T1 MRI 
 
 
More details about the type of comparison and the appropriate weighted contrasts used 
to localize significant decreases and/or increase in tracer uptake will be provided in the 
respective experimental chapters. 
In general, for each contrast a t statistic is computed for each voxel to produce a 
SPM(t). To enable comparison between studies with different degrees of freedom the 
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SPM(t) is subsequently transformed to SPM(Z). Voxel based Z scores are then 
assembled into a 3D image, known as statistical parametric map or Z map. Significant 
clusters of mean group differences (or correlation) can then be identified, through the 
use of appropriate thresholding, and for display purposes shown projected onto a 3D 
glass brain or onto a single subject T1 MRI image as in figure 3-10. 
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In vivo assessment of brain monoamine 
systems in idiopathic Parkinson’s 
disease and in parkin gene carriers 
 
4 
 
4.1 Summary of objectives 
 
In this study, I have used 
18
F-dopa PET to assess in vivo the involvement of extra-
striatal monoaminergic pathways in a group of patients with advanced PD, and to 
ascertain whether idiopathic PD and monogenic forms of parkinsonism have a 
common pattern of non-dopaminergic dysfunction. I compared function of brain 
monoaminergic systems in a group of idiopathic PD patients and in a group of patients 
with parkin-linked parkinsonism matched for levels of striatal 
18
F-dopa uptake. 
Additionally, I have studied the pattern of monoaminergic innervation in the brains of 
12 asymptomatic heterozygote parkin mutation carriers and a few cases with PINK1 
mutations.  
I particularly focused on: (1) hypothalamus, which contains intrinsic dopamine 
neurons, but also a dense innervation from midbrain raphe serotonin neurons and 
lateral medullary noradrenaline neurons; (2) locus coeruleus, containing noradrenergic 
neurons; (3) midbrain raphe serotonin neurons.  
 
4.2 Summary of results 
 
Compared to controls, parkin patients showed significant 
18
F-dopa reductions in the 
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caudate, putamen, ventral striatum, locus coeruleus, midbrain raphe, and pallidum. 
The same structures showed reduced uptake in idiopathic PD patients, who 
additionally had significant reductions in hypothalamus, ventral anterior thalamus, and 
pineal gland. Direct comparison of parkin with idiopathic PD patients showed that 
hypothalamus was relatively targeted in idiopathic PD and midbrain raphe in parkin 
disease. Patients with PINK1 mutations and parkin heterozygotes also showed 
monoaminergic dysfunction.  
These findings suggest that parkin patients and idiopathic PD patients with similar 
levels of striatal dysfunction have different patterns of extra-striatal monoaminergic 
involvement, with more widespread dysfunction evident in idiopathic PD.  
 
4.3 Scientific background 
 
To date, only a relatively small number of imaging studies have investigated in vivo 
the involvement of extrastriatal monoaminergic systems in PD patients to complement 
pathological studies.  
Rakshi and colleagues (1999) used a voxel-based analysis of 
18
F-dopa uptake images 
to explore focal changes in dopaminergic function throughout the brain volume in 
patients with early and advanced PD. They found that patients with advanced PD had 
significant extrastriatal decreases in 
18
F-dopa uptake in the ventral and dorsal midbrain 
regions compared to both controls and patients with early stages of disease. In these 
areas, the reduction in 
18
F-dopa uptake could reflect degeneration of serotoninergic 
and noradrenergic along with dopaminergic neurons. More recently, Moore and 
colleagues (2008) have demonstrated that 
18
F-dopa uptake can be reliably quantitated 
in a variety of extra-striatal regions in patients with idiopathic PD by using a region of 
interest approach. In their cohort of PD patients, who had a range of disease severity, 
they found that extrastriatal dopamine and other monoamine systems were involved 
along with the nigrostriatal dysfunction, particularly in later disease. 
Serotoninergic and noradrenergic function have not been directly investigated in 
patients with mendelian forms of PD.  
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Neuropathological findings in these patients are distinct from idiopathic PD, with few 
Lewy bodies and a more uniform involvement of the substantia nigra compacta (Mori 
et al., 1998; Hayashi et al., 2000; van de Warrenburg et al., 2001; Farrer et al., 2001; 
Morales et al., 2002; Farrer et al., 2004; Sasaki et al., 2004; Zimprich et al., 2004; 
Khan et al., 2005a), and of striatal function imaged with PET (Khan et al., 2002a; 
Khan et al., 2002b; Hering et al., 2004; Scherfler et al., 2004; Khan et al., 2005a; 
Adams et al., 2005; Hernandez et al., 2005). However, it is not known whether 
neurochemical differences are limited to the dopaminergic pathways or also extend to 
other neurotransmitter systems. The few post-mortem studies available in parkinsonian 
patients with genetic mutations have shown neuronal loss and gliosis in the locus 
coeruleus and median raphe (Mori et al., 1998; Hayashi et al., 2000; van de 
Warrenburg et al., 2001; Farrer et al., 2001; Morales et al., 2002; Farrer et al., 2004; 
Sasaki et al., 2004; Zimprich et al., 2004; Khan et al., 2005a).  
 
4.4 Patients and methods 
 
4.4.1 Patients 
One of my aims was to compare brain monoaminergic innervation in patients with 
advanced idiopathic PD and parkin-patients with a similar degree of striatal 
dopaminergic dysfunction. The CSC Neurology group has collected a large database 
of 
18
F-dopa PET images of healthy volunteers and patients with idiopathic PD over the 
years. For this reason only parkin gene carriers underwent a PET scan for this study 
and patients with idiopathic PD and control subjects were selected from the Unit‟s 
database. Patients with idiopathic PD patients were carefully selected to match striatal 
18
F-dopa uptake of parkin-patients.  
Twelve patients with compound heterozygous parkin mutations (M/F= 8/4, age 
45.7±14 years, disease duration 18.8±7.7 years, UPDRS motor score (UPDRS-3) in 
“off‟ condition 45.2±23), 12 asymptomatic carriers of a single parkin mutation (M/F= 
7/5, age 52.4±10.2 years), and 4 patients with PINK1 mutations (M/F=2/2, age 
51.7±16.3 years, disease duration 13.5±12.1 years, UPDRS-3 in „off‟ condition 
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33±28.9) underwent 
18
F-dopa PET. Their PET findings were compared with those of 
11 healthy volunteers (M/F= 6/5, age 66.6± 5.5 years) and 12 patients with advanced 
idiopathic PD matched for striatal dopaminergic dysfunction  (Figure 1) (M/F= 8/4, 
age 60.4± 7.8 years, disease duration 9.1±3.7 years, UPDRS-3 in „off‟ condition 
41.2±8.4). None of the subjects were taking medication that would act on 
serotoninergic and noradrenergic systems.  
Table 4.1 summarizes the demographics of all patients investigated. 
 
 
Table 4.1. Patient Characteristics  
 
 
Healthy 
subjects 
 
(n=11) 
 
Single 
parkin 
mutation 
carriers 
(n=12) 
 
parkin 
patients 
 
(n=12) 
 
IPD 
 
 
(n=12) 
 
PINK1 
patients 
 
(n=4) 
 
 
M/F 
 
6/5 
 
7/5 
 
8/4 
 
8/4 
 
2/2 
Age 
(years, mean ±SD) 
66.6± 5.5 52.4±10.2 45.7±14 60.4± 7.8 51.7±16.3 
Disease Duration 
(years, mean ±SD) 
= = 18.8±7.7 9.1±3.7 13.5±12.1 
UPDRS in “off” = = 45.2±23 41.2±8.4 33±28.9 
 
4.4.2 PET procedure 
PET scanning took place at the Cyclotron Building, Hammersmith Hospital, 
Hammersmith Imanet, GE Healthcare, London, UK, and all PET scans were 
performed with a similar protocol and the same scanner - an ECAT EXACT HR++ 
(CTI/Siemens 966) camera. The high resolution, high sensitivity tomograph permits 
interrogation of the function of small volume structures. All patients had their 
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dopamine replacement therapy stopped for at least 12h (and cabergoline 3 days) before 
PET. Scan data were acquired in list mode (event-by-event) 3D acquisition over 95 
minutes following a bolus injection of 110 MBq of 
18
F-dopa. 
 
4.4.3 PET analysis  
The analysis was performed using an a priori defined ROI approach and the end-point 
was between-group differences in extrastriatal 
18
F-dopa uptake, expressed as influx 
constants Ki. 
Parametric images of 
18
F-dopa influx constants Ki and integrated ADD images of 
18
F-
dopa uptake were created as described in Chapter 3. Both Ki and ADD images were 
then transformed to ANALYZE format using an in house program, ECAT_transfer. 
Once in ANALYZE format the parametric and ADD image from each scan were 
visually inspected using ANALYZE software (Mayo clinic, MN). 
ROI analysis was performed on datasets transformed into standard MNI stereotaxic 
space using the SPM software package. First the ADD images were normalized to a 
smoothed 
18
F-dopa image template in MNI space. The parametric Ki images were then 
spatially normalized using the same parameters created during transformation of the 
ADD images.  
 
4.4.3.1 Extraction of ROI data.  
Standard object maps in MNI space were used to sample ROIs for caudate nucleus, 
putamen, globus pallidus, ventral striatum, ventral anterior thalamus, subthalamic 
nucleus, hypothalamus, locus coeruleus, median midbrain raphe, red nucleus, and the 
pineal gland. These regions were chosen because of their monoaminergic transmitter 
content, post-mortem evidence of neurodegeneration and/or in vivo evidence of 
involvement in PD. The characteristics of these standard object maps have been 
described in Table 4-2. Briefly, the regions were traced to be within the anatomical 
boundaries of each structure using the single subject MRI in MNI space obtained from 
SPM software. In cases where tracing was not possible (subthalamic nucleus, 
hypothalamus, raphe, and locus coeruleus), the ROIs were rectangles placed over the 
structures on repeated slices. 
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Table 4-2 Regions of interest identified on the template object map 
 
Caudate ROI traced to be within the anatomical boundaries of the head 
of the caudate nucleus  
Putamen ROI traced to be within the anatomical boundaries of the 
nucleus excluding the lowest portion of the post-commissural 
putamen 
Ventral striatum ROI traced to include the nucleus accumbens and the lowest  
portion of the post-commissural putamen 
Globus pallidus interna ROI traced to be within the anatomical boundaries of the 
nucleus 
Globus pallidus externa ROI traced to be within the anatomical boundaries of the 
nucleus 
Ventral ant. thalamus ROI traced to be within the anatomical boundaries of the  
rostral ventral thalamus, lateral to the internal medullary  
lamina, ventral to the lateral dorsal nucleus 
Subthalamic nucleus ROI traced to be within the anatomical boundaries of the  
nucleus extending into adjacent internal capsula and Forel‟s 
field 
Hypothalamus Rectangular ROI placed over ventral diencephalon lateral to 
the third ventricle, medial to the internal capsule and between 
optic chiasm rostrally and mammillary body caudally 
Locus coeruleus Rectangular ROI placed over the lateral periventricular gray, 
ventral  
to the fourth ventricle, medial to the dentatorubrothalamic 
tract 
Midbrain raphe Rectangular ROI placed over the raphe from the ventral 
border of the aqueduct to the ventral border of the reticular 
formation including the dorsal and medial raphe and some 
adjacent medial reticular  
formation 
Red nucleus ROI traced to be within the anatomical boundaries of the 
nucleus 
Pineal gland Rectangular ROI lying dorsal to the superior colliculus and 
posterior commissure in the ambiens cistern 
 
Adapted from Moore et at., 2008
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The standard object map was then applied to each spatially normalized ADD and Ki 
image. Visual inspection of each plane for both images was made to ensure correct 
placement of the object region over the structure. After applying target regions to 
structures the Ki data for each image was then generated using ANALYZE. 
 
4.4.4 Statistical analysis 
Statistical analyses of clinical data were performed with InStat3 for Macintosh 
(University of Medicine and Dentistry, NJ, USA). Comparisons between groups were 
made using a non-parametric unpaired test (Mann-Witney statistics). 
 
4.5 Results  
 
Regional mean 
18
F-dopa Ki values obtained for the normal subjects, the idiopathic PD 
group, the 12 parkin patients, and the asymptomatic carriers of a single parkin 
mutation, are shown in Figure 4-1, Figure 4-2, and Table 4-3. 
 
Figure 4-1. 
18
F-dopa influx constant Ki values (mean ± standard error)  (y-axis) in 
striatal regions. * Indicates significant differences between normal subjects and 
parkin-patients or patients with Idiopathic Parkinson’s disease (IPD)
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Figure 4-2. 
18
F-dopa influx constant Ki values (mean ± standard error)  (y-axis) in extrastriatal regions. * Indicates 
significant differences between normal subjects and parkin-patients or IPD patients; ‡ Indicates significant differences 
between parkin-patients and patients with Idiopathic Parkinson’s disease (IPD) 
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Table 4.3. Regional mean 
18
F-dopa Ki values (± Standard Deviation) in the normal subjects, in the 
Idiopathic Parkinson’s disease (IPD) group, in the parkin patients group, and in Carriers of a single 
parkin mutation. 
 Healthy subjects 
 
(n=11) 
Single parkin 
mutation carriers 
(n=12) 
parkin patients 
 
(n=12) 
IPD 
 
(n=12) 
Caudate 0.0114±0.0006 0.0106±0.0011* 0.0074±0.0013*** 0.0077±0.0022*** 
Putamen 0.0124±0.0010 0.0110±0.0019* 0.0050±0.0012*** 0.0046±0.0013*** 
Ventral striatum 0.0117±0.0009 0.0107±0.0013 0.0082±0.0014*** 0.0087±0.0022*** 
Globus pallidus interna 0.0052±0.0010 0.0052±0.0009 0.0043±0.0008* 0.0042±0.0009* 
Globus pallidus externa 0.0059±0.0008 0.0059±0.0016 0.0045±0.0013* 0.0041±0.0011* 
Ventral ant. thalamus 0.0033±0.0002 0.0029±0.0007 0.0028±0.0006 0.0025±0.0007** 
Subthalamic nucleus 0.0043±0.0015 0.0043±0.0013 0.0037±0.0011 0.0039±0.0009 
Hypothalamus 0.0048±0.0007 0.0048±0.0010 0.0046±0.0008 0.0037±0.0007**§ 
Locus coeruleus 0.0050±0.0009 0.0048±0.0015 0.0035±0.0008** 0.0039±0.0012** 
Midbrain raphe 0.0068±0.0015 0.0060±0.0014 0.0049±0.0013**§ 0.0057±0.0005 
Red nucleus 0.0057±0.0010 0.0057±0.0018 0.0047±0.0010 0.0048±0.0009 
Pineal gland 0.0045±0.0014 0.0046±0.0012 0.0049±0.0032 0.0032±0.0012* 
*p<0.05 compared to healthy subjects; ** p<0.01 compared to healthy subjects; *** p<0.001 compared to healthy subjects; 
 § p<0.05 Direct comparison of parkin patients versus IPD patients. 
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4.5.1diopathic Parkinson‟s disease patients 
As mentioned above, PD patients included in this study were selected from a cohort of 
idiopathic PD patients to match striatal 
18
F-dopa uptake of parkin patients (Figure 4.1).  
This was done in order to assess brain monoaminergic innervation in groups of 
patients with similar striatal dopaminergic dysfunction. Mean putaminal 
18
F-dopa Ki 
value was 0.0050±0.0012 in the parkin patients and 0.0046±0.0013 in the idiopathic 
PD group. 
Between-group comparison of the idiopathicPD patients with the normal controls 
showed reduction of mean 
18
F-dopa uptake in the striatum (p<0.001 for caudate, 
putamen and ventral striatum), globus pallidus (p<0.05), locus coeruleus (p<0.01) 
hypothalamus (p<0.01), ventral anterior thalamus (p<0.01), and pineal gland (p<0.05) 
in the idiopathic PD group. 
18
F-dopa uptake was also reduced in the median raphe, but 
this did not reach significance (p=0.07). 
 
4.5.2 Parkin patients 
Between-group comparison of the parkin patients with the normal controls showed 
reduction of mean 
18
F-dopa uptake in the striatum (p<0.001 for caudate, putamen and 
ventral striatum), globus pallidus (p<0.05), the median raphe (p<0.01), and locus 
coeruleus (p<0.01) in the parkin group.  
 
4.5.3 Parkin patients/ idiopathic Parkinson‟s disease patients comparison  
The direct between-group comparison of the parkin with the idiopathic PD patients 
showed that the hypothalamus was relatively targeted in idiopathic PD and the median 
raphe in parkin disease (p<0.05). 
 
4.5.4 Asymptomatic carriers of a single parkin mutation 
Between-group comparison of the 12 asymptomatic heterozygote carriers of a single 
parkin mutation with the normal controls showed significant reductions of mean 
18
F-
dopa uptake in striatum - caudate (p<0.05) and putamen (p<0.05) – but not elsewhere. 
Individual subject analyses revealed that two cases had significantly reduced striatal 
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and two others had reduced locus coeruleus 
18
F-dopa uptake (2 SDs below the normal 
means).  
 
4.5.5 PINK1 patients 
A between-group comparison of the four PINK1 patients with the normal controls 
revealed a significant reduction of mean 
18
F-dopa uptake in caudate (p<0.01), putamen 
(p<0.01), and ventral striatum (p<0.05). Individual analyses of these patients revealed 
that Subject 2, who had a more severe involvement of striatal regions compared to the 
other three subjects, also had reduced Ki values for hypothalamus, globus pallidus 
externa, ventral anterior thalamus, and red nucleus. Subjects 1 and 3 had a reduced 
ventral anterior thalamus Ki. Regional mean 
18
F-dopa Ki values obtained for the four 
PINK1 patients are shown in Table 4.4.  
 
 
Table 4.4. Regional mean 
18
F-dopa Ki values in the PINK1 patients  
  
Patient 1 
 
Patient 2 
 
Patient 3 
 
Patient 4 
 
Mean value±SD 
Caudate 0.0055§ 0.0018§ 0.0088§ 0.0081§ 0.0060±0.0032** 
Putamen 0.0040§ 0.0022§ 0.0104§ 0.0103§ 0.0067±0.0043** 
Ventral striatum 0.0090§ 0.0060§ 0.0108 0.0109 0.0092±0.0023* 
Globus pallidus int. 0.0047 0.0033 0.0042 0.0059 0.0045±0.0011 
Globus pallidus ext. 0.0050 0.0030§ 0.0058 0.0068 0.0052±0.0016 
Ventral ant. thalamus 0.0016§ 0.0025§ 0.0022§ 0.0040 0.0026±0.0010 
Subthalamic nucleus 0.0027 0.0028 0.0035 0.0045 0.0034±0.0008 
Hypothalamus 0.0041 0.0027§ 0.0049 0.0060 0.0044±0.0014 
Locus coeruleus 0.0049 0.0053 0.0053 0.0057 0.0053±0.0003 
Midbrain raphe 0.0064 0.0044 0.0075 0.0075 0.0065±0.0015 
Red nucleus 0.0047 0.0026§ 0.00044 0.0073 0.0048±0.0019 
Pineal gland 0.0047 0.0026 0.0035 0.0090 0.0050±0.0028 
p<0.05 compared to healthy subjects;  ** p<0.01 compared to healthy subjects;  
§ values 2 Standard Deviations below normal means. 
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Figure 4.3. Summary of results. The arrow indicate a significant decrease in mean 
18
F-dopa Ki value compared to the healthy volunteers. IPD= Idiopathic Parkinson’s 
disease; GPi= globus pallidus interna; GPe= globus pallidus externa; VA Thalamus= 
ventral anterior thalamus 
 
 
4.6 Discussion 
 
Patients with advanced idiopathic PD showed reduced 
18
F-dopa uptake in the striatum, 
globus pallidus, locus coeruleus, hypothalamus, ventral anterior thalamus, and pineal 
gland compared to the normal controls. These results give further support to 
previously published findings (Moore et al., 2008). 
 
This is the first in vivo PET study to focus on both striatal and extrastriatal 
monoaminergic structures in patients with parkin-linked parkinsonism and in 
asymptomatic carriers of a single parkin mutation.   
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The parkin patients showed reduced 
18
F-dopa uptake in dopaminergic and non-
dopaminergic neuronal systems when compared to normal controls. In particular, 
18
F-
dopa uptake reductions were observed in striatum, globus pallidus, locus coeruleus, 
and midbrain raphe. Interestingly, mean 
18
F-dopa uptake in the hypothalamus was 
similar to that in the healthy controls.  
When compared to idiopathic PD patients matched for striatal dysfunction, the parkin 
patients had a significantly reduced 
18
F-dopa uptake in the median raphe. Conversely, 
18
F-dopa uptake in the hypothalamus was significantly reduced in the PD patients. 
 
Taken together these findings indicate different patterns of involvement of 
monaminergic systems in idiopathic PD and parkin-linked parkinsonism. They also 
suggest that extrastriatal dysfunction in parkin patients may be more restricted than in 
idiopathic PD patients with a similar degree of striatal dysfunction since 
hypothalamus, ventral anterior thalamus, and pineal gland do not seem to be affected 
in the former. 
In line with post-mortem studies, the locus coeruleus was the mostly affected 
extrastriatal area in both idiopathic PD and parkin patients with a similar degree of 
reduction in this structure in the two groups. The reduction of 
18
F-dopa uptake in the 
locus coeruleus probably reflects the well-known degeneration of the noradrenaline 
containing-neurons that are the major neuron type in this nucleus. With its projections 
to most central nervous system regions, including the cerebral cortex, hippocampus, 
thalamus, hypothalamus, midbrain, brainstem, cerebellum, and spinal cord (Kobayashi 
et al., 1975; Foote et al., 1983), abnormal function of the locus coeruleus may 
influence symptoms in both idiopathic PD and parkinsonism due to parkin mutations. 
In animal models of PD, reduction of noradrenergic activity within the locus coeruleus 
alters neurochemical electrophysiological, and behavioural indices of 
neurotransmission in the nigrostriatal dopaminergic system, and influences the 
response of this system to experimental lesions (Marien et al., 2004). A large body of 
data indicates that the locus coeruleus is important in behavioral state control, 
particularly arousal (Berridge and Waterhouse, 2003), and in mechanisms of attention 
and response selection (Aston-Jones and Cohen, 2005) so that the pathology of the 
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locus coeruleus almost certainly contributes to the behavioral disturbances observed in 
idiopathic PD (Rommelfanger and Weinshenker, 2007). 
 
Midbrain raphe 
18
F-dopa uptake was severely affected in parkin patients. PD patients 
also showed reduced 
18
F-dopa uptake in the median raphe with respect to the healthy 
controls, which, however, did not reach significance (p=0.07).  
The midbrain raphe is the principal source of serotoninergic innervation to the 
forebrain (Steinbusch, 1981), and a reduction of 
18
F-dopa uptake can thus be attributed 
to impairment of serotonin terminal function though some dopamine terminals are also 
present. Doder and colleagues (2003) reported that severity of resting tremor in PD 
patients correlates with decreased 5-HT1A receptor availability in median raphe, as 
assessed with 
11
C-WAY 100635 PET. The more severe involvement of the midbrain 
raphe in our parkin patients might, therefore, explain the higher prevalence of tremor 
found in these patients (90%) (Khan et al. 2003). 
 
The hypothalamus has a complex internal structure as it contains intrinsic dopamine 
neurons, but also a dense innervation from midbrain raphe serotonin neurons and 
lateral medullary noradrenaline neurons. In idiopathic PD patients, the reduction of 
18
F-dopa uptake in this region could, therefore, reflect dysfunction of any or all of 
these pathways. Interestingly, mean 
18
F-dopa uptake in the hypothalamus of parkin 
patients was similar to that in the healthy controls suggesting that this structure may be 
not involved in the pathological process associated with parkin mutation. This finding 
needs to be confirmed in larger cohorts of parkin patients. 
Finally, I assessed the pattern of monoaminergic dysfunction in the brains of 
asymptomatic carriers of a single parkin mutation. As a group, asymptomatic 
heterozygous carriers of a single parkin mutation showed only a mild but significant 
reduction of 
18
F-dopa uptake in the caudate and putamen when compared to the 
normal controls. However, individual analyses of these subjects revealed that two of 
them had reduced locus coeruleus 
18
F-dopa uptake with normal striatal uptake. This 
finding suggests that, at least in some carriers, locus coeruleus might be involved 
independently from the dopaminergic system. It has recently been reported the rate of 
 102 
nigrostriatal dysfunction progression in a subgroup of these subjects (n=6). The 
authors found a mean 0.56% annual reduction in putamen and 0.62 % annual 
reduction in caudate 
18
F-dopa uptake. These findings would suggest that heterozygous 
parkin gene mutations might not represent a major risk factor for late onset PD 
(Pavese et al., 2009). 
 
Due to the small sample size the patients with PINK1 mutation in the current study 
may not be representative of these forms of parkinsonism. Nevertheless results from 
the analysis of individual cases suggest a different pattern of monoaminergic 
involvement in these patients than idiopathic PD. 
 
In summary, these results indicate different patterns of involvement in autosomal 
recessive parkinsonism and idiopathic PD involving dopaminergic, noradrenergic, and 
serotoninergic pathways. The clinical relevance of this differential monoaminergic 
involvement remains to be clarified.  
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Progression of monoaminergic 
dysfunction in Parkinson’s disease 
 
5 
 
5.1 Summary of objectives 
 
The rate of progression of the degenerative process in extrastriatal areas in PD is still 
unclear.  In this study, I have used serial 
18
F-dopa PET to assess longitudinal changes 
in tracer uptake in brain noradrenergic, serotoninergic and extrastriatal dopaminergic 
structures over a 3-year period in a group of early PD patients. Changes over time in 
18
F-dopa uptake in extra-striatal structures were then compared with the rates of 
progression of striatal dysfunction in the same patients in order to better elucidate the 
time-course of the different aspects of the neurodegenerative process in PD. 
 
5.2 Summary of results 
 
Progressive decreases in 
18
F-dopa Ki occurred over three years in the majority of the 
investigated areas, the fastest annual declines occurring in putamen (8.1%), locus 
coeruleus (7.8%), and globus pallidus interna (7.7%). Caudate and hypothalamus 
showed 6.3% and 6.1% annual Ki decline, respectively. At baseline, some structures 
showed increased levels of 
18
F-dopa uptake in PD compared to controls (internal 
pallidum, locus ceruleus), indicating possible compensatory upregulation of 
monoamine turnover. These increased levels had normalised (globus pallidus interna) 
or become subnormal (locus coeruleus) at follow-up suggesting exhaustion of these 
mechanisms within the first few years of disease.   
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These findings suggest that loss of monoaminergic function in extrastriatal regions, as 
reflected by
 18
F-dopa PET, is slower than loss of nigrostriatal dopaminergic function. 
When assessing the efficacy of novel neuroprotective agents on nigrostriatal 
dysfunction in PD, 
18
F-dopa PET could provide supplementary information 
concerning function of extrastriatal monoaminergic structures.  
 
5.3 Scientific background 
 
Current knowledge concerning rates of PD progression in non-dopaminergic structures 
is limited. As discussed in Chapter 1, Braak and colleagues (2003, 2004) assessed 
brain patterns of abnormal immunostaining for α-synuclein and suggested that Lewy 
bodies and Lewy neurites first appear in the medullary dorsal nucleus of the vagus. 
The pathology then ascends to involve non-dopaminergic brainstem structures in the 
pons, such as the locus ceruleus and median raphe, antedating by several years the 
involvement of the substantia nigra in the midbrain and the appearance of the classical 
motor signs. Lewy body and Lewy neurites then progressively extend in a rostral 
direction to involve the nucleus basalis, the forebrain, and, in the final stages, the 
neocortex. However, while the pathology of PD may be ascending in nature, the 
associated dysfunction is highly variable from structure to structure and the rate of 
disease progression in individual non-dopaminergic regions and in extrastriatal 
dopaminergic structures remains unclear. Additionally, the relationship between 
decline in striatal function in PD and dysfunction in extra-striatal areas remains to be 
clarified.  
Longitudinal imaging studies could help clarify these issues. However, no such studies 
have so far been conducted. There is only one cross-sectional study published (Moore 
et al., 2008) where 
18
F-dopa PET was used to assess extrastriatal degeneration in PD 
patients with different degree of striatal dysfunction. Forty-one PD patients were 
arbitrarily assigned to three different groups, designed groups PD1, PD2, and PD3, 
based on the severity of putamen Ki reduction. PD1 patients had asymmetrical Ki 
decreases largely restricted to caudal putamen, PD2 patients had asymmetrical Ki 
decreases involving both rostral and caudal putamen, and PD3 patients had Ki 
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decreases throughout the entire putamen. Results indicate a progressive decline of 
monoaminergic function in extrastriatal areas from the PD1 to the PD3 group. 
However, the cross-sectional design and the large between group differences in 
disease duration and disability do not allow one to adequately estimate the progression 
rate of the degenerative process in these structures. 
 
5.4 Patients and Methods 
 
5.4.1 Patients 
Ten patients (M/F= 6/4; mean age± SD = 57.4 ±7.2 years) with early stage PD (mean 
disease duration ± SD = 25.5 ±7.6 months, mean UPDRS motor score in “off‟ 
condition ± SD =17.2±4.8) were enrolled in this study. A clinical diagnosis of 
probable idiopathic PD was made according to the UK Parkinson‟s Disease Society 
Brain Bank diagnostic criteria for Parkinson‟s disease. None of the patients had 
significant co-morbidity, current or previous history of other neurological conditions, 
dementia, or depression. Table 5-1 summarizes the demographics of all patients 
investigated.  
Each patient was scanned with 
18
F-dopa PET twice, at baseline and again at follow-up 
37.1±21.5 months later. All patients had their dopamine replacement therapy stopped 
for at least 12 hours before PET while cabergoline was stopped three days before 
scanning. On the day of each scan, disease severity in an „off‟ state was assessed by 
UPDRS evaluation, which was performed half an hour before PET scanning.  
Brain 
18
F-dopa uptake values in PD patients at both baseline and follow-up were 
compared with those of 11 healthy volunteers from the Unit‟s database (M/F= 6/5; 
mean age ± SD = 66.6±5.5 years). None of these healthy volunteers had any 
significant medical history of current or previous neurological or psychiatric disorders. 
Three of the healthy volunteers had previously had two
18
F-dopa PET scans 15 days 
apart. Both scans were analyzed to assess reproducibility of extrastriatal 
18
F-dopa 
uptake quantification. 
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All subjects gave their written informed consent to be scanned (approved by the Ethics 
Committee of Hammersmith, Queen Charlotte‟s & Chelsea and Acton Hospitals 
Trust), according to the declaration of Helsinki. Permission to administer 
18
F-dopa was 
obtained from the Administration of Radioactive Substances Advisory Committee 
(ARSAC), UK.  
 
 
Table 5-1. Patient Characteristics 
 
 Healthy subjects 
(n=11) 
Parkinson’s disease patients 
(n=10) 
  At baseline At follow-up 
(37.1±21.5 months) 
M/F 6/5 6/4 
Age 
(years, mean ±SD) 
66.6± 5.5 57.4 ±7.2 61.1 ± 7.1 
Disease Duration 
(months, mean ±SD) 
= 25.5 ±7.6 62.6±21.3 
Hoen & Yahr  = 2 ± 0.5 2.5 ± 0.5 
UPDRS in “off” = 17.2 ± 4.8 31 ± 3.6 
 
 
 
5.4.2 PET procedure 
All patients and healthy volunteers were scanned at the Cyclotron Building, 
Hammersmith Hospital, using an ECAT EXACT HR
++
 (CTI/Siemens 966) PET 
scanner.  
All subjects received 150mg oral carbidopa one hour prior to scanning, in order to 
improve 
18
F-dopa availability to the brain (Hoffman et al., 1992).  
The scanning protocol involved list mode (event-by-event) 3D acquisition over 95 
minutes following a bolus injection of 110 MBq of 
18
F-dopa. 
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5.4.3 PET analysis 
The analysis was performed using an a priori ROI approach.  
Parametric images of the influx constant Ki and integrated ADD images of 
18
F-dopa 
uptake were created as described in Chapter 3. Both Ki and ADD images were 
transformed to ANALYZE format using ECAT_transfer.  
ROI analysis was performed on datasets transformed into standard MNI stereotaxic 
space. The summed ADD images were normalized to the 
18
F-dopa PET template in 
MNI space using SPM software and the individual 
18
F-dopa Ki maps were 
subsequently spatially normalised by applying the transformation parameters obtained 
during normalisation of the corresponding summed images.  
 
5.4.3.1 Extraction of ROI data. 
Standard object maps in MNI space were used to extract ROI for eleven structures; the 
putamen, caudate nucleus, ventral striatum, globus pallidus interna and externa, 
subthalamic nucleus, red nucleus, ventral anterior thalamus, hypothalamus, midbrain 
raphe, and locus ceruleus. More details about the characteristics of these ROIs have 
been provided in paragraph 4.4.3.1 and in table 4-2. 
The standard object maps were applied to the spatially normalised 
18
F-dopa Ki maps 
and the values for specific 
18
F-dopa uptake in individual regions were extracted using 
ANALYZE software (Mayo clinic, MN). To ensure correct placement of the ROIs, 
each plane of the normalised Ki maps and summed images was inspected. Manual 
corrections were made for any misalignment between Ki maps and the object maps to 
ensure the template was placed over the Ki map target region. 
 
5.4.4 Statistical methods 
In all subjects, I calculated the averaged right and left Ki for each ROI.  
Percentage reductions below the averaged mean of the healthy volunteers were  
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calculated for each structure in individual PD patients both at baseline and follow-up 
according to the formula:   
 
100 x (mean 
18
F-dopa Ki healthy volunteers - 
18
F-dopa Ki patient)/ mean
18
F-dopa Ki 
healthy volunteers 
 
Individual patient values were then averaged for each structure. A negative value 
indicates an increase above the averaged mean of the healthy volunteers. 
 
Percentage individual changes in 
18
F-dopa uptake from baseline in PD patients were 
calculated for each structure as follows  
 
100 x (baseline 
18
F-dopa Ki – follow-up 
18
F-dopa Ki)/baseline 
18
F-dopa Ki 
 
Percentage changes per annum were then calculated as follows 
 
12 x (% change 
18
F-dopa Ki from baseline/ months from baseline to follow-up) 
 
Finally, individual patients values were averaged for each structure.  
 
The Mann-Whitney U-statistic was used to compare PD patients and healthy 
volunteers and Wilcoxon matched-pairs to compare baseline and follow-up 
18
F-dopa 
Ki values within the PD group. The relationship between the annual 
18
F-dopa Ki 
decline in putamen and that in each of the other ROIs was investigated with the 
Spearman Rank Correlation statistic. 
 
5.5 Results 
 
Table 5-2 shows the means (± standard deviation) of the Ki values obtained for each 
region assessed for healthy volunteers and PD patients at both baseline and follow-up, 
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in addition to percentage differences per annum for the PD group. Table 5-3 shows 
regional mean 
18
F-dopa Ki values  (± standard deviation) in the three healthy 
volunteers who had two
18
F-dopa PET scans 15 days apart.  
 
5.5.1 Parkinson‟s disease patients and healthy volunteers comparison  
5.5.1.1 Baseline 
When comparing PD patients at baseline with control subjects, I found decreased 
18
F-
dopa uptake in the majority of the ROIs sampled. Putamen, ventral anterior thalamus, 
and globus pallidus externa were the most affected structures with 41.1%, 21.5%, and 
10.8% reductions below the averaged means of the healthy volunteers. Reductions 
were also seen in hypothalamus (10%), caudate (6.7%), subthalamic nucleus (6.5%), 
and ventral striatum (5.8%). However, only the 
18
F-dopa decreases in putamen and 
ventral anterior thalamus reached statistical significance (Mann-Whitney U-tests 
p<0.01 and p<0.05, respectively). The globus pallidus interna, midbrain raphe, and 
locus coeruleus all showed raised 
18
F-dopa uptake compared to healthy volunteers 
(+19.8%, +16.9%, and +2.8%, respectively). The 
18
F-dopa Ki increases in globus 
pallidus interna and raphe reached statistical significance (Mann-Whitney U-tests, 
p<0.05, in both ROIs). 
 
5.5.1.2 Follow-up 
At follow-up, PD patients showed declines in 
18
F-dopa in all the regions sampled. 
Putamen Ki was most affected falling by 55.9% below the averaged mean of the 
healthy volunteers, followed by caudate (25.9%), hypothalamus (24.5%), ventral 
anterior thalamus (21.2%), globus pallidus externa (19.6%), locus coeruleus (18%), 
ventral striatum (17.8%), subthalamic nucleus (15.3%), red nucleus (13%), globus 
pallidus interna (2.9%), and median raphe (1.9%). Comparing PD patients at follow-
up with control subjects revealed statistically significantly decreased Ki values in the 
putamen (p<0.001), caudate nucleus (p<0.001), ventral striatum (p=0.001), globus 
pallidus externa (p<0.001), hypothalamus (p<0.001), locus coeruleus (p<0.05), and 
ventral anterior thalamus (p<0.05) with the Mann-Whitney U-statistic. 
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5.5.2 Baseline versus follow-up comparison in Parkinson‟s disease patients 
The decreases in 
18
F-dopa uptake from baseline reached statistical significance in 
caudate (p<0.05), putamen (p<0.01), globus pallidus interna (p<0.01), locus coeruleus 
(p<0.01), and hypothalamus (p<0.01). The most rapid annual decline in 
18
F-dopa Ki 
was observed in putamen (8.1%) followed by locus coeruleus (7.8%), and globus 
pallidus interna (7.7%). Caudate and hypothalamus showed  6.3% and 6.1% annual 
declines, respectively (Table 5-2). In the remaining structures, the annual decline in 
18
F-dopa uptake was less than 5%. 
No correlations were found between the rate of annual decline in 
18
F-dopa uptake in 
putamen and that of other structures. However, there was a trend towards a correlation 
between rate of 
18
F-dopa decline in putamen and globus pallidus interna (r=0.60, 
p=0.073). 
 
5.5.3 Comparisons between first and second scan in healthy volunteers 
In the three healthy volunteers who had repeat 
18
F-dopa PET scans, no significant 
changes in tracer uptake were seen in any of the sampled ROIs. Percentage changes 
between the two scans are reported in Table 5-3. 
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Table 5-2. Regional mean 
18
F-dopa Ki values (± Standard Deviation) in the normal subjects and in the Parkinson’s 
disease patients at Baseline and Follow-up  
 Healthy Subjects 
(n=11) 
Parkinson’s Disease Patients 
(n=10) 
  Baseline Follow-up % changes annum 
mean 
Caudate 0.0114±0.0006 0.0106±0.0016 0.0084±0.0022§ *** -6.3 
Putamen 0.0124±0.0010 0.0073±0.0023** 0.0055±0.0009§§ *** -8.1 
Ventral striatum 0.0117±0.0009 0.0110±0.0014 0.0096±0.0011§ *** -4.9 
Globus pallidus interna 0.0052±0.0010 0.0062±0.0005* 0.0051±0.0007 §§ -7.7 
Globus pallidus externa 0.0059±0.0008 0.0053±0.0007 0.0047±0.0007 *** -2.4 
Ventral ant. thalamus 0.0033±0.0002 0.0026±0.0006 * 0.0026±0.0006 * +0.9 
Subthalamic nucleus 0.0043±0.0015 0.0040±0.0009 0.0036±0.0007 -1.1 
Hypothalamus 0.0048±0.0007 0.0044±0.0003 0.0037±0.0004 §§ ** -6.1 
Locus coeruleus 0.0050±0.0009 0.0051±0.0007 0.0041±0.0006§§ * -7.8 
Midbrain raphe 0.0068±0.0015 0.0080±0.0009* 0.0067±0.0013§ -4.7 
Red nucleus 0.0057±0.0010 0.0057±0.0012 0.0050±0.0009 3.2 
= significantly decreased compared to baseline (Wilcoxon matched-pairs signed-ranks test: § p<0.05, §§ p<0.01).  
= significantly increased compared to healthy subjects, and   = significantly decreased compared to healthy subjects (Mann-
Whitney test:  *p<0.05, ** p<0.01, and; *** p<0.001)  
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Figure 5-1. 
18
F-dopa influx constant Ki values (mean ± standard deviation)  (y-axis) in striatal and extrastriatal regions in 
normal subjects (HV) and patients with Parkinson’s disease at baseline (PD-B) and follow-up (PD-FU). Significant differences 
between groups are reported in Table 5-2. 
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Table 5-3. Regional mean 
18
F-dopa Ki values (± Standard Deviation) in the normal subjects with two scans  
 
 Healthy subjects 
         (n=11) 
Healthy subjects with two scans 
(n=3) 
     First scan   Second scan % Changes 
mean (absolute value) 
Caudate 0.0114±0.0006 0.0105±0.0006 0.0112±0.0007 3.7 
Putamen 0.0124±0.0010 0.0125±0.0011 0.0127±0.0012 1.6 
Ventral striatum 0.0117±0.0009 0.0128±0.0007 0.0130±0.0004 2.4 
Globus pallidus interna 0.0052±0.0010 0.0051±0.0005 0.0049±0.0003 5.1 
Globus pallidus externa 0.0059±0.0008 0.0058±0.0008 0.0059±0.0009 1.7 
Ventral ant. thalamus 0.0033±0.0002 0.0027±0.0002 0.0028±0.0004 4.8 
Subthalamic nucleus 0.0043±0.0015 0.0047±0.0009 0.0049±0.0014 6.3 
Hypothalamus 0.0048±0.0007 0.0043±0.0008 0.0043±0.0005 5.5 
Locus coeruleus 0.0050±0.0003 0.0051±0.0015 0.0050±0.0002 5.9 
Midbrain raphe 0.0068±0.0015 0.0069±0.0012 0.0065±0.0008 6.1 
Red nucleus 0.0057±0.0010 0.0056±0.0007 0.0059±0.0007 5.0 
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5.6 Discussion 
 
This is the first longitudinal, prospective, in vivo study to report the rate of disease 
progression in extrastriatal monoaminergic structures in early stages of PD.  
Using serial 
18
F-dopa PET imaging, a marker of AADC activity in monoaminergic 
neurons, I found that the putamen had the fastest annual decline in 
18
F-dopa uptake 
(8.1%) followed by locus coeruleus (7.8%), and globus pallidus interna (7.7%). 
Caudate and hypothalamus showed a 6.3% and 6.1% decline per annum respectively, 
whereas the remaining structures showed less than 5% annual decline in 
18
F-dopa 
uptake (Table 5-2). Additionally, I found no significant correlations between the rate 
of annual decline in 
18
F-dopa uptake in putamen and that in other structures. These 
findings suggest that the degeneration in extrastriatal monoaminergic structures in PD 
occurs independently from nigrostriatal degeneration and at a slower rate. These 
results are in line with several post-mortem studies, which have shown that in 
advanced PD cases, the cell loss in non-dopaminergic nuclei ranges between 30 and 
50%, whereas it is close to 80% in the nigral region (Jellinger et al., 1991; Zarow et 
al., 2003; Thannickal et al., 2007).  
 
In agreement with previous studies (Rakshi et al., 1999; Whone et al., 2003: Moore et 
al., 2008), baseline mean 
18
F-dopa uptake in globus pallidus interna and midbrain 
raphe was significantly raised in our early PD patients. As discussed in previous 
chapters of this thesis, increases in 
18
F-dopa uptake in these structures is likely to 
reflect upregulation of AADC activity and dopamine turnover in surviving terminals 
and could represent a compensatory adaptive mechanism to preserve functionality. 
The longevity of these compensatory mechanisms is unknown. In cross-sectional 
studies, advanced PD patients showed significant reductions in globus pallidus interna 
and raphe 
18
F-dopa uptake compared to both controls and PD patients with early 
disease, suggesting that compensatory mechanisms involving these structures 
eventually fail during the time course of the disease. In this longitudinal study, tracer 
uptake in these two nuclei fell slightly below the control mean value after a three-year 
follow up, suggesting that compensatory hyperactivity reverses within the first years 
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of disease. The annual declines observed in 
18
F-dopa uptake in globus pallidus interna 
and midbrain raphe could, therefore, simply reflect the loss of their compensatory 
upregulation rather than cellular loss. Longer follow-ups with three or more imaging 
assessments are required to assess the effective rate of disease progression in these 
structures once the compensatory mechanisms have disappeared.  
The locus ceruleus showed the second highest mean annual 
18
F-dopa decline in the PD 
group. At follow-up, our patients had significantly lower 
18
F-dopa uptake in the locus 
coeruleus than controls (p<0.05) with a mean 18% reduction below the averaged mean 
of the healthy volunteers. Reduced 
18
F-dopa Ki in this nucleus most likely reflects the 
progressive loss of noradrenergic terminal function. Interestingly, at baseline, PD 
patients had higher locus coeruleus 
18
F-dopa uptake than the healthy volunteers, 
although the difference between the two groups was not statistically significant. Lewy 
body pathology in the locus coeruleus is a well-documented post-mortem finding in 
PD (Zarow, et al., 2003) and appears in stage 2 of the disease (Braak et al., 2004). The 
preservation of 
18
F-dopa uptake in the locus coeruleus of PD patients at baseline 
observed in this study could indicate that AADC upregulation also occurs in this 
nucleus. Alternatively, it could imply that Lewy body pathology is not necessarily 
associated with neuronal dysfunction in this area in the early phases of the disease.  
The hypothalamus is commonly affected in PD. Lewy body inclusions have been 
demonstrated in every nucleus of the hypothalamus, particularly the tuberomamillary 
nucleus and the lateral and posterior hypothalamic nuclei (Langston and Forno, 1978; 
Sandyk et al., 1987, Wakabayashi and Takahashi, 1997). Reduced hypothalamic
 18
F-
dopa uptake has previously been reported in PD patients (Moore et al., 2008). The 
cohort of patients with advanced PD investigated in the experimental study described 
in chapter 4 of this thesis also showed reduced hypothalamic
 18
F-dopa Ki compared to 
both controls and patients with parkin-linked parkinsonism. Moreover, our group has 
recently reported a significant reduction in dopamine D2 receptor availability, as 
measured by 
11
C-raclopride PET, in the hypothalamus of PD patients compared with 
age-matched healthy volunteers (Politis et al., 2007). In this study, I found no 
significant difference in mean 
18
F-dopa uptake in the hypothalamus between PD 
patients and healthy volunteers at baseline although it was reduced by 10%. Three 
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years later, the PD patients showed a significant 20.2% reduction (p<0.05) below the 
controls‟ mean value in 18F-dopa uptake with an annual 6.2% decline from baseline. 
These findings confirm that hypothalamic involvement is common in PD and suggest 
that this structure could be targeted at very early stages of the disease with a fast 
progression rate once degeneration has started. 
The hypothalamus has a complex internal structure including intrinsic dopaminergic 
neurons and a dense innervation from sertoninergic midbrain raphe and lateral 
medullary noradrenergic neurons. In PD patients, the reduction of 
18
F-dopa uptake in 
this region could reflect dysfunction in any or all of these pathways. Further post-
mortem and in vivo studies, preferably with PET ligands specific for each of these 
neurotransmitter systems, are required to better understand the pathogenesis of 
hypothalamic involvement in PD. 
 
The mean annual decline in putamen and caudate 
18
F-dopa Ki noted in this study is 
comparable with data from previous studies (Morrish et al., 1996, 1998). The rate of 
progression of dopaminergic dysfunction in the ventral striatum has not been assessed 
previously. The ventral striatum, which encompasses the nucleus accumbens and the 
ventromedial parts of caudate and putamen, is generally considered a limbic center and 
has widespread connections with other limbic structures including the amygdala, 
hippocampus, and the prefrontal cortex (Groenewegen and Trimble, 2007). The 
ventral striatum is strongly innervated by dopaminergic fibers from the midbrain 
ventral tegmental area. In PD, the ventral tegmental area shows a less pronounced loss 
of dopaminergic neurons than the contiguous substantia nigra pars compacta.  In line 
with these observations, I found a relatively slow mean annual decline (4.9%) in 
18
F-
dopa uptake in ventral striatum compared to both putamen (8.1%) and caudate (6.3%).  
 
Annual decline in 
18
F-dopa uptake in red nucleus, and in the remaining extrastriatal 
monoaminergic structures assessed in this study was less than 5%, suggesting that 
degeneration occurs at a slow rate in these structures.    
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Finally, this study provides evidence that uptake of 
18
F-dopa in extrastriatal structures 
can be measured reliably and with good reproducibility. In the three healthy volunteers 
who had repeat 
18
F-dopa PET scans, no significant differences in tracer Ki between the 
first and second scans were seen in any of the sampled ROIs. The mean percentage of 
change (absolute value) between the two scans ranged from 1.6 % (putamen) to 6.3% 
(subthalamic nucleus). 
18
F-dopa PET and the dopamine transporter marker 
123
I--CIT SPECT have been used 
as surrogate markers of nigrostriatal degeneration in clinical trials of putative 
neuroprotective drugs in PD (Oertel et al., 2000; Rakshi et al., 2002; Rascol et al., 
2000; Parkinson Study Group, 2002; Whone et al., 2003; Pavese et al., 2005). 
Unfortunately, no unequivocal evidence of neuroprotection has been demonstrated for 
any drugs tested so far. Interpretation of data generated by these trials has also been 
limited by adaptive compensatory effects upregulating dopamine turnover and 
downregulating transporter binding over time, direct effects on receptor availability 
and enzyme activities by the drug itself, and placebo effects. All these confounding 
factors potentially can interfere with the imaging outcome and must be addressed 
when designing new clinical trials of neuroprotective agents in PD patients. In this 
study, I have shown that 
18
F-dopa PET can be successfully used to assess disease 
progression in serotoninergic and noradrenergic extrastriatal areas along with 
nigrostriatal degeneration. The technique could, therefore, provide supplementary 
information on the progression of the degenerative process in extrastriatal 
monoaminergic structures when assessing the effects of novel neuroprotective agents 
in PD. 
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PET investigation of chronic fatigue  
in Parkinson’s disease 
 
6 
 
6.1 Summary of objectives  
 
I used 
18
F-dopa PET and 
11
C-DASB PET to study the role of aberrant dopaminergic 
and serotoninergic neurotransmission in the pathophysiology of fatigue in PD. 
The overall objective of this study was to test the hypothesis that chronic fatigue in PD 
is due to reduced serotoninergic and dopaminergic innervation of the non-motor 
components of the basal ganglia including the ventral striatum, and associated limbic 
circuits. These are the structures that facilitate the link between emotion/motivation 
(limbic system) and motor response. The hypothesis is that patients with PD who 
experience central fatigue have pathology causing reductions in serotonin and 
dopamine turnover within the basal ganglia and limbic circuits. 
 
6.2 Summary of results  
 
Using a region of interest analytical approach, I found that PD patients with fatigue 
had significantly lower serotonin transporter binding than patients without fatigue in 
caudate, putamen, ventral striatum and thalamus. Striatal 
18
F-dopa uptake was similar 
in the fatigued and non-fatigued groups. Voxel-based analysis localised further relative 
serotonin transporter binding reductions in cingulate and amygdala of the fatigue 
group, and 
18
F-dopa uptake reductions in caudate and insula. In conclusion, fatigue in 
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Parkinson‟s disease is associated with reduced serotoninergic function in basal ganglia 
and limbic structures. Insular dopaminergic dysfunction could also play a role. These 
findings imply that strategies to increases brain level of serotonin would be a rational 
approach for relieving fatigue symptoms in Parkinson‟s disease and may also be 
relevant to alleviating fatigue in other clinical conditions. 
 
6.3 Scientific background 
 
Disabling fatigue is a common non-motor symptom of PD and is estimated to occur in 
about one-third of patients. (Karlsen et al., 1999; Abe et al., 2000; Friedman and 
Friedman, 2001; Lou et at., 2001; Herlofson and Larsen, 2002). Sometimes the 
symptom antedates the development of motor disturbances. Hagell and Brundin 
(2009) have recently reported that in a cohort of 118 consecutive PD patients, 18 
(15.3%) had fatigue before any motor disturbance. 
The PRIAMO study (Barone et al., 2009) reported that fatigue occurred in 58.1% of a 
cohort of 1072 patients ranging from 37.7% in HY stage 1 patients to 81.6% in stages 
4-5. Affected patients typically complain of a feeling of constant exhaustion or 
tiredness, either mental, physical, or both (Brown et al., 2005).  However, severity of 
mental fatigue does not correlate well with physical fatigue, suggesting that the two 
conditions are caused by independent mechanisms in PD (Lou et al., 2001).   
The reason for the high prevalence of fatigue in PD remains poorly understood. In 
most studies, the presence and severity of fatigue does not correlate with disease 
duration or degree of motor disability. Additionally, no direct relationship between 
presence of fatigue and type, dosage, and duration of anti-parkinsonian medication has 
been found (Abe et al., 2000; Friedman and Friedman, 2001; Hagell and Brundin, 
2009). Conversely, the presence of depression, nocturnal sleep disturbance, and 
autonomic impairment are all thought to exacerbate the subjective experience of 
fatigue (Karlsen et al., 1999; Lou et al., 2001; Alves et al., 2004; Hagell and Brundin, 
2009).  However, these factors cannot completely explain the high prevalence of 
fatigue in PD, as the symptom is common in non-depressed patients and is also 
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experienced by patients with no complaint of sleep disorders (Friedman and Friedman, 
1993; Karlsen et al., 1999; Lou et al., 2001). 
It has been proposed that basal ganglia dysfunction plays a role in the mechanism of 
fatigue in diseases of the central nervous system (Chaudhuri et al., 2000; Chaudhuri et 
al., 2003; Chaudhuri et al., 2004). Several observations would support this view:  In 
patients with multiple sclerosis, fatigue has been reported to be associated with 
reduced glucose metabolism in the frontal cortex and the basal ganglia (Roelcke et al., 
1997). Bilateral posteroventral pallidotomy for treatment of PD can also lead to 
profound fatigue, sleepiness, changes in behaviour, and poor initiative in executive 
functions despite improvement in motor control (Ghika et al., 1999). However, a 
recent study among levodopa-naïve PD patients found that patients with fatigue had 
similar striatal dopamine transporter uptake compared to patients without fatigue 
(Schifitto et al., 2008). These findings indicate that non-dopaminergic basal ganglia 
pathways are most likely to be involved in fatigue generation in PD or, if 
dopaminergic dysfunction plays a role, it involves extrastriatal projections.  
Several studies have suggested that serotoninergic deficiency is a pathophysiological 
factor in chronic fatigue syndrome without parkinsonism (Narita et al., 
2003;Yamamoto et al., 2004; Cleare et al., 2005; Katafuchi et al., 2006). Accordingly, 
reduced serotonin transmission could have a role in the occurrence of fatigue in 
patients with PD.  
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6.4 Patients and methods 
 
6.4.1 Patients 
Twenty PD patients with a clinical diagnosis of idiopathic PD (UK Parkinson‟s 
Disease Society Brain Bank diagnostic criteria for Parkinson‟s disease) were recruited 
for this study. Patients with dementia [Mini Mental State Examination (Folstein et al., 
1975) <23], depression [Hamilton Rating Scale for Depression (Hamilton, 1960) >16 
and Beck Depression Inventory (Beck et al., 1961) >9], and sleep disturbances, 
specifically excessive daytime sleepiness (EDS) [Epworth Sleepiness Scale Johns, 
1991) >8] were not enrolled.   
 
The patients were divided into
 
two groups according to the presence (n = 10) or 
absence (n =
 
10) of fatigue. A presence of fatigue was defined as a score > 8 on the 
Parkinson Fatigue Scale (PFS-16) (Brown et al., 2005). The PFS-16 has specifically 
been designed to measure fatigue in a PD population taking in account possible 
overlapping with other motor and non-motor symptoms of PD. In particular, it 
provides a measure of fatigue, which is independent of affective, sleep, and cognitive 
disturbances. The scale contains 16 questions. Seven of them are related to the 
presence or absence of subjective experience of fatigue, whereas the remaining nine 
measure the impact of fatigue on daily activity.  Each item has five response options 
from 1 (strongly disagree) to 5 (strongly agree).  In this paper I scored each item using 
a binary scoring method.  In this method, the response “agree” and “strongly agree” 
are scored 1, and all other responses are scored 0. The total score ranges from 0- 16, 
16 being worse score and 8 the cut-off score to identify patients who perceive fatigue 
to be a problem (Brown et al., 2005).  
 
The two groups of PD patients with and without fatigue were matched for age, disease 
duration, daily intake of levodopa equivalent units (LEU), and UPDRS
 
scores in both 
“off” and “on” conditions. Table 6.1 summarizes the demographics of all patients 
investigated. All the subjects had a stable response to their dopamine replacement 
therapy and none were taking medication targeting serotoninergic and noradrenergic 
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systems. LEUs were calculated as follows: 100 mg levodopa = 2mg cabergoline = 
1mg pramipexole or 1 mg pergolide = 5 mg ropinirole = 4 mg rotigotine patch = 0.5 
mg rasagiline. The conversion factors below were used for controlled release levodopa 
and levodopa/carbidopa/entecapone combination: 125 mg controlled release levodopa 
= 65 mg levodopa; 50 mg levodopa/carbidopa/entecapone combination = 65 mg 
levodopa.  
 
Eight PD patients with fatigue (PD-F) and seven PD patients without fatigue (PD-NF) 
had both 
18
F-dopa and 
11
C-DASB PET. The remaining 5 patients had only one scan as 
they withdraw their consent after the first PET session. In summary, ten PD-F patients 
and nine PD-NF patients had 
18
F-dopa PET and eight PD-F patients and eight PD-NF 
patients had 
11
C-DASB PET  (Table 6.1). 
 
The study received approval from the Ethics Committee of Hammersmith, Queen 
Charlotte‟s & Chelsea and Acton Hospitals Trust. Permission to administer 18F-dopa 
and 
11
C-DASB was obtained from the Administration of Radioactive Substances 
Advisory Committee (ARSAC), UK.  
 
Since the main aim of this project was to compare function between PD patients with 
and without fatigue no healthy control subjects were scanned during this study. 
However, 
11
C-DASB PET findings for the two PD groups were compared with those 
of 9 healthy volunteers (all males, age 44.6± 5.5 years) from the Unit‟s database. None 
of these healthy volunteers had any significant medical history including current or 
previous medical history of neurological or psychiatric disorders.  
 
6.4.2 PET protocol 
PET scanning took place at the Cyclotron Building, Hammersmith Hospital, 
Hammersmith Imanet, GE Healthcare, London, UK, and all PET scans were 
performed using an ECAT EXACT HR+ (CTI/Siemens 962) camera. All patients had 
their dopamine replacement medication stopped for at least 12h before PET.  
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The scanning protocol for 
18
F-dopa involved 3D acquisition over 94 minutes and 30 
seconds following a bolus injection of 185 MBq of 
18
F-dopa.  
 
The scanning protocol for 
11
C-DASB involved 3D acquisition over 90 minutes and 30 
seconds following a bolus injection of 450 MBq of 
11
C-DASB.  
 
6.4.3 PET analysis  
Parametric images of the influx constant Ki and integrated ADD images of 
18
F-dopa 
uptake were created as described in Chapter 3. Both Ki and ADD images were then 
transformed to ANALYZE format using an in house program, ECAT_transfer. Once 
in ANALYZE format the parametric and ADD image from each scan were visually 
inspected using ANALYZE software (Mayo clinic, MN). 
Spatial normalization of ADD images and Ki maps into standard MNI stereotaxic 
space was performed using the SPM software package implemented in Matlab5. First 
the ADD images were normalized to a smoothed 
18
F-dopa template in MNI space.  
Then the transformation parameters were applied to the respective 
18
F-dopa Ki maps.  
 
As described in Chapter 3, parametric images of specific 
11
C-DASB BPND
 
were 
generated on a voxel wise basis for the whole brain using a basis function 
implementation of the simplified reference region compartmental model with the 
cerebellum providing the reference tissue input function (Gunn et al., 1997).  
Integrated ADD images of 
11
C-DASB uptake were also created for spatial 
normalization purposes. ADD images and parametric images of 
11
C-DASB BPND were 
then normalized, using SPM software, to a smoothed 
11
C-DASB ADD image template.  
 
6.4.3.1 Extraction of ROI data  
To extract ROI data I used a standard object map in MNI space. The standard object 
map contained regions defined for caudate nucleus, putamen, ventral striatum, 
thalamus, and median raphe. The same standard object map was applied to each 
spatially normalized image of 
18
F-dopa Ki or 
11
C-DASB BPND and corresponding 
ADD images. Visual inspection of each plane for both images was made to ensure 
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correct placement of the object regions over the correspondent structures. After 
applying target regions to structures, 
18
F-dopa Ki and 
11
C-DASB BPND values were 
quantified using ANALYZE software. 
18
F-dopa Ki and 
11
C-DASB BPND
 
values 
obtained from the different ROIs were averaged
 
over both hemispheres for statistical 
analysis. 
 
6.4.3.2 Voxel-based analysis 
SPM software was used to localize significant changes in tracer uptake between PD-
NF and PD-F patients at a voxel level. Normalized parametric images of 
18
F-dopa Ki 
and 
11
C-DASB BPND were spatially smoothed using a 6 x 6 x 6 mm (full-width at half 
maximum) isotropic Gaussian kernel.  
 
For each tracer, between-group comparisons were performed by using weighted 
contrasts to localize significant decreases in mean voxel tracer uptake in PD-F patients 
compared to PD-NF patients. The contrast was used to generate maps of Z scores on a 
voxel basis using the general linear model (Friston et al., 1995). The statistical maps 
were visualized at a threshold p  < 0.01 (Z score = 2.33), and any resulting cluster with 
a p <0.05 is reported. 
 
 
 
6.4.4 Statistical analysis 
Statistical analyses of clinical data were performed with SSPS 16 for Windows (SPSS 
Inc., Chicago, Illinois).  
 
Comparisons between groups were made using a non-parametric unpaired test (Mann-
Whitney U-test) or non-parametric ANOVA (Kruskal-Wallis test) as appropriate. Post 
Hoc comparisons after Kruskal-Wallis test were performed using two-tailed Mann-
Whitney U-test. Resulting p values were corrected according to the Bonferroni 
method.  
 
Correlations between variables were tested with Spearman rank correlation. 
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Table 6-1. Patient Characteristics 
 
 11C-DASB 
PET 
18
F-Dopa 
PET 
 
Age 
(yrs) 
Disease 
Duration 
(yrs) 
LEU PFS-16 
score 
UPDRS 
off 
UPDRS 
on 
PD-NF patients         
#1     M X X 53 7 450 1 30 15 
#2     M X X 71 4 200 1 42 25 
#3     M // X 63 3 590 2 32 28 
#4     F X X 46 3 750 3 33 15 
#5     F X X 76 4 915 5 36 27 
#6     M X X 52 2 835 5 26 19 
#7     M X X 77 6 715 6 40 25 
#8     M X // 70 4 550 6 36 20 
#9     F // X 59 4 550 7 32 18 
#10   F X X 69 4 250 7 28 17 
Mean ± SD   63.6±10.7 4.1±1.4 580±235 4.3±2.4 33.5±5.1 20.9±4.9 
 
PD-F patients 
        
#11   M X X 69 5 750 10 35 25 
#12   F  X X 57 3 785 10 22 14 
#13   F X X 66 7 1480 11 42 22 
#14   M // X 59 5 550 13 42 25 
#15   M X X 55 3 280 13 32 17 
#16   F  X* X 58 6 635 14 36 17 
#17   M X X 77 8 600 14 38 21 
#18   M X X 70 3 1000 15 34 23 
#19   M X X 66 11 1135 16 38 31 
#20   F // X 70 4 520 16 30 18 
Mean ± SD1   64.7±7.2 5.5±2.6 773±348 13.2±2.3 34.9±6 21.3±5 
* In this patient the spatial normalization of the individual parametric image to the 
11
C-DASB template was unsuccessful and the patient was 
excluded from the analysis. x= performed; // = non performed 
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6.5 Results  
 
Severity of fatigue in the whole group of 20 PD patients did not correlate with age 
(Spearman r =0.24), disease duration (Spearman r =0.28), LEU intake (Spearman r 
=0.32), UPDRS motor subscale-3 score in off stage (Spearman r =0.32), or UPDRS-3 
score in on stage (Spearman r =0.08). 
 
6.5.1 
18
F-dopa findings 
Regional mean 
11
F-dopa Ki values in PD-F patients and PD-NF patients are shown in 
Table 6-2. 
 
 
Table 6-2. Regional mean 
18
F-dopa Ki values (± Standard Deviation) in 
Parkinson’s disease patients with (PD-F) and without (PD-NF) fatigue 
 PD-NF 
(n=9) 
PD-F 
(n=10) 
Caudate 0.0082±0.0014 0.0071±0.0016† 
Putamen 0.0051±0.0010 0.0045±0.0009 
Ventral striatum 0.0089±0.0013 0.0084±0.0013 
Thalamus 0.0026±0.0008 0.0025±0.0008 
Raphe 0.0038±0.0007 0.0040±0.0008 
Mann-Whitney U-test: †p=0.094 
 
PD-F patients and PD-NF patients had similar levels of mean 
18
F-dopa uptake in 
putamen, ventral striatum, thalamus, and median raphe. PD-F patients showed a trend 
towards lower mean 
18
F-dopa uptake in caudate than PD-NF patients  (p=0.095).  
 127 
Categorical comparisons with SPM between PD-F patients and PD-NF patients 
localized clusters of relative significant decreases in 
18
F-dopa Ki in caudate bilaterally 
and left insula (Table 6-3, Figure 6-1) in the cohort of PD-F patients. 
 
 
 
 
Table 6-3. Areas of significant decreases in 
18
F-dopa Ki in Parkinson’s disease 
patients with fatigue compared Parkinson’s disease patients without fatigue 
 
Z score MNI co-ordinates Area p value 
(corrected) 
 x  y z   
3.68 -38 -28 18 L Insula P<0.001 
3.50 -13 6 14 L caudate P<0.001 
2.75 15 15 7 R caudate P<0.01 
 
 Coordinates are Montreal Neurological Institute (MNI) space; R=right; L=left 
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Figure 6-1. Reduced 
18
F-dopa uptake in Parkinson’s disease patients with fatigue. 
Projections of statistical parametric maps showing areas of significant decreases in 
18
F-dopa Ki in the patients with Parkinson’s disease with fatigue (n=9) compared to 
patients with Parkinson’s disease without fatigue (n=10).  
In the sagittal and coronal images, decreases are seen in the left insula and left 
temporal gyrus. Only the cluster in the left insula, however, is statistically significant. 
In the transaxial image, decreases are seen in the left caudate and left insula.  The 
colorstripe indicates t values. Areas are superimposed on the averaged T1 MRI image 
in MNI space available in SPM 
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6.5.2 
11
C-DASB findings 
For one PD-F patient spatial normalization of their parametric BPND image to the 
11
C-
DASB template was unsuccessful so this case was excluded from analysis. Regional 
mean 
11
C-DASB BPND values in normal subjects, PD-F patients, and PD-NF patients 
are shown in Table 6-4 and Figure 6-2. Figure 6-3 shows 
11
C-DASB ADD images 
from a normal subject, a PD-NF patient, and a PD-F patient. Kruskal-Wallis one-way 
analysis of variance showed a statistically significant effect of group (controls, PD-F, 
and PD-NF patients) on 
11
C-DASB BPND values for caudate (p<0.001), putamen 
(p<0.001), ventral striatum (p<0.001), and thalamus (p<0.001). There was no 
statistically significant effect of group on 
11
C-DASB BPND for median raphe (p=0.26).  
Post hoc analyses with the Mann-Whitney U-test and Bonferroni adjustment showed 
that control subjects had significant higher 
11
C-DASB BPND values than both groups 
of PD patients in the caudate, putamen, and ventral striatum and significantly higher 
11
C-DASB BPND values than PD-F patients in thalamus. In all these brain regions, PD-
NF patients had significantly higher BPND values than PD-F patients.  
 
Table 6-4. Regional mean 
11
C-DASB binding potential values (± Standard 
Deviation) in the normal subjects and in Parkinson’s disease patients with (PD-
F) and without (PD-NF) fatigue 
 Healthy 
subjects 
(n=10) 
PD-NF 
(n=8) 
PD-F 
(n=7) 
   Caudate 1.68±0.87 0.80±0.17**[-52%] 0.28±0.16**§§ [-83%] 
   Putamen 2.10±0.9 1.09±0.15* [-48%] 0.51±0.26**§§ [76%] 
  Ventral striatum 1.86±0.63 1.06±1.17**[43%] 0.48±0.34**§ [-74%] 
  Thalamus 1.49±0.37 1.13±0.21 [32%] 0.5±029**§ [-66%] 
   Raphe 1.49±0.31 1.53±0.33 [0%] 0.89±0.74 [-40%] 
 
Mann-Whitney U-test, p values corrected with Bonferroni method for multiple 
comparison: *p<0.05 compared to healthy subjects; **p<0.01 compared to healthy 
subjects; Direct comparison PD-NF and PD-F: §p<0.05;  §§p<0.01; The percentage in 
brackets represents percentage of  reduction from normal controls‟ mean value 
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Figure 6-2. 
11
C-DASB binding potential (mean ± standard error) (y-axis) in striatal 
and extrastriatal regions. * Indicates significant differences between normal subjects 
and Parkinson’s disease patients with (PD-F) or without (PD-NF) fatigue; §Indicates 
significant differences between PD-NF and PD-F patients 
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Figure 6-3. ADD images of 
11
C-DASB binding potential from a normal subject, a 
Parkinson’s disease patients without fatigue, and a Parkinson’s disease patients with 
fatigue. The colorstripe indicate binding potential values for 
11
C-DASB binding 
potential 
 
 
Categorical comparisons with SPM between PD-F patients and PD-NF patients 
localized clusters of significant relative bilateral decreases in 
11
C-DASB BPND in 
caudate, putamen, ventral striatum, thalamus, cingulate gyrus, and amygdala (Table 6-
5, Figure 6-4) in the cohort of PD-F patients. 
 
6.5.3 Clinical correlations 
Correlation analyses between clinical characteristics of PD patients and regional 
11
C-
DASB BPND or 
18
F-dopa Ki are summarized in Table 6-6 and Table 6-7. 
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Table 6-5. Areas of significant decreases in 
11
C-DASB binding potential in  
Parkinson’s disease patients with fatigue compared to Parkinson’s disease patients 
without fatigue 
 
Z score MNI  co-ordinates Area p value 
(corrected) 
 x y z   
5.13 25 5 9 R putamen p<0.001 
4.83 -26 2 8 L putamen p<0.001 
4.80 14 9 12 R caudate p<0.001 
4.60 -14 12 6 L caudate p<0.001 
4.40 -34 -12 20 L insula p<0.001 
4.40 -10 6 40 L cingulate BA24/32 p<0.001 
4.07 4 -14 42 R cingulate BA24/32 p<0.001 
3.83 8 -8 10 R thalamus p<0.001 
3.58 -10 -14 6 L thalamus p<0.001 
3.24 4 -28 46 R paracentral lobule BA 31 p<0.01 
3.20 18 -2 -22 L amygdala p<0.01 
 
Coordinates are Montreal Neurological Institute (MNI) space; R=right; L=left; BA= 
Brodmann area 
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Figure 6-4. Reduced 
11
C-DASB binding potential (BP) in Parkinson’s disease patients 
with fatigue.  Projections of statistical parametric maps showing areas of significant 
decreases in 
11
C-DASB BP in the patients with Parkinson’s disease with fatigue (n=7) 
compared to patients with Parkinson’s disease without fatigue (n=8). Areas are 
superimposed on the averaged T1 MRI image in MNI space. 
A.  Sagittal image showing clusters of reduced 
11
C-DASB BP in right cingulate and 
right thalamus.  
B. Coronal image showing clusters of reduced 
11
C-DASB BP in right and left striatum 
and left cingulate. 
C.  Transaxial image showing clusters of reduced 
11
C-DASB BP in right and left 
striatum and right and left thalamus. 
D.  Transaxial image showing clusters of reduced 
11
C-DASB BP in right and left 
cingulate.  
E. Coronal image showing clusters of reduced 
11
C-DASB BP in right and left striatum, 
and left amygdala.  The colorstripe indicates T values 
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Table 6-6. Correlation analysis for regional 
11
C-DASB binding potential and  
clinical characteristics in the total group of Parkinson’s disease patients (n=15) 
  
Spearman Rank correlation coefficient (rho) 
 Caudate Putamen Ventral 
Striatum 
Thalamus Raphe 
Age -0.29 -0.32 -0.27 -0.48 -0.61* 
Disease 
Duration 
-0.38 -0.29 -0.40 -0.31 -0.54* 
UPDRS off -0.40 -0.38 -0.35 -0.42 -0.46 
*p<0.05  
 
 
 
 
 
Table 6-7. Correlation analysis for regional 
18
F-Dopa Ki and clinical 
characteristics in the total group of Parkinson’s disease patients (n=19) 
  
Spearman Rank correlation coefficient (rho) 
 Caudate Putamen Ventral Striatum Thalamus Raphe 
Age -0.33 -0.05 -0.19 0.23 -0.25 
Disease 
Duration 
-0.07 -0.10 -0.04 0.04 -0.21 
UPDRS off -0.56* -0.51* -0.28 -0.26 -0.33 
*p<0.05  
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6.6 Discussion 
 
This study has shown that the presence of fatigue in PD is associated with relative 
serotoninergic denervation in the basal ganglia and associated limbic circuits 
compared to non-fatigued cases. With an ROI analytical approach, I found that SERT 
availability, as reflected by 
11
C-DASB binding, was significantly reduced in both 
dorsal and ventral striatum, and in the thalamus of PD-F patients compared to PD-NF 
patients.  
 
Voxel based analysis comparing PD-NF and PD-F groups confirmed and extended the 
findings from the ROI analysis. In the PD-F group, clusters of significant decreases in 
11
C-DASB BPND were localized in the whole striatum, in the thalami, and in additional 
cortical regions, including cingulate gyrus (Brodmann areas 24 and 32 bilaterally), 
right paracentral lobule (Brodmann area 31), left insula, and right amygdala relative to 
non-fatigued cases (Figure 6-4). 
 
An explorative voxel-based comparison between 
18
F-dopa images of PD-NF and PD-F 
patients localized significant (p<0.01) 
18
F-dopa uptake reductions in the caudate and 
left insula in the latter group (Figure 6-1). An ROI analysis showed a trend for lower 
18
F-dopa Ki values in the caudate (averaged right and left) of PD-F patients compared 
to PD-NF patients (p=0.094) but no other differences between the two groups. This 
finding is in line with a recent SPECT study showing similar striatal dopamine 
transporter binding in early PD patients with and without fatigue (Schifitto et al., 
2008). Taken together, these findings are against dopaminergic nigrostriatal 
degeneration per se being a factor in the pathogenesis of fatigue in PD. However, 
reduced 
18
F-dopa uptake in the insular cortex of PD-F patients suggests a possible link 
between fatigue and loss of extrastriatal dopaminergic function. 
 
The PD-NF and PD-F patients were carefully matched for gender, age, disease 
duration, daily LEU, and severity of motor symptoms, as measured by UPDRS, in 
both “off” and “on” condition. PD patients with dementia, overt depression, and EDS, 
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a common confounder of fatigue, were not included in the study and so the differential 
PET findings observed in the PD-F groups should be specific for fatigue in PD. 
 
11
C-DASB has high specificity and sensitivity for SERT (nanomolar affinity) and 
much lower affinity for the dopamine and norepinephrine transporters (micromolar 
affinity) (Houle et al., 2000). It is likely that decrease of 
11
C-DASB binding reflects a 
functional loss of SERT-expressing terminals in the corresponding areas of the brain 
due to degeneration of the serotoninergic pathways. It could be argued that low 
11
C-
DASB binding simply reflects downregulation of SERT expression. However, several 
post-mortem studies have now demonstrated depletion of serotonin and SERT levels 
in the striatum as well as in extrastriatal areas in PD patients (Scatton et al., 1983; 
Shannak et al., 1994; Kish et al., 2008). In particular, Kish and colleagues (2008) have 
recently reported that SERT and other serotoninergic markers, including serotonin 
itself, were significantly reduced in the striatum of PD patients compared to controls. 
There was a preferential loss of SERT and serotonin in caudate compared with the 
putamen. These workers also found that changes in striatal SERT binding in PD brains 
reflected an actual reduction in levels of SERT protein. 
 
The basal ganglia receive sensory and motor input from all cortical areas and are a 
relay in neuronal pathways processing emotional, motivational, associative and 
cognitive functions. A major role of the basal ganglia is to integrate sensorimotor, 
associative, limbic and motor information into efficient thought and action (Bolam et 
al., 2000). It has been suggested that structural lesions and/or changes in the 
neurotransmitter balance within the basal ganglia and associated structures disrupt the 
process of integration of limbic input concerning emotional status and consequent 
motor output. Dissociation of motivation from executive motor movement could lead 
to a reluctance to act and a feeling of fatigue (Chaudhuri et al., 2000). In line with this, 
Hagell and Brundin (2009) have recently reported that lack of motivation is a 
significant predictor of fatigue in PD patients.  These findings provide strong evidence 
in support of this pathophysiological model of fatigue in PD. PD-F patients showed 
reduced SERT expression in the main components of the basal ganglia including the 
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ventral striatum where the limbic-to-motor integration take place (Mogenson et al., 
1980).  
 
Decreases of 
11
C-DASB binding in PD-F patients were also found in limbic structures 
including: (i) Brodmann areas 24 and 31, corresponding to the ventral portion and the 
isthmus of the cingulate gyrus respectively, both involved in emotion processing; (ii) 
Brodmann area 32, corresponding to the dorsal anterior cingulate cortex anterior, 
which is involved in decision making processes; and (iii) the amygdala, which is 
involved in the processing of emotional reactions and emotional memory as well as 
spatial and motor learning.  
 
The insular cortex is also a component of the limbic system. It has reciprocal 
connections with anterior cingulate, amygdala, basal ganglia and prefrontal cortex and 
could represent a center of multi-modal sensory-motor-limbic integration (Agustine, 
1996). It is known to play a role in regulating autonomic functions. Changes in 
11
C-
DASB binding and 
18
F-dopa uptake were observed in the left insular cortex of PD-F 
patients. An asymmetrical involvement of the insular cortex is unexpected and this 
apparent lateralization of PET findings could reflect lack of power due to the relatively 
small number of patients in this study. 
 
To date the DAT blocker, methylphenidate, at a dose of 10 mg three times a day, is the 
only drug that has shown significant improvement of fatigue in PD patients 
(Mendonca et al., 2007) in controlled studies while open label studies have indicated 
beneficial effect of some dopaminergic agents such as levodopa and apomorphine 
infusion (Honig et al., 2009; Naidu et al., 2009). Selective serotonin reuptake 
inhibitors (SSRIs) are commonly used in the treatment of chronic fatigue syndrome 
(CFS) and are often used in PD patients with history of fatigue. These medications 
increase synaptic levels of serotonin by inhibiting SERT activity.  However, if this 
finding of low 
11
C-DASB binding reflects an effective loss of SERT protein, as 
observed in post-mortem parkinsonian brain, SSRIs are less likely to be efficacious in 
these patients. Alternative strategies to increase brain level of serotonin and 
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serotoninergic transmission in non-depressed PD patients with fatigue should be 
tested.  
 
Fatigue is a common symptom in other diseases including CFS, multiple sclerosis, and 
stroke. It is possible that a dysfunction of brain serotoninergic pathways in the basal 
ganglia/limbic systems may be common to the occurrence of fatigue in these 
conditions. Preliminary reports of a serotoninergic dysfunction in CFS patients 
without PD support this hypothesis. Using the PET ligand 
11
C-(+)McN5652, 
Yamamoto and colleagues (2004)  have reported reduced SERT binding in the rostral 
subdivision of anterior cingulate (Brodmann areas 24/32) in CFS patients  compared 
with controls. Cleare and colleagues (2005) found widespread reduction of 
11
C-WAY-
100635, a specific radioligand for serotonin 5-HT1A receptors, in CFS patients. 
Reductions in 
11
C-WAY-100635 binding were particularly marked in the 
hippocampus bilaterally. Other limbic areas, including amygdala, insular, and anterior 
cingulate, also showed significant tracer binding reduction in the CFS group. Although 
serotoninergic function has not been investigated in vivo in multiple sclerosis patients 
with fatigue, an early PET study (Roelcke et al., 1997) demonstrated that these 
patients had reduced glucose metabolism in basal ganglia and in lateral and medial 
prefrontal cortex, the same areas where serotoninergic dysfunction was seen in my 
cohort of PD patients with fatigue. Future research is required to clarify the role of 
serotoninergic dysfunction in the pathogenesis of fatigue in these clinical conditions. 
 
There are a few more findings of this study that need further consideration:  
In line with other PET studies suggesting raphe involvement in advanced PD (Rakshi 
et al., 1999; Moore et al., 2008), 
11
C-DASB BPND values in the raphe inversely 
correlated with disease duration in the cohort of PD patients. Yet, raphe median 
11
C-
DASB BPND values in PD-NF and PD-F patients were similar and were not 
significantly different from the control subjects. Since the majority of the serotonin 
innervation of the brain arises from the raphe nuclei (Hornung, 2003), one might have 
expected more severe raphe involvement in PD-F patients to parallel the 
striatal/cortical changes. However, my findings are in agreement with previous reports. 
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Albin and colleagues (2008), who used 
11
C- DASB PET to assess brain serotoninergic 
pathway function in patients with early PD, also found that the magnitude of SERT 
binding reductions in PD patients compared to controls was greater in the forebrain 
than in brainstem regions. Additionally, receptor autoradiography with 
3
H-citalopram, 
a marker of SERT, showed a normal density of 
3
H-citalopram binding sites in the 
median raphe of PD patients, despite severe binding reductions in both the basal 
ganglia and cerebral cortex (Chinaglia et al., 1993). A possible explanation for these 
findings is that the degenerative process in the raphe-striatal neurons in PD targets the 
nerve terminals rather than the cell bodies. 
 
While PD-NF and PD-F patients were age-matched, the healthy control subjects used 
for the 
11
C- DASB PET comparisons were 20 years younger than the PD patients. An 
age-related decline in the availability of SERT when measured with PET and SPECT 
has been reported. Buchert and colleagues have recently reviewed this topic (2006).  
The percentage reduction in SERT availability per decade across published series 
varies from 2% to 10.5% (median 50
th
 percentile 4.5%). Based on these observations, 
the maximum decline in 
11
C- DASB binding in my two PD cohorts that could be 
ascribed to aging, is around 21%. This is far less than the decline observed in this 
study, as the PD-F patients had a reduction close to 80% of the control mean in most 
of the regions assessed by ROI approach  (table 6-4). Therefore, the reduction in 
11
C- 
DASB binding observed in the PD-F groups is unlikely to be explained by aging 
alone. 
 
While findings from this study indicate that the level of dopaminergic nigrostriatal 
dysfunction does not differentiate PD patients with and without fatigue, they do not 
exclude loss of striatal dopamine playing a role in its pathogenesis. Although fatigue is 
associated with more severe involvement of the serotoninergic system in PD patients, 
it is likely that changes in the serotonin/dopamine balance within the basal ganglia 
also contribute.  
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Finally, by excluding patients with dementia, depression, and EDS I have reduced the 
effects of possible confounding factors and shed light on the pathogenesis of 
“primary” fatigue in PD. However, all these other factors are known to exacerbate the 
subjective experience of fatigue and in some cases could be the predominant cause for 
fatigue like symptoms. Distinct neurochemical substrates could underlie these 
situations and need to be investigated carefully so that focused interventions can 
optimize the treatment of fatigue in PD patients.  
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PET markers of serotonin function in 
Parkinson’s disease - a combined 18F-
dopa
 
and
 11
C-DASB PET study 
 
7 
 
7.1 Summary of objectives  
 
The overall objective of this study was to verify the hypothesis that 
18
F-dopa PET can 
be used to evaluate the distribution and the function of serotoninergic systems in the 
brain of patients with PD. This was achieved by assessing the relationship between 
18
F-dopa uptake and measurements of SERT availability by 
11
C-DASB PET within 
brain serotoninergic structures.  
I particularly focused on: (1) The raphe nuclei complex in the midline of the brainstem 
where serotoninergic neurons are predominantly located. (2) The hypothalamus, which 
contains intrinsic dopamine neurons, but also a dense innervation from midbrain raphe 
serotonin neurons. (3) The anterior cingulate, a region
 
of very high SERT density in 
autopsy human brains (Mantere et al., 2002). 
 
7.2 Summary of results  
 
18
F-dopa uptake in the raphe nuclei complex of PD patients was significantly 
correlated with SERT availability in the same structure. Trends towards significant 
correlations between 
18
F-dopa Ki values and 
11
C-DASB binding values were also 
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observed in the hypothalamus and the anterior cingulate cortex, suggesting a large 
serotoninergic contribution to 
18
F-dopa uptake in these regions. Conversely, no 
correlations were found in brain structures with mixed dopaminergic, serotoninergic, 
and noradrenergic innervations, or with predominant dopaminergic innervation. 
These findings provide evidence that 
18
F-dopa PET represents a reliable marker for 
raphe serotoninergic function in PD and validate previous studies where 
18
F-dopa PET 
has been used to assess serotoninergic function in PD.  
 
7.3 Scientific background 
 
As described in previous chapters of this thesis, 
18
F-dopa uptake when expressed as an 
influx constant, Ki, reflects the activity of the enzyme AADC in the axonal plexus. 
Since this enzyme is present in high concentration in all catecholaminergic neurons 
and in even greater concentrations in serotoninergic neurons (Jaeger et al., 1984), 
18
F-
dopa uptake in different brain structures is likely to reflect the overall pattern of 
distribution of monoamine neuronal systems in those areas, including the dopamine, 
noradrenaline and serotonin innervation (Brown et al., 1999; Moore et al., 2003). 
In a PET study in ten healthy subjects, Brown and colleagues (1999) quantified, for 
the first time, specific 
18
F-dopa uptake in both striatal and extrastriatal regions in the 
human brain, including regions with no substantial dopaminergic innervation. 
Interestingly, they found a wide range of 
18
F-dopa regional uptake rate constants (Kc) 
values even for regions with low dopamine concentrations. The authors also assessed 
the relationship between regional 
18
F-dopa Kc values and regional amine 
neurotransmitter concentrations and AADC activity in the human brain, obtained from 
post-mortem studies in the published literature. They found a poor correlation between 
regional 
18
F-dopa Kc values and regional dopamine concentrations throughout the 
brain, whereas, regional 
18
F-dopa Kc values correlated well with both AADC activity 
and the sum of local concentrations of dopamine, norepinephrine, epinephrine, and 
serotonin. These findings provide support for the proposition that 
18
F-dopa PET is 
marker for AADC activity and overall brain monoaminergic function. However, in 
areas in which a definite innervation predominates, specific 
18
F-dopa uptake is likely 
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mainly to reflect the activity and density of the predominant neuronal population. 
Indeed 
18
F-dopa uptake in the striatum - where dopamine innervation from the nigral 
complex is the major monoaminergic component - correlates with striatal dopamine 
levels and also with nigrostriatal cell counts in post-mortem and animal studies (Snow 
et al., 1993; Pate et al., 1993).   
Similar considerations may apply to brain structures with extensive serotoninergic or 
noradrenergic components such as the raphe nuclei complex and the locus coeruleus 
respectively.  However, the relationship between 
18
F-dopa uptake in these structures 
and other markers of serotoninergic or noradrenergic function has not yet been 
assessed. 
 
7.4 Patients and methods 
 
7.4.1 Patients 
Eighteen patients with a clinical diagnosis of idiopathic PD (UK Parkinson‟s Disease 
Society Brain Bank diagnostic criteria) were included in this study. Fourteen of them 
were participants in the study described in chapter 6 (six had a clinical complaint of 
fatigue). Four additional PD patients were recruited for this study. Table 7.1 
summarizes the demographics of all patients investigated. 
 
 
Table 7-1. Patient Characteristics 
 
 Parkinson’s disease patients 
(n=18) 
M/F 12/6 
Age 
(years, mean ±SD) 
67.8 ±10.5 
 
Disease Duration 
(years, mean ±SD) 
9.3 ±9.8 
 
UPDRS in “off” 32.3 ± 12.0 
 144 
None of the patients had significant co-morbidity, previous history of psychiatric or 
neurological conditions (e.g. depression, cognitive impairment, stroke, head injury, 
epilepsy). All the patients had a stable response to their dopamine replacement therapy 
and none were taking medication targeting serotoninergic and noradrenergic systems.  
 
All subjects gave their written informed consent to be scanned (approved by the Ethics 
Committee of Hammersmith, Queen Charlotte‟s & Chelsea and Acton Hospitals 
Trust), according to the declaration of Helsinki. Permission to administer 
18
F-dopa and 
11
C-DASB was obtained from the Administration of Radioactive Substances Advisory 
Committee (ARSAC), UK.  
 
7.4.2 PET protocol 
PET scanning took place at the Cyclotron Building, Hammersmith Hospital, 
Hammersmith Imanet, GE Healthcare, London, UK, and all PET scans were 
performed using an ECAT EXACT HR+ (CTI/Siemens 962) camera. All patients had 
their dopamine replacement medication stopped for at least 12h before PET.  
 
The scanning protocol for 
18
F-dopa involved 3D acquisition over 94.5 minutes 
following a bolus injection of 185 MBq of 
18
F-dopa. The scanning protocol for 
11
C-
DASB involved 3D acquisition over 90.5 minutes following a bolus injection of 450 
MBq of 
11
C-DASB.  
 
7.4.3 PET analysis  
Parametric images of the influx constant Ki and integrated ADD images of 
18
F-dopa 
uptake were created as described in Chapter 3. Both Ki and ADD images were then 
transformed to ANALYZE format using an in house program, ECAT_transfer. Once 
in ANALYZE format the parametric and ADD image from each scan were visually 
inspected using ANALYZE software. 
Spatial normalization of ADD images and Ki maps into standard MNI stereotaxic 
space was performed using SPM software package implemented in Matlab5. First the 
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ADD images were normalized to a smoothed 
18
F-dopa template in MNI space.  Then 
the transformation parameters were applied to the respective 
18
F-dopa Ki maps.  
 
As described in Chapter 3, parametric images of specific 
11
C-DASB BPND
 
were 
generated on a voxel wise basis for the whole brain using a basis function 
implementation of the simplified reference region compartmental model with the 
cerebellum providing the reference tissue input function (Gunn et al., 1997).  
Integrated ADD images of 
11
C-DASB uptake were also created for spatial 
normalization purposes. ADD images and parametric images of 
11
C-DASB BPND were 
then normalized, using SPM software, to a smoothed 
11
C-DASB ADD image template.  
 
7.4.3.1 Extraction of ROI data  
Standard object maps in MNI space were used to extract ROI data. The standard object 
map containing regions defined for caudate nucleus, putamen, ventral striatum, 
thalamus, hypothalamus, and raphe has been described in details in paragraph 4.4.3.1 
and in Table 4-2. An additional standard object map was employed to extract ROIs 
values for amygdala, anterior cingulate, posterior cingulate, and prefrontal cortex. The 
characteristics of this standard object maps have been described in Table 7-2. 
 
 
Table 7-2 Additional regions of interest identified on the template object map 
 
Amygdala ROI traced to include the entire amygdaloid complex rostral 
to the ventral hippocampus 
 
Anterior cingulate ROI traced to include the frontal part of the cingulate cortex 
dorsal to corpus callosum, Brodmann areas 24, 33, and 32  
 
Posterior cingulate ROI traced to include the posterior part of the cingulate cortex 
dorsal to corpus callosum, lying behind the anterior cingulate 
cortex. Brodmann areas 23 and 31 
 
Prefrontal cortex ROI traced to include the anterior part of the frontal lobes of  
the brain, lying in front of the motor and premotor areas 
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The standard object maps were applied to each spatially normalized image of 
18
F-dopa 
Ki or 
11
C-DASB BPND and corresponding ADD images. Visual inspection of each 
plane for both images was made to ensure correct placement of the object regions over 
the correspondent structures. After applying target regions to structures, 
18
F-dopa Ki 
and 
11
C-DASB BPND values were quantified using ANALYZE software. 
18
F-dopa Ki 
and 
11
C-DASB BPND
 
values obtained from the different ROIs were averaged
 
over both 
hemispheres for statistical analysis. 
 
7.4.4 Statistical analysis 
Statistical analyses of clinical data were performed with SSPS 16 for Windows (SPSS 
Inc., Chicago, Illinois). The Kolmogorov-Smirnov test was used to test data sets for 
normality. Correlations between variables were tested with Pearson rank correlation. 
 
7.5 Results  
 
All data sets passed the normality test. Correlation analyses between regional 
11
C-
DASB BPND and 
18
F-dopa Ki are summarized in Table 7-3.  
 
There was a significant correlation (p=0.042) between 
18
F-dopa Ki values and 
11
C-
DASB BPND values in the raphe complex (Table 7-3 and Figure 7-1A). A trend 
towards a significant correlation between 
18
F-dopa Ki values and 
11
C-DASB BPND 
values was also observed in the hypothalamus (p=0.063) and the anterior cingulate 
cortex (p=0.078) (Table 7-3 and Figure 7-1B and C). No correlations were found 
between uptake of the two radiotracers in any of the remaining regions assessed in this 
study (Table 7-3) 
PET images in figure 7-3 show examples of 
18
F-dopa Ki uptake and 
11
C-DASB 
binding in the median raphe of two patients with PD. 
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Table 7-3. Correlation analysis for regional 
11
C-DASB binding potential and  
18
F-dopa Ki in Parkinson’s disease patients (n=18) 
 
  
Correlation coefficient 
(r) 
 
Coefficient of determination 
(r squared) 
 
p value 
Caudate 0.211 0.044 p=0.401 
Putamen 0.151 0.023 p=0.549 
Ventral Striatum 0.060 0.004 p=0.814 
Thalamus 0.123 0.015 p=0.626 
Hypothalamus 0.426 0.181 p=0.063 
Raphe 0.483 0.234 p=0.042 
Amygdala 0.157 0.025 p=0.535 
Anterior cingulate 0.425 0.181 p=0.078 
Posterior cingulate  -0.171 0.029 p=0.496 
Prefrontal cortex 0.115 0.013 p=0.650 
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Figure 7-1. Scatterplots of individual 
11
C-DASB BPND values and 
18
F-dopa Ki values 
in raphe nuclei complex (A), hypothalamus (B), and anterior cingulate (C)
 149 
  
 
 
 
 
 
6.6  
 
 
 
 
 
 
 
 
 
Figure 7-2. ADD images of 
11
C-DASB binding and 
18
F-dopa uptake from two 
Parkinson’s disease (PD) patients. The patient depicted at the top shows high 11C-
DASB binding and 
18
F-dopa uptake in the raphe nuclei complex (indicated by the 
white arrow), whereas the patient depicted at the bottom shows low 
11
C-DASB binding 
and 
18
F-dopa uptake in the raphe nuclei complex. The same color scale was used to 
display 
11
C-DASB binding and 
18
F-dopa Ki uptake 
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7.6 Discussion 
 
This is the first study to assess in vivo the relationship between 
18
F-dopa uptake and 
serotonin terminal function in human brains. 
11
C-DASB PET was used to obtain an 
index of regional brain serotonin presynaptic terminal function to correlate with local 
18
F-dopa uptake. As previously mentioned in chapter 3, 
11
C-DASB has high specificity 
and sensitivity for SERT and much lower affinity for the dopamine and 
norepinephrine transporters and therefore represents a specific marker of 
serotoninergic innervation (Houle et al., 2000). Additionally, 
11
C-DASB binding 
potential values are remarkably consistent under test-retest conditions for most brain 
regions (Kim et al., 2006). 
 
In the cohort of 18 patients with PD examined in this study, there was a significant 
correlation (p=0.042) between 
18
F-dopa Ki values and 
11
C-DASB BPND values in the 
raphe nuclei complex (Figure 7-1A). No other significant correlations were found 
between the two radiotracers in any of the remaining regions assessed in this study 
(Table 7-3). However, a trend towards a significant correlation between 
18
F-dopa Ki 
values and 
11
C-DASB binding values was observed in the hypothalamus (p=0.063) 
and the anterior cingulate cortex (p=0.078) (Figure 7-1B and C).  
 
The raphe nuclei complex in the midline of the brainstem contains the majority of the 
brain serotoninergic neurons (Dahlström and Fuxe, 1964). The rostral cell groups in 
the pons and midbrain, which includes the dorsal raphe nucleus, project extensively to 
the forebrain, whereas the caudal raphe nuclei in the medulla project towards the 
spinal cord and brainstem. In this study, the ROI placed over the raphe mainly 
included the dorsal and medial raphe and some adjacent medial reticular formation. In 
this region serotonin neurons are largely represented, whereas catecholaminergic 
neurons are much less numerous and are exclusively located in the rostral part of the 
dorsal raphe nucleus (Baker et al., 1991).  In line with these anatomical findings, 
results from this study show that 
18
F-dopa uptake in the raphe of PD patients mirrors 
local measurement of SERT availability, indicating that 
18
F-dopa uptake in this 
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structure mostly reflects density and AADC activity of serotoninergic terminals. 
Therefore, 
18
F-dopa PET can be used as a reliable marker of raphe serotoninergic 
function in PD. 
 
The hypothalamus and the anterior cingulate cortex also have a significant 
serotoninergic innervation (Bogdanski et al., 1957; van de Kar and Lorens, 1979; 
Mantere et al., 2002; Takano et al., 2010). The observed trend towards a significant 
correlation between 
18
F-dopa Ki values and 
11
C-DASB binding values in 
hypothalamus and anterior cingulate cortex may indicate a large serotoninergic 
contribution to 
18
F-dopa uptake in these regions.  
 
No correlation between 
18
F-dopa Ki values and 
11
C-DASB BPND values was found in 
caudate, putamen, and ventral striatum. This result is not surprising considering that 
the striatum receives a very dense dopaminergic innervation originating from the 
substantia nigra pars compacta and the ventral tegmental area (Lindvall and Björklund, 
1978; Gerfen, 1987) and a more moderate serotoninergic innervation from the dorsal 
raphe nucleus (Azmitia and Segal, 1978; Steinbusch, 1984). Additionally, previous 
results from both human and animal studies have shown that 
18
F-dopa Ki values 
correlate well with striatal dopamine levels and with nigrostriatal cell counts (Snow et 
al., 1993; Pate et al., 1993). 
 
Finally, no correlations were found between the two tracers in brain structures with 
mixed dopaminergic, serotoninergic and noradrenergic innervations. Reductions in 
18
F-dopa uptake in these structures, as observed in PD (Moore et al., 2003 and also in 
chapter 4 and 5 of this thesis), are likely to reflect dysfunction in any or all of these 
pathways. Nevertheless, 
18
F-dopa uptake in these regions still represents a useful 
marker of overall monoaminergic function and may provide the rationale for further 
investigations with more specific PET ligands if the involvement of a particular 
neurotransmitter is suspected. 
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In this study, the relationship between 
18
F-dopa uptake and 
11
C-DASB binding values 
was assessed in patients with PD rather than healthy volunteers. This allows one to 
assess the regional correlations between the two tracers in subjects who might have 
different degrees of serotoninergic impairment, as reported in both post-mortem and 
imaging studies (Kish et al., 2008; Politis et al., 2010).  The strict correlation between 
18
F-dopa Ki and 
11
C-DASB BPND values in the raphe in this cohort of PD patients 
suggest that 
18
F-dopa PET is as sensitive as 
11
C-DASB in detecting pathological and 
or functional changes in this structure.  
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Review of major findings and 
Conclusions 
 
8 
 
 
8.1 Summary of main findings 
 
The experiments described in this thesis were undertaken with a view to improve 
understanding of the degenerative process in non-dopaminergic structures in 
idiopathic PD and in monogenic forms of parkinsonism.  
Both pathological and neurochemical studies have demonstrated that serotoninergic, 
noradrenergic, and cholinergic neurons are significantly affected in PD. However, the 
extent and time course of degeneration of non-dopaminergic pathways in living 
patients with PD and atypical forms of parkinsonism remains to be fully elucidated. To 
date, only a relatively small number of imaging studies have been performed to 
investigate the involvement of extrastriatal monoaminergic structures in PD patients 
and no such studies have been performed in patients with monogenic forms of 
parkinsonism or in asymptomatic heterozygote carriers of a recessive mutation. 
Degeneration and/or dysfunction of these monoaminergic nuclei could be responsible 
for the occurrence of non-motor symptoms including fatigue and depression. 
However, the physiopathogenetic mechanisms and the neurochemical substrates of 
non-motor symptoms in PD have not been extensively investigated.  
The rate of progression of the degenerative process in extrastriatal areas also remains 
unclear.  Several functional imaging studies with both PET and SPECT have been 
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performed to assess in vivo disease progression in PD patients. However, all of them 
have exclusively focused on the progression of nigrostriatal degeneration.   
 
In this thesis, I have used PET imaging to clarify the extent and time course of the 
involvement of striatal and extrastriatal monoaminergic structures in PD and to 
elucidate the pathogenesis of fatigue, a disabling non-motor symptom which is 
reported by a significant number of PD patients.  
 
The main findings of this thesis can be summarized as follows: 
 
1) Parkin and idiopathic PD patients with similar levels of striatal dysfunction 
have different patterns of extra-striatal monoaminergic involvement, more 
widespread dysfunction being evident in idiopathic PD. 
 
2) Compared to controls, asymptomatic heterozygote carriers of a single parkin 
mutation have significant reductions of mean 
18
F-dopa uptake in striatum but 
not elsewhere. However, individual subject analyses revealed that two cases 
had significantly reduced locus coeruleus 
18
F-dopa uptake. 
 
3) Loss of monoaminergic function in extrastriatal regions, as reflected by 18F-
dopa uptake, is slower than loss of nigrostriatal dopaminergic function.  
 
4) Compensatory upregulation of monoamine turnover in extrastriatal regions 
during the early phase of PD disappears within a few years of disease.   
 
5) Fatigue in PD is associated with reduced serotoninergic function in the basal 
ganglia and limbic structures. 
 
6) 18F-dopa PET can be used as a reliable marker of raphe serotoninergic function 
in PD. 
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8.2 Implications of findings 
 
This PhD programme has provided several novel observations, expanding our 
knowledge of the pathological process in PD. One of the novel findings has been the 
demonstration that, despite a similar pattern of reduction in striatal 
18
F-dopa uptake in 
parkin and idiopathic PD patients, the two groups have distinct patterns of extrastriatal 
monoaminergic involvement, with more widespread dysfunction in idiopathic PD. 
Interestingly, while 
18
F-dopa uptake in the raphe nuclei complex was severely affected 
in parkin patients, it was only mildly reduced in idiopathic PD patients. Since 
reductions in 
18
F-dopa uptake in this region reflect impairment of serotonin 
innervation, as demonstrated in chapter 7, parkin patients seem to have a greater 
serotoninergic dysfunction than idiopathic PD patients. Having said that, both 
pathological and neuroimaging studies in PD patients have reported that SERT 
binding reductions in PD patients compared to controls are greater in the basal ganglia 
and cerebral cortex than in brainstem regions (Albin et al., 2008; Chinaglia et al., 
1993), suggesting that the degenerative process targets the serotoninergic presynaptic 
terminals rather than the cell bodies. It is therefore possible that the degenerative 
process targets the serotoninergic presynaptic terminals in idiopathic PD and the 
perikarya in parkin patients. Taken together these findings could indicate that the 
neurochemical abnormalities in idiopathic PD and in parkin-linked parkinsonism are 
different. Future research should elucidate the clinical relevance of the different 
monoaminergic involvement in the two conditions. 
In addition to these data, I have also assessed for the first time the pattern of 
monoaminergic dysfunction in the brains of asymptomatic carriers of a single parkin 
mutation. Confirming previous studies from this Unit, I found a mild but significant 
reduction of 
18
F-dopa uptake in the caudate and putamen in the asymptomatic 
heterozygous carriers compared to the normal controls.  No other significant 
differences were found between the two groups in any of the assessed monoaminergic 
structures, although two heterozygous carriers had reduced locus coeruleus 
18
F-dopa 
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uptake with normal striatal uptake. This finding suggests that, at least in some carriers, 
locus coeruleus might be involved independently from the dopaminergic system.   
Kay and colleagues (2007), have recently reported that heterozygous parkin point 
mutations are as common in control subjects as in PD patients against the hypothesis 
that heterozygous parkin sequence variants are risk factors for PD. Additionally, the 
rate of nigrostriatal dysfunction progression seems to be very slow in asymptomatic 
heterozygous carriers (Pavese et al., 2009). Taken together these findings would 
suggest that heterozygous parkin gene mutations are not a major risk factor for late 
onset PD. 
 
The study described in chapter 5 has produced several new findings regarding the time 
course of the monoaminergic degeneration in PD patients. Using serial 
18
F-dopa PET 
scans, I found that putamen had the fastest annual decline in 
18
F-dopa uptake followed 
by locus coeruleus and globus pallidus interna. Caudate and hypothalamus showed a 
6.3% and 6.2% decline per annum respectively, whereas the remaining structures 
showed less than a 5% annual decline in 
18
F-dopa uptake. No significant correlations 
were found between the rate of annual decline in 
18
F-dopa uptake in putamen and that 
in any of the other assessed regions of interest. Taken together these findings indicate 
that the degeneration in extrastriatal monoaminergic structures in PD occurs 
independently from nigrostriatal degeneration and at a slower rate. Of particular 
importance is the observation that hypothalamic involvement is common in PD and is 
targeted at very early stages of the disease with a fast progression rate once 
degeneration has started. Hypothalamic dysfunction may contribute to sleep disorders, 
endocrine dysfunction and weight loss in PD patients.  
Confirming findings of previous studies, I found increased 
18
F-dopa uptake in globus 
pallidus interna and midbrain raphe in patients with early PD, which is likely to 
represent a compensatory upregulation of AADC activity and dopamine turnover in 
these regions. The longitudinal assessment of these patients reported in chapter 5 
showed that tracer uptake in these two nuclei fell slightly below the control mean 
value after a three-year follow up, suggesting that compensatory hyperactivity reverses 
within the first years of disease.  
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In conclusion, the study in chapter 5 has shown that with serial 
18
F-dopa PET scans it 
is possible to assess disease progression in serotoninergic and noradrenergic 
extrastriatal areas along with nigrostriatal degeneration. This could be relevant in the 
choice of an imaging biomarker when designing future clinical trial to assess the 
effects of novel neuroprotective agents in PD. 
One of the major findings of this thesis has been the demonstration that the presence 
of fatigue in PD is associated with relative serotoninergic denervation in the basal 
ganglia and associated limbic circuits. In the study described in chapter 6, I found that 
PD patients with fatigue had significantly lower SERT binding than patients without 
fatigue in caudate, putamen, ventral striatum and thalamus. Additionally, in the fatigue 
group, voxel-based analysis localised 
18
F-dopa uptake reductions in caudate and 
insula, and further SERT reductions in cingulate and amygdala.   
These findings have shed light on the neurobiology of fatigue in PD and might have 
important therapeutic implication as they provide the rationale for strategies to 
increase brain level of serotonin and serotoninergic transmission in the treatment of 
this common complaint among PD patients.  
Finally, another important observation in this thesis is the good relationship between 
18
F-dopa uptake and SERT availability in the raphe nuclei complex of PD patients. 
This evidence suggests that 
18
F-dopa PET represents a reliable marker of 
serotoninergic function in the raphe and validate previous studies where 
18
F-dopa PET 
has been used to assess serotoninergic function in PD.  
18
F-dopa PET imaging is also 
used to assess the involvement of the dopaminergic system in several psychiatric 
diseases, including depression and schizophrenia. Based on the results of this thesis, it 
appears that the technique could provide supplementary information on the function of 
serotoninergic function in these conditions.   
 
8.3 Strengths and limitations 
 
One of the considerable strengths of this study is that I have used PET scanners with 
high resolution and high sensitivity that permit interrogation of the function of small 
volume structures. 
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I have also used a rigorous methodological approach to analyze PET images. In order 
to minimize the number of possible volumetric variations when drawing ROIs on 
individual PET images, I used standard ROI maps of predefined volumes of interest in 
MNI space that were applied to each spatially normalized parametric image. This 
technique has several advantages. First, the method allows the same cubic volume to 
be interrogated in all scans. Second, the normalization of baseline and follow-up 
images to the same orientation and space increases the confidence that the same 
anatomical structures are assessed in longitudinal studies.  
 
Special attention was given to patients‟ selection. In chapter 4, for example the main 
aim of that study was to investigate brain monoaminergic innervation in parkin-
patients and patients with idiopathic PD.  However, I wanted to exclude that a 
different extrastriatal monoaminergic pattern in the two conditions could be related to 
the different degrees of striatal involvement in the two groups. Therefore only parkin 
gene carriers underwent a PET scan for this study and patients with idiopathic PD 
were carefully selected from the Unit‟s database to match striatal 18F-dopa uptake of 
parkin-patients.  
In chapter 6, the two groups of PD patients with and without fatigue were matched for 
all possible confounding factors, including age, disease duration, daily intake of LEU, 
and UPDRS
 scores in both “off” and “on” conditions. Additionally, since I wanted to 
elucidate neurochemistry of primary fatigue, patients with dementia, depression, and 
EDS were excluded from the study. 
 
However, a number of methodological weaknesses and limitations to the experimental 
studies reported in this thesis also need to be acknowledged. Some of these limiting 
issues are specific to the study design in each of the thesis‟ experiments whereas 
others are generally applicable to the field of brain imaging. 
 
PET is a very expensive modality and the cost of a PET scan is quite high particularly 
in a research context. The impact of irradiating healthy volunteers is also relevant as it 
raises important ethical issues.  Considering that the CSC Neurology group has 
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collected a large database of 
18
F-dopa and 
11
C-DASB PET images of healthy 
volunteers over the years, it was decided to not scan new healthy volunteers for the 
studies of this thesis.  
Whilst striatal 
18
F-dopa does not appear to be age-dependent in healthy controls 
(Sawle et al., 1990), an age-related decline in the availability of SERT when measured 
with PET and SPECT has been reported (Buchert et al., 2006).  
In the study in chapter 6, PD patients with and without fatigue were age-matched, 
whereas the healthy control subjects used for the 
11
C-DASB PET comparisons were 20 
years younger than the PD patients. Therefore, the effect of age on the 
11
C-DASB 
reductions in the two cohorts of PD patients cannot be completely excluded. However, 
the reductions in 
11
C-DASB binding that I found in the PD patients with fatigue (about 
80% of the control mean in most of the regions assessed by ROI approach) is much 
bigger than the maximum decline (around 21%) that could be ascribed to aging on the 
basis of previous studies. Additionally, I found no significant correlations between age 
and tracer binding in caudate, putamen, ventral striatum, and thalamus in the cohort of 
15 PD patients. 
Therefore, the reduction in 
11
C- DASB binding observed in PD patients with fatigue is 
unlikely to be explained by aging alone. 
 
Probably the most notable weakness in this thesis is the lack of clinical details on the 
differences in non-motor symptoms between idiopathic PD and parkin-patients in 
Chapter 4. Unfortunately, as the idiopathic PD patients were selected from our data 
base to match striatal 
18
F-dopa uptake in parkin-patients, data on sleep problems or 
other non-motor symptoms in these patients were not always available. Therefore, I 
was not able to compare the different groups on the basis of their non-motor 
symptoms. The clinical relevance of the different monoaminergic involvement in the 
two conditions remains to be elucidated. 
 
In all the experiments of this thesis 
18
F-dopa PET has been used as a marker of 
monoaminergic terminals. In areas in which a definite innervation predominates, 
specific 
18
F-dopa uptake is likely to reflect the activity and density of the predominant 
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neuronal population (eg dopamine innervation in the striatum and serotoninergic 
innervation in the raphe). However, in brain structures like the hypothalamus, the red 
nucleus, and the pineal gland that have a mixed dopaminergic, serotoninergic and 
noradrenergic innervations, 
18
F-dopa uptake probably reflects the combined effect of 
activity and density of different groups of monoaminergic afferents to these structures. 
Therefore, the reductions of 
18
F-dopa uptake in these regions that I have observed in 
PD patients could reflect dysfunction in any or all of these pathways. Nevertheless, 
18
F-dopa uptake in these regions still represents a useful marker of overall 
monoaminergic function and may provide the rationale for further investigations with 
more specific PET ligands if the involvement of a particular neurotransmitter is 
suspected. 
 
Another possible limitation of this thesis is that the studies were not performed using a 
partial volume effect correction. In imaging, the partial volume effect is the loss of 
contrast between two adjacent tissues in an image caused by insufficient resolution 
that results in same voxels containing both tissues. As a consequence, the signal in 
these voxels is an average of the signal of both tissues.  
Partial volume effect in my studies could have led to a decrease of the absolute Ki or 
BPND values. However, partial volume effect is particularly relevant in the case of 
brain atrophy, such as in Alzheimer‟s disease. In PD, gross brain morphology is not 
altered by the disease process.  Additionally, my ROIs were drawn well within the 
anatomical boundaries of each structure to avoid overlapping with adjacent tissues. 
Therefore, it is unlikely that relative regional difference in Ki and BPND values 
between controls and PD patients in this thesis have been greatly altered by partial 
volume effects. 
 
8.4 Possible directions for future work 
 
The experimental work presented in this thesis has important implications for future 
work in the field. Some possible directions for future research are outlined below. 
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Future research should elucidate the clinical relevance of the different monoaminergic 
involvement in idiopathic PD and in parkin-linked parkinsonism. 
Particular attention should be given to non-motor symptoms in both conditions. 
Monoaminergic involvement in a larger number of patients with PINK1 mutation and 
in other genetic form of parkinsonism should also be pursued. I believe that a better 
understanding of the similarities and differences between idiopathic PD and genetic 
forms of parkinsonism may shed light on the neurobiology of these conditions. 
 
The study in Chapter 5 has shown that 
18
F-dopa PET can be successfully used to 
assess disease progression in serotoninergic and noradrenergic extrastriatal areas along 
with nigrostriatal degeneration. However, the annual declines observed in 
18
F-dopa 
uptake in some structures (globus pallidus interna, midbrain raphe, and locus 
coeruleus) could simply reflect the loss of their compensatory upregulation rather than 
cellular loss. Longer follow-ups with three or more imaging assessments are required 
to assess the effective rate of disease progression in these structures once the 
compensatory mechanisms have disappeared. 
The part of the study dealing with reproducibility in healthy volunteers only included 
three subjects scanned twice and needs to be extended. 
Further studies can be designed to establish whether serial 
18
F-dopa PET scans can be 
used as an imaging biomarker of disease progression in serotoninergic and 
noradrenergic extrastriatal areas along with nigrostriatal degeneration in clinical trials 
to assess the effects of novel neuroprotective agents in PD. 
 
Fatigue is very common in many neurological conditions (eg, multiple sclerosis, 
stroke) as well as non-neurological disorders (eg, CFS) and there is no real evidence to 
suggest that this symptom is fundamentally different between diagnoses.  My finding 
of reduced serotoninergic activity in PD patients with fatigue can therefore be seen in 
a wider perspective. Future research should be directed at determining the role of 
serotoninergic dysfunction in the pathogenesis of fatigue in these clinical conditions. 
In particular, it would be interesting to assess serotoninergic function in patients with 
CFS.  However, it is likely that it is the change in the serotonin/dopamine balance 
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within the basal ganglia that contributes to fatigue in PD. Therefore, I believe that the 
imaging assessment of patients with CFS should be performed combining 
dopaminergic and serotoninergic PET ligands.   
It would also be interesting to design and carry out clinical trials to assess the 
beneficial effect of serotonin agents such as 5-Hydroxytryptophan on fatigue in PD 
patients.   
 
The imaging approach used in this thesis could also be applied to elucidate 
physiopathological mechanisms underlying other non-motor symptoms including 
sleep disorders, depression, and psychosis in PD. It would also be extremely valuable 
to correlate in vivo PET measures with neuropathological changes seen at post mortem 
if the patients and their relatives agreed to prospective brain donation. 
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